var title_f40_7_41072="HIE outcome";
var content_f40_7_41072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    HIE outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sidhartha Tan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41072=[""].join("\n");
var outline_f40_7_41072=null;
var title_f40_7_41073="A1C pramlin vs Pbo A";
var content_f40_7_41073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79842%7EPC%2F60521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79842%7EPC%2F60521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mean change &plusmn; standard deviation in A1c and body weight in patients with type 1 diabetes treated with insulin plus either pramlintide or placebo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 440px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p&lt;0.05.",
"     <br>",
"      &bull; p&lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Buse, J, Weyer, C, Maggs, D. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright &copy; 2002 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mean change &plusmn; standard deviation in A1c and body weight in patients with type 2 diabetes treated with insulin plus either pramlintide or placebo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p&lt;0.05.",
"     <br>",
"      &bull; p&lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Buse, J, Weyer, C, Maggs, D. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright &copy; 2002 The American Diabetes Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41073=[""].join("\n");
var outline_f40_7_41073=null;
var title_f40_7_41074="Ut perf bowel in suction";
var content_f40_7_41074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine fundal perforation with suction curette",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Illustration showing complicated uterine fundal perforation with suction curette: small bowel drawn into the uterine cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART. Copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41074=[""].join("\n");
var outline_f40_7_41074=null;
var title_f40_7_41075="Phenazopyridine: Drug information";
var content_f40_7_41075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenazopyridine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/44/11972?source=see_link\">",
"    see \"Phenazopyridine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/23/7539?source=see_link\">",
"    see \"Phenazopyridine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AZO Standard&reg; Maximum Strength [OTC] [DSC];",
"     </li>",
"     <li>",
"      AZO Standard&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      AZO Urinary Pain Relief&trade; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      AZO Urinary Pain Relief&trade; [OTC];",
"     </li>",
"     <li>",
"      Azo-Gesic&trade; [OTC];",
"     </li>",
"     <li>",
"      Baridium [OTC];",
"     </li>",
"     <li>",
"      Phenazo [OTC];",
"     </li>",
"     <li>",
"      Pyridium&reg;;",
"     </li>",
"     <li>",
"      Urinary Pain Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Urinary",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary analgesic:",
"     </b>",
"     Oral: 100-200 mg 3 times/day after meals for 2 days when used concomitantly with an antibacterial agent",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F208710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/23/7539?source=see_link\">",
"      see \"Phenazopyridine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary analgesic:",
"     </b>",
"     Oral: Children: 12 mg/kg/day in 3 divided doses administered after meals for 2 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F208700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer every 8-16 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Standard&reg;: 95 mg [DSC] [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Standard&reg; Maximum Strength: 97.5 mg [DSC] [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Urinary Pain Relief&trade;: 95 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AZO Urinary Pain Relief&trade; Maximum Strength: 97.5 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azo-Gesic&trade;: 95 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baridium: 97.2 mg [contains sodium 0.184 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phenazo: 95 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pyridium&reg;: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urinary Pain Relief: 95 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9603405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of urinary burning, itching, frequency, and urgency in association with urinary tract infection or following urologic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Phenazopyridine may be confused with phenoxybenzamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pyridium&reg; may be confused with Dyrenium&reg;, Perdiem&reg;, pyridoxine, pyrithione",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomach cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, hemolytic anemia, hepatitis, methemoglobinemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenazopyridine or any component of the formulation; kidney or liver disease; patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Yellow discoloration: Drug should be discontinued if skin or sclera develop a yellow color.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; use is contraindicated in patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use of this agent in the elderly is limited since accumulation can occur in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Limitations of use: Does not treat urinary infection, acts only as an analgesic.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phenazopyridine crosses the placenta. Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F208689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F208688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (AZO Standard Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     97.5 mg (12): $3.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Baridium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     97.2 mg (32): $5.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phenazo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95 mg (30): $1.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $2.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phenazopyridine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95 mg (30): $10.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $49.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $92.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pyridium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $118.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $228.19",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F208690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Almax (CO);",
"     </li>",
"     <li>",
"      Anazo (TH);",
"     </li>",
"     <li>",
"      Azo Cefasabal (PE);",
"     </li>",
"     <li>",
"      Cistalgina (AR);",
"     </li>",
"     <li>",
"      CP-Pyridine (HK);",
"     </li>",
"     <li>",
"      Karidine (CL);",
"     </li>",
"     <li>",
"      Nefrecil (PL);",
"     </li>",
"     <li>",
"      Pirimir (MX);",
"     </li>",
"     <li>",
"      Pyredal (NO);",
"     </li>",
"     <li>",
"      Pyridium (AE, BF, BH, BJ, BR, CI, CN, CR, CY, DE, EG, ES, ET, FR, GH, GM, GN, GT, HN, IN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NI, OM, PA, PE, QA, SA, SC, SD, SL, SN, SV, SY, TN, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Pyronium (BE);",
"     </li>",
"     <li>",
"      Sedural (IL);",
"     </li>",
"     <li>",
"      Tiotal (PY);",
"     </li>",
"     <li>",
"      Urogen (TW);",
"     </li>",
"     <li>",
"      Urogesic (SG);",
"     </li>",
"     <li>",
"      Urogetix (ID);",
"     </li>",
"     <li>",
"      Uroprin (TW);",
"     </li>",
"     <li>",
"      Uropyrin (TW);",
"     </li>",
"     <li>",
"      Uropyrine (BE);",
"     </li>",
"     <li>",
"      Uroxacin (CO);",
"     </li>",
"     <li>",
"      Yi Du (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An azo dye which exerts local anesthetic or analgesic action on urinary tract mucosa through an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and via other tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (65% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9761 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41075=[""].join("\n");
var outline_f40_7_41075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208696\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208720\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208698\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208710\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208699\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208700\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208668\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603405\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208684\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208727\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208718\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208687\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208672\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299859\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208679\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801080\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208702\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208689\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208688\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208690\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208671\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208686\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/44/11972?source=related_link\">",
"      Phenazopyridine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/23/7539?source=related_link\">",
"      Phenazopyridine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_7_41076="Varicella-zoster immune globulin (human): Patient drug information";
var content_f40_7_41076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Varicella-zoster immune globulin (human): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=see_link\">",
"     see \"Varicella-zoster immune globulin (human): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/47/1781?source=see_link\">",
"     see \"Varicella-zoster immune globulin (human): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16317530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Varizig&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5088784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      VariZIG&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16337849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to prevent chickenpox infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16337850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to varicella zoster immune globulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to immune globulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have IgA deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This is not a list of all drugs or health problems that interact with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16337851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is made from human plasma (part of the blood) and may have viruses that may cause disease. This drug is screened, tested, and treated to lower the chance that it carries an infection. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older, use this drug with care. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16337852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain where it was placed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16337853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Coughing up blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16337854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16342403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16337855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16337856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88619 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41076=[""].join("\n");
var outline_f40_7_41076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317530\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5088784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337849\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337850\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337851\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337852\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337853\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337854\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342403\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337855\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337856\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=related_link\">",
"      Varicella-zoster immune globulin (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/47/1781?source=related_link\">",
"      Varicella-zoster immune globulin (human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_7_41077="Technique of ray amputation";
var content_f40_7_41077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Technique of ray amputation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 691px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKzAfYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuc8eXV3aaArafdyWlxNfWVsJ41RmRZbqKNiA6sudrt1Bro65r4g/8gG1/wCwtpn/AKXQUAH/AAjmqf8AQ5+IP+/Nj/8AI1H/AAjmqf8AQ5+IP+/Nj/8AI1dLRQBzX/COap/0OfiD/vzY/wDyNR/wjmqf9Dn4g/782P8A8jV0tFAHNf8ACOap/wBDn4g/782P/wAjUf8ACOap/wBDn4g/782P/wAjV0tFAHNf8I5qn/Q5+IP+/Nj/API1H/COap/0OfiD/vzY/wDyNXS0UAc1/wAI5qn/AEOfiD/vzY//ACNR/wAI5qn/AEOfiD/vzY//ACNXS0UAc1/wjmqf9Dn4g/782P8A8jUf8I5qn/Q5+IP+/Nj/API1dLRQBzX/AAjmqf8AQ5+IP+/Nj/8AI1H/AAjmqf8AQ5+IP+/Nj/8AI1aHifWrfw54e1LWb6OV7Wwt3uJViALsqjJC5IGcDuRXCr8ZdETS9UvbrStatf7PsINTeGWOEvJBMQEZCkjLk7gcMwPtQB1X/COap/0OfiD/AL82P/yNR/wjmqf9Dn4g/wC/Nj/8jVjat8R00jStPvtT8M69bjUb2CwsoSbRnnkmDFMbZyqj5cEsR1HvizfePksr7TtNm8P62ddv1kli0tPszTCNMbpGYTeUq+mXyTxjNAGh/wAI5qn/AEOfiD/vzY//ACNR/wAI5qn/AEOfiD/vzY//ACNXOL8W9Guf7BTS9O1fUbvWZLmCC1hSKOSKS3AMqS+bIiqQDnqc/llLb4t6RfWvhebS9K1m/m8RfaVs7aJIUcNB/rA5klVR35DEHHXpQB0n/COap/0OfiD/AL82P/yNR/wjmqf9Dn4g/wC/Nj/8jVt6fcS3VlFNPaT2UrjLW85QvH7EozLn6MRVqgDmv+Ec1T/oc/EH/fmx/wDkaj/hHNU/6HPxB/35sf8A5GrpaKAOa/4RzVP+hz8Qf9+bH/5Go/4RzVP+hz8Qf9+bH/5GrpaKAOa/4RzVP+hz8Qf9+bH/AORqP+Ec1T/oc/EH/fmx/wDkaulooA5r/hHNU/6HPxB/35sf/kaj/hHNU/6HPxB/35sf/kaulooA5r/hHNU/6HPxB/35sf8A5Go/4RzVP+hz8Qf9+bH/AORq6WigDmv+Ec1T/oc/EH/fmx/+RqP+Ec1T/oc/EH/fmx/+Rq6WigDmv+Ec1T/oc/EH/fmx/wDkaj/hHNU/6HPxB/35sf8A5GrpaKAOa/4RzVP+hz8Qf9+bH/5Go/4RzVP+hz8Qf9+bH/5GrpaKAOa/4RzVP+hz8Qf9+bH/AORqP+Ec1T/oc/EH/fmx/wDkaulooA5r/hHNU/6HPxB/35sf/kaj/hHNU/6HPxB/35sf/kaulooA5r/hHNU/6HPxB/35sf8A5Go/4RzVP+hz8Qf9+bH/AORq6WigDmv+Ec1T/oc/EH/fmx/+RqP+Ec1T/oc/EH/fmx/+Rqh+I3jfTPAPh8avrMd1NC0yW6RWqK0sjtkgKCyg8Anr0FZ978SdOjufDMGmadqerzeIbV7uxSz8gZRFVm3GWRADhumexHWgDW/4RzVP+hz8Qf8Afmx/+RqP+Ec1T/oc/EH/AH5sf/kasXVfiK2meINJ0W58JeIf7S1VZGs4layIk8tA8gz9owpUHuRk9M1a8N+PE8RatqNnpmgay8On6hLpt1eMbZYopo8buPO3kcjkKetAGh/wjmqf9Dn4g/782P8A8jUf8I5qn/Q5+IP+/Nj/API1c54T+LekeJLzQYYNK1m1h103AsLi5SEpKYM+YMRysy4weWUA+tekUAc1/wAI5qn/AEOfiD/vzY//ACNR/wAI5qn/AEOfiD/vzY//ACNXS0UAc1/wjmqf9Dn4g/782P8A8jUf8I5qn/Q5+IP+/Nj/API1dLRQBzX/AAjmqf8AQ5+IP+/Nj/8AI1H/AAjmqf8AQ5+IP+/Nj/8AI1dLRQBzX/COap/0OfiD/vzY/wDyNR/wjmqf9Dn4g/782P8A8jV0tFAHNf8ACOap/wBDn4g/782P/wAjUf8ACOap/wBDn4g/782P/wAjV0tFAHNf8I5qn/Q5+IP+/Nj/API1L4InvJbTUodQvpr6S1v5bdJ5kjV2RcYyI1Vc89gK6Sua8Ef8x/8A7C9x/wCy0AdLRRRQAVzXxB/5ANr/ANhbTP8A0ugrpa5r4g/8gG1/7C2mf+l0FAHS0UUUAFFFFABRRRQAUVRv9X03TmVdQ1CztWYZAnmWMn8zU1le2t9F5tlcw3EXTfE4cfmKALFFFFABRRRQBieNNEPiXwnrGiC4+zf2hayW3nbN/l71I3bcjPXpkV5WvwKJ0fULH+27K0F3pSaVjTdK+zRNtkV/PmTzW82U7cbsr1r2+igDyS6+EEV9ommaVeSeHYLSz1S11GSPTtC+zpdrErq0cymZg28Njd254OeN3Ufh3Bb+INK1rwdNY+H72wt5bQQpYB7WWF23FWiRo8Hd82Qw565rvqKAPHW+BulXI0JNTv8A+0ILOfULm/Se2BN9NdoFZwd37sqVUjAY5A5BGaZN8G7qfT/CNpda7p2op4bNylvHqej/AGiKaGVVVUlTzV3FAvDAjJ2nAxz7LRQBnaDYtpmj2lky2S+QgTbZW32aAeyR7m2j2ya0aKzrvW9Ls7gQXmp2NvOcfu5Z1RvyJzQBo0Vi3cc2o6rJbNPJHYQRKXWFyjSSMTwWHIAAB4Izu56U5fDunoQ0S3EUg53x3MgP1J3c/jmgDYornotTfSZp7bWp/MVE82C52fNMu4LtKqOXDMowo+bcuBnip1utauvmt7G2s4j937XKWkP1ROB/30T6gUAbVFYg1O8spY01m1jjikYIt1bOXjDE4G8EApn15HqRxW3QAUUUUAFFFFABRRRQAUUUUAFFcfc6tf6tqhttKRvsyAsGVxGJQGKks5ViqZDAbQWJBOVGNz/7M1WNjItopb0TW7kkfQMm0/QgCgDraK5fR9ZuY7kWuo+ayGX7OssqqssUu0MI5dvynKkFXXg9CAcbuooAKKwNb8T2OkzCGVt82QCDIkaITzhndlXPfaCTjnGKr2Hi21uHxKkYiyAbi3uI7iJCTxvKElfqRgdzQB09FFFAHCeOfh7b+NPEuh3ms30p0nTFlYadFviMsrjAkMqOrDaOgA9ecEiuY0X4J2lpceGk1jULbWdJ0Jrxbexu9PV1eKfBVGLOQShyQ2OeOBivYqKAOO1TwTBd+MvB+t2lxHZW3hyO5iiso7cbXWWIRgAggIFA4ABz04rB8MfC9tB8Yapraz6BeG+1WbUvMudF3XkAkP8Aq47jzvlA9dnUtxzXp9FAHj3gX4LReC7/AMO6hpGsRpqOnrNBfzCxAXUYJJC4VlD/ACsuQA+T90ZGABXsNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc14I/wCY/wD9he4/9lrpa5rwR/zH/wDsL3H/ALLQB0tFFFABXNfEH/kA2v8A2FtM/wDS6CulrmviD/yAbX/sLaZ/6XQUAdLRRUVxPHbW8s87BIo0Lux6KAMk/lQBga7qs6XsVhZM6M7BHmRA7hiCRGgPAbClstwBj+8KqGynzk6d4gdv77aoqk++0S4H4CkjjeCz0e+u12XFzqIupw3BQyRuiqf90MiZ/wBmuwzQByEWp3mlTn7UL1rZIzLLDd+W0scYIDSI8ZIYLkZU/NjkZ6HU1y5lmltrCylaNrhHlkmjPzLEuM7T/eJZQD2GT2pZpIpfFltGrKzx2U/mKCCVDPFjI98N+RrI8M5h1WytW/5dra6tEz12xToqfjs2GgCTw5occukWlyby7jFzEkzR28giUFgD95QGbr1ZiT3NOu9GEep2qSXc7GbckM5wJ4XALDEgwWXCtlWyDxnjipLuy8IR3EiXUWixz7suj+Wpz7j1pt9Z6ZZWKvoFrYwXt2wtYbi2jTcm8/MwIHO1QzY77aAK9r460e3T7LrGoQxajFI8MyxoxUsrFc5AIAOM4J4zg11VndQXluk9pNHNC4yrowIP0Ncx4VbR9M0mewme0tpFnmEsEzKrAeY20MGPI27QCeoxVLw9FBpmvTXOkAR6NqF4bdYoz+6LCEN5qDoBuR044PHoKAO7ooooAKKKKACiiigAooooAxdaeW5vrTSoZGiFwryzupw3lIVBVT2LF1Gew3YwcGtK0s7e0thb2sEUUAGAiKAPyrC1HUrGDxfpSm7g86RJrNohIN4ZtjqSOoH7ph9WFdLQBzGgQJpfiPVNMiJEDxRXduh4CKS6si+wKg47BgBwBXT1zHiuyL6jo9/BcS200MxtvOjwcLLxhgeGG9Y+D+GDg1eNnrco2zavbRxn+K1stj/m7uP/AB2gB+oQxXGvaUJEUyQLNcRk9VIAQ/8AoytasNYjB4j02MySShbG4XfIcsx8yHkn1rcoAinijnhkimQPFIpVlYZDA8EVk6LJJZ3Emk3TMzRKXtpGOTLDkDk/3lJCn/gJ71t1jeJVeGyTUYAxmsGNxtXrIgB3p75XOB/eCntQBs0UyN1ljV42DIwBUjkEetPoAKKKKACiiigArL8RTGPSpIomZZrpltYynVS5C7h/uglvoK1KxtQH2jxLpUB5WCOa7PswAjX9JH/KgCs7Wuja9bmZ4rWzls1tomdgqBkb5Uye5DnA6nB9K6BSGUMpBU85HOaivGjS1laaMyxhSWRULlh6bR1+lc9Zad4Yv52SLRLYS4LMJdMMWR77kANAEVwVuLPxReQgSLG+YSOQ0kMakEH2kBH1WuqikEsSSLyrKGB9jVHUo4bXQbuOONI4I7ZwEUABVCngelJYObbw9bvJ96K1Vjn1CCgDB0mG5+xaVrFpB9qeYTTyRBgrMs5DggnjIwowSOPpVy8in1S/0syaTNAkEzSSyTtEQE8p12gK7E5LAYxjGa0fC8Xk+GtJiPVLOFT+CCrt5OlraT3EnCRIZG+gGT/KgDiNH8caBpli1jf6lsksppbU7o3O1UkZVycf3QOeldxbzR3MMc0EiSQyKGR0IIYHoQfSuU0n+2F8MxWR0iLzpYTvke5Ux7nBLEjGerE4xVywtv8AhHLm0tYznTrnEXOf3c+D82M8B8dP73PVjQB0lFFFABRRRQAUUUUAFFFFAEF5dQ2drLcXLiOGNSzOegFZa3GtXfz2tta2cB5Q3RZ5GHqUXG36ZJ9QDxS3kZv9ehtn/wCPWzRLpl/56SMzBPwXYzfXae1bVAGZpN9LcPcW95EsV5bsBIqMSrAjKspx0PP0IIpup3s8dzDZaekcl5MpfMpISJAQCzY5PJAAHX1ABNMdPL8WwOvAnsnDj18t02/+jGp8CZ8UXsh7WVuo/wC/k2f5CgCP+yLub5rvWb0ueogCRIPoNpP5k1DJJd6J+/u7qW80wD968ir5luP75Kgbk9eMjr0zjfpCAQQRnPagBFIYAg5B5yO9OrC0gf2XfHSNzfZyhms89FjyA0Q/3SRj/ZYD+HNbtABXNeCP+Y//ANhe4/8AZa6Wua8Ef8x//sL3H/stAHS0UUUAFc18Qf8AkA2v/YW0z/0ugrpa5r4g/wDIBtf+wtpn/pdBQB0tY3i0b9DkgP3LmWG1ceqSypG36Ma2axvFfy6I8p+7BNBcN/uxzI7fopoA07m3huoHhuYklhcYZHUMCPpWZ/wjeljGyGZFHRI7mVFH/AQ2K2aKAKlhYWunxGKyt4oEJyQigbj6n1PvXNWfyeMZCvQ3s0f4G2gc/wDjy12Ga47Qj9p1ewueD9o+2Xqn1jLokTfjHtNAHWNBE2d0SHPJyo5rIms7OLXdPjhghhYCW7JjULuZVEeTjrxKamm8RaRDK8c+oW8bIxVt7bQpBwQSeKghlju/FMcsMiSRLp+5XU5DCSQcg9x+7oA01FnfKJFEFwBwGGHA/GsDxqtpdPo2k3k5giurrc2yUxHbEjPwwII+YIOOxrYvNG0+7Iaazh8xeVlRdrr9GGCPwNU9OiTUdX1C9mQSQxEWcAYZGEOZGHuX+U/9cxQBzttNa6LqYm8OXkl9pMUDvfw/apLoR4ZMOjszbWALnZnkA4GcV3qsrqGUgqRkEcg0YG3AAx0xWR4R+XQLWHtbF7UfSJ2jH6LQBs0UUUAFFFFABWNrE8897b6ZZyNFJIplnmXGYogccf7THgHsNx7Vs1z2j6nZ3HiHWoftds15FMlusQlXfsWJH+7nP3pHoA0P7IsRpxsUgVbc4OFyDuByG3dd2ed3XPOc1jwxas+sSaZe6r/oyxLNFJDAI5pVyQys+SOOMlVU/MMEV1NYM1zGfG9nbKczLp88jADoDJEBn8moAfrOnxxeF7u1s12eVCXi5JIdfmU5PX5gDWraTi4tYZl+7KgcfQgGsTxjrVlpGi3Ru7qGGaWJkhRmALOQQoA+venWPiDQrayt4P7XsQIo1QFp1A4AHXNFx8rSu1oUvEdzJaeLdCuAcW8aTLOP9mRokB/Byh9hmusrlL/UdG1HUrJFvbO7jukmsWSKZXyHUNg4P/TMj8a1PD88xgeyvmZr2zIjkdusq87Jf+BAc+hDDtQKxr0hAIweRS1la/rNvolg1xctlj8sMK/flfsqj+vQDk4AJoAj8IceHrSLqsG+3UnqRG5QH8lFbNUNCs3sNJtbaVg0yIDKw6NIeWP4sSav0AFFFFABRRRQAVjj5fFx3f8ALWxG3/gMh3f+hrWxWNqw8nXtEuB1eSW1P+60Zk/nCtAFi+vprWULHpt7dIRkyQmLAPphnB/TFMg1V5ZkjbTNQi3HG6RF2r9SGNalFAGV4mZf7DuonOPtIFqCOzSsIwfzcU7xERD4c1Nl4CWkpHthDWbrV9b/APCU6Np88gjVVkuyW4UuBtjQk9zukYDr+6J7UniHU7TUNL1HS9OuY7zUZ4HgWGBg5jZlIBcj7i85y2PbnAoAlvEvVS0is4L2RFhUHy544ogcfxH7+foMVLqMT/8ACLXcNwX8yWB4yGk3lS4IwGwM9euKtXunTzyh7fU7u0AULsiEZU+/zKeayvFrSaV4QuZpLma5aCSKQvJtDMPNQ4+UAdOOlAGpdyaqk22ws7GSAAYea6aMk46bRG2B75/CqfiQzt4ZmluY44rmIpNtSQuqsjhhhiBnp6Ct1WDKGU5BGQa57x/KYvCt2FmjhaR4ohJIwCqWkUZJwcdc0AdHRXH6D4g1OKK4/wCEhs3FrFtaPUooWSORT1Lxt86be5I245yBwOuVg6gqQVIyCOQRQA6iiigAooooAKzNQ1IwXCWtpAbq+ddwiDBQi5xvdj91c+gJPYHBxeuZo7a3lnmbbFGhdj6ADJNZnhyCRbI3dwu27vG+0TA9Vz91f+ArtH4e9AFI2mvpqT6irabueERNaZkw21iVPm9j8zD7nerEWtz3ESvaaRfTblGfmiVVbuGJfPByDgHkHrW7WP4X/wCQZLxjN7dkfT7RJzQBU8P/AGu61bU7rUxEt1bOLWKKFiyRxlEkPzEDcSWGTgfdGB1zp23Ot35PURQgfTL/ANc1W0/934l1ePtIkE/4kMn/ALIKr6vfR6JrKX184j0+6jS2eZvuwyBmKFj2Db2GegIGetAHQ0U1WV1DKQVIyCOQadQBi+KlMem/b4+JtPYXSkddq/fH4puFbIIIBHQ81keK5MaFdQIA010htYl9Xf5R+Azn6CtWNAkaqOQoAFAD65rwR/zH/wDsL3H/ALLXS1zXgj/mP/8AYXuP/ZaAOlooooAK5r4g/wDIBtf+wtpn/pdBXS1zXxB/5ANr/wBhbTP/AEugoA6WqGv2pvdC1G1HBntpIgf95SP61fpkrrHE7ucKqlifagDIis7TXbGxvbtHljkgRxEzt5R3AHJTOGPPUg07/hGNB/6AmmZ9fssef5UvhFCnhXRlcYZbKEEH18sVr0Aczr9nILCHQtEEFqbvcGJBxFAMb2CgjJO5VABGN2c8Vg/D/wC1y+MPFP265a4Nm0VpCSoUImCdqqOFHTtn1JrqtIBu9V1HUGHyq/2SAn+4h+c/i5YfRRXP+FD5HxH8Z27Y/eG1uE9SDGQf1rObalH+uh2YaEZ0q11qopr/AMCiv1O6rjtL1KSf4ma5Z5UxQWVuBxyDlj1/4HXWyOsaM7sFUDJJOAK8++F0LX+o+JPEjM0kWpXZjtmYY3QxkgED8cf8Bom/eikPDU4+yq1JrRJJera/RM9DchVJJwAMk1j+DpkuvDGnXaDb9qi+1MPRpCXb9WNWfEUxt/D+pTKcGO2kYH3CnFUvBMfk+Ho4RwsM9xCB6BJ3UD8hWhxG9WD4SuYX00Is0bSvNPNsDDcFeZ2Bx6YYVrahcC0sLm4bhYY2kP0AJ/pXC6V4GljtNOki1H7K9skUsAhg2vHIIwGDtuw6sdxORk5xmgD0KiqGj3pv7TfIoS4jYwzxj+CReCB7dwe4IPer9ABRRVbUrgWenXVyeRDE8n5An+lAGTLu167ntw8iaXbuY5CjFTcyDquRyEXocdTx0BDXpdH06SxWzaxtvsq/diWMBUPYqB0PuORSeH7X7HollA3MixAue7ORlj+JJNO1bUYtOhVpAXlkby4YU+/M/OFUfQZz0AyTgA0Ac5Bc6nYwX6S6zb+VaXJt1+02hmkYFVaNVKupZtrqOQSTzUfh/QNUnRLrVrqW0uJDIZ/LYedNuIwGcDCKFVRtTkf3s5rW0HQfss8uoak/2jU55XmJ6pBuAGyMeyhV3Hk47DCjoaAPOfiXpdjpfh20uLO2jikj1G2lebGXYh+rseW69STXo1cl8U7J9Q8AaxHFnzI4hOpXqPLYPx/3ya3ND1BNV0axv4vu3MKSj2yAcVktKjXkjvqe9gqb7SkvvUWv1OQ+JtnbXmpeEra4t4p1m1NQ6SIGDoFOQQeo56VtXPhKzFzHc6Vc3mlXcalVe1kym087TEwKbc9sD2IrL8Tn7d8S/ClinItY7i9lHoNoVD/31XdUQ+KT/rYMX7tChH+6398n/kYF5LqMNsYdQtnuoGGHuNPdo5B7+XncP+AsT7VR1jTrCHwlrF7Yws00ljKwnlLPKwCkgFnJbGR0J4rrahu7dLq0mt5RmOVDGw9iMGtTgJQQRkcilrL8MTvc+H9OkmP78wIso9JAAGH5g1qUAFFFFABRRRQAVj+Jvlt7GUfejvrfH/ApAh/RzWxWN4g/eTaRbdpr5Cf+AK8o/WMUAbNFFFAFB9Mtpby6uLhFm+0RRxPHKoZNqFyOMertWJZ295a+MHSI2NvaTWqsYUhYkhHI4bcAD84/hNdVXEXa6BD42tWby57tYZi+N07xyeZEVz129T6YoA7eoLq3iuoTFcxrLExBKsMgkEEcfUVPRQAgGBgdKx/EQDSaSh5Vr5M/grkfqBWzWXr9vLPbW7W6b5YbmGYKCASA43f+OlqANMgEEEZB7GsXQR9hu7zSR/qbfbLbj+7E+cL9FKsB6DaK2xWBqc6WXifTZ5Q4huIZLZpAMqr74/LDHtklgPcgd6AN+iiigAooqhrN8bCwkmRPMmyEijzjfIxCqv5kc9hzQBn+Irlry2vNGsYzPe3EDI5zhIFcEBnb9cDJPpjmpwutwqX36fcgDiBY3hP/AH2WbP8A3yPwqzpFiLG08ssHuHPmTy4wZZDjLH6+nYYA4Apmuah/ZtiZEia4unPl29upAaaQ5woz06ZJPAAJPANAGDqfiC9uNEurzTrdrK2gJW4uLnAePa+2UInILKA3J4yOAwq/p1/IbaCDQ9OlmtY1CLcXMhiRgBwQSC7fXbg+tReHvDskNnA+vSx3l6rtMUQEQxyMSzFVP3juJO49OwUcV01AHJaump2N22qy6zo9gHjEBFxaPIuASwG7zk55aoNJutT8T+GbSZpdKnMxhmaSAugiYFJCu078kdOo/Cuj1xbt9NmGnyQRybGy00ZcY2noAw5/GoPCYuB4d077XJDIxgjKmJCi7doxwWPP40AXLGxtrGJo7SFYYmYvsTO1T3wOijjoMDPPU1coooAx9X+fW9DjPQTSS49xEw/9mrYrG1kiPWNEmbhfPeEn03Rtj9VArZoAK5rwR/zH/wDsL3H/ALLXS1zXgj/mP/8AYXuP/ZaAOlooooAK5r4g/wDIBtf+wtpn/pdBXS1zXxB/5ANr/wBhbTP/AEugoA6WsfxYzf8ACP3kSEq9yFtFI6qZWEYP4F81sVjeJjmPTUP3Xvoc/g24fqooA10RUQKoAUDAA7CnUUUAFcDrbf2L8T9H1J+LXVbZtNlbsJQd6Z9z0rvq5vx3ov8Ab3ha9s48i6A822YcFZV5XB7cjH0NZ1Itx03R2YCpGFblqfDJOL8k+vy3+Rl/E+8mlsLPw/p7Yv8AWpfs4I6pEOZG+m3j6E11emWMGm2FvZ2abLeCNY419ABivOvhfcz+LNYu/FOpR4eCGOwt1PRSFBlYfVj+RxXqVTSfPep329DfMIPDKOD6x1l/if8AkrL1uNZQykMAQeoPNRWlrFaRGOBdqNI8hGc/M7FmP5sTU9FbHmHP+OrmO18K3zXB2wShLeRh/CkjrGx/AOTXQVna7pkWr6a1lcf6l5I3dcZ3BJFcqfY7cfjVu2h8i3ii3u+xQu9zlmwMZJ9aAMy2HkeLL1F4W4tYpSB03KzqWPuRsH/Aa2a5SG/kHjCa5Kg6fIF01JO6zpucnP8AdO7Z7OmO9dXQAVR1uH7To1/ADgy28iZ9MqRV6sXxE7T+RpUJ/eX25ZD/AHIAB5jfkQoPYuD2oAvaRN9p0qznxjzYUfHplQao2GjCHW73VblvNu5j5cRJLCGEY+Rc9MkbjjGeBzjNbEaLGiqgCqoAAHQD0p1ABRRRQBHIiyoyOAyMMEHoRXnWmQeI/Bfnadpmk/23oxdpLRluVjkgBOfLbd1AJOCP/rD0miolDm1vZnTh8S6KlBxUovdO9tNno07/AD6nF+C9E1CPUdQ8QeIhGuq3wWNYY23LbRL0QHuSQCcf412lFFOMVFWRGIryxE+eXpZbJLRJegUUUVRiZGhxta3WqWjcItyZ4h/sSAMT/wB/DJWvWNkxeLyP4bixHHvHIf8A47WzQAUUUUAFFFFABWLd/vPFmmIeVjtLiXHo26JQfyZ62qxjn/hMFz0+wnH/AH8Gf6UAbNFFFABXP6leXcPiG0EGmTTgQSqH8yNQcmM8ZbPbuBXQVz+rR6o+t2Js7qyhj2yKBLbNKegz0kX0oA6AGikGcc9aWgAooooAKqapZpqGnXNpKSqTRtGSOq5GMj3HWrdFAGfoF5JfaRazzgLcFSkyjosqkq4/BlYVoVj6Chhu9YgxiNLwvGPZ40cn/vtnrYoAKxdV/ea9osTfcV5ZserKmB/6Ga2qxZM3viWLy8eVp6EyOOcyOOE9sL8x/wB5aAJdba4ktxZ2cLtNcgp5mSqQrxl2YEcjPAByT0wMsrNE0Cz0lAYjNPc7drXNzK0sjDOSNzE4HsMD2rYooAKKKKAMjxElpJZql+l48bNhRbLMxzg9RFzj68Vn/DxrdvCem/ZReAfZ4i32lZRyY1zt8zqv+7xXT1Fbwx28McMCLHFGoVEUYCgDgAUAS0UUUAU9Tso9QsJrWUlVkHDr1Rgcqw9wQD9ai0W7a806N5iPtMZMU4AwBIhKvj2yCR6jBrRrFs/9F8UahAOEu4kul93X92/6CKgDarmvBH/Mf/7C9x/7LXS1zXgj/mP/APYXuP8A2WgDpaKKKACua+IP/IBtf+wtpn/pdBXS1zXxB/5ANr/2FtM/9LoKAOlrG8VnZpkU3Tybu2kJ9FEybj/3zurZqnq9mNR0q8s2O0XELxE+m5SM/rQBcoqhol4dQ0mzumXY8sas6f3Hx8y/UHIq/QAUUUUAcN8I1WLQNRgVQph1O5jOOmQwrua4b4Z/u5vF0BHC65cMMdAGC8V3NZUfgR35pri5vvr96uFFFFanAFFFFAGZrVn5+j3UVuiCYKZYeOBKp3o3/fYBq1p10l9p9tdxfcniWVfoQDVmsbwh/wAi3Yenl8fTJx+lAGzWLoo+16lqWovyDKbSD/ZjiJDfiZPM57gL6VtVm+HwBotmw6yxiY/V/mP6tQBpUUUUAFFFU5HnmneGFljVANzkZOT2A+nc/lQBPNNHBGXlcKvTJPeq4M9yQVBgh9x87j/2Ufr9DUsFrHE2/l5Txvc5P09h7VYoAqtbMq/uJpUbr8zFwfb5s/pimi4ni4ngJA/jh+Yfl1H05+tXKKAIIriOT7u8H0ZGU/qKnoooAx7vnxbpuOos7jP03w1sVkRIZfFE8vVILVIwfRnZiw/JU/OtegAooooAKKKKACsa7/d+K9Mc8JJa3EWfVt0TKPyVzWzWP4jUomn3ajLWt5E2PZyYmJ+iyMfwoA2KKKKACud1mxuZtb05o9VvLdWZ1CRJEQvyEk5ZGP610Vcd4pbw+mv6YdUjsnuGkZXM0YYhfKcjJI4HFAHWxqUjVWcuQMbmxk+/FSU1MbRt+7jjFOoAKKKKACiiigDMt2x4hvox0+zQOfqWlH8lFadZNuP+Krvz2+xW/wD6MnrWoAz9Zvjp9iZI4/NuZGEUEWceZI33RnsO5PYAntRo9gNPskiZ/NnYmSeYjBlkPLMR2ye3YYA4FViTc+KdhwY7O2D4PP7yRiAfqFRh9GrZoAKKKKACiq11O0RRIkDyyHCgnAx6n2qP7JJLzdzs4PVE+Rf8T+dAD5byNXMaBppR1jjwSPr2H4kU3zrtfmktVK+kcm5h+BA/nVmONIkCRoEUdAowBT6AIoZ45h8jAkdQeCPqO1S0hUHqM0tABWNd8eLdLPrZXQ/8fg/wrZrHb994vjx/y62L7v8AtrIuP/RDUAbFc14I/wCY/wD9he4/9lrpa5rwR/zH/wDsL3H/ALLQB0tFFFABXNfEH/kA2v8A2FtM/wDS6CulrmviD/yAbX/sLaZ/6XQUAdLRRRQBj6HH9lu9TsztCrObiId9kuWJP/bTzfwrYrGvP9F8T2E44S7ie1f3ZfnT9BJ+dbNABRRRQBw3gb934v8AGsHpeRSf99x5/pXc1w/hpDH8TvGQx8ssdlJnHpGV/wAa7isqXw283+Z35jrWT7xh/wCkRCiiitTgCiiigCrqlyLPTbu5PSGJ5PyBP9Kh0C2Nnoen2zfeigjQ/UKAaTxCobQNSVhlTbSAj6qa0aACs3w6wbRrZQc+UDCfqjFD/wCg1pVjeG/3a6lan71vfzZP/XQ+cP0lFAGzRRRQAVFCm15W/vPn9AP6VLRQAUUUUAFFFFABQSByeBRWN4hEl1FDpkBKteMUlYHBSAD94R7kEKD2Lg9qAE8MEz2c+otn/iYTG5Uf9M8BIz7ZREOPUmtqmRosaKiKFRQAABgAU+gAooooAKKKKACqWtW73WkX0ERxJJA6IfRipANXaKAKmlXQv9MtLteFniSUD0yAat1jeFPk0nyO1vPNAB6BZGC/pitmgArnPEP9qPqujnT7CKeKG4MjyST+WADDKuOFY4yy8+uK6OigCKAyNCjTIscpALIrbgp9AcDNS0UUAFFFFABRRRQBm26/8VDfOOn2aBfxDSn/ANmFaVZOkOZdU1sn/lncpEPp5Mbfzc1rUAY2m8eI9ZB6lIGH02t/UGtmsdf3Xi5x2uLIH8Y5D/8AHK2KACiiigCuibruSU/wqI1/mSPzA/CrFFFABRRRQAUUUUAFY2hZubzU9RYcTTeRFnr5cWV/9D8w/QipPEF1LbafstTi8uXFvB3w7fxfRRlj7LV6yt47Ozgtoc+XCgjXJycAYHP4UAT1zXgj/mP/APYXuP8A2WulrmvBH/Mf/wCwvcf+y0AdLRRRQAVzXxB/5ANr/wBhbTP/AEugrpa5r4g/8gG1/wCwtpn/AKXQUAdLRRRQBjeKfksbe4H3re7gkz6DzArf+Os1bNY/i4f8U5fn0j3fkQa2KACiiigAooooAKKKKACiiigDO8Qf8gS+HdoWUfUgitGsnxNIU0xFHWS5t4sezTIp/QmtagArFtv9H8VXkZ4S7to5lH950Yq5/JohW1WNqw8nXNEuB1aSW1Y+iuhf/wBCiWgDZooooAKKKKACiiigAooooAKxof33iy5bqLazRF9i7sW/RErZrG0jnXNdY9RLEg+giU/zY0AbNFFFABRRRQAUUUUAFFFFAGNoHy3Osx/3L5iP+BRo3/s1bNY+jYGr68o/5+Yz+cEdbFABRRRQAUUUUAFFFFABRRWdr949ho13cQDdOsZWFT/FIeEX8WKigCv4V/eabLcnn7VdTzA/3kMjBD/3wErZqrplomn6baWcRJS3iSJSepCgAfyq1QBmXYVNe0+VurRTQj6ko38kNadY2uErqWgN0H25lP0NvN/XFbNABRRRQAUUUUAFFFFABRRRQBiwKt54juJy25LBBbqpH3ZHAdz7/KYwD/vVtVjeF/n02W4PJnup5c+o81gn/joUVs0AFc14I/5j/wD2F7j/ANlrpa5rwR/zH/8AsL3H/stAHS0UUUAFc18Qf+QDa/8AYW0z/wBLoK6Wua+IP/IBtf8AsLaZ/wCl0FAHS0UUUAY3i7nw/dKOrlE/76dR/WtmsbxV82nQR/8APS8tl/DzkJ/lWzQAUUUUAFFFFABRRRQAUUUUAY2s/v8AV9FtV5xM9049URCP/Q5IzWzWLa5ufFN9L1jtIEtlPo7kvIP++fJNbVABWP4oB+w28i/ejvbVgfQecgb/AMdLVsVFNEk8ZSVQyZBIPqCCP5UAS0UUUAFFFFABRRRQAUUUUAFY+j/8hnXh/wBPEZ/8gp/hWxWfZ2jw6tqFwSPKuBGVAPIZQQf020AaFFFFABRRRQAUUUUAFFFFAGRpH/Ib13/rtF/6JSteoY4I4pZZI0CvKQzkdWIAAz+AAqagAooooAKKKKACiiigArH1ZRd6npdmW+VZDdyL/fWMAKPwd42/4DWxWLpP+lazql8eUVls4j7Jksf++2Yf8BoA2qKKKAMrXYJJlsGhQs0V5E529lyQx/ImtWiigAooooAKKKKACiiigAooooAgsraKytYre3XbFGoVQSScfWp6KKACua8Ef8x//sL3H/stdLXNeCP+Y/8A9he4/wDZaAOlooooAK5r4g/8gG1/7C2mf+l0FdLWD4z0+81TRBBpgga7ju7S6RbiRo0bybiOUqWCsRkIRkKeaAN6iua+2eMP+gF4f/8AB1N/8iUfbPGH/QC8P/8Ag6m/+RKANPWLaW6k04RgFI7pZZMnGFVWIP8A31trSrmvtnjD/oBeH/8AwdTf/IlH2zxh/wBALw//AODqb/5EoA6Wiua+2eMP+gF4f/8AB1N/8iUfbPGH/QC8P/8Ag6m/+RKAOlormvtnjD/oBeH/APwdTf8AyJR9s8Yf9ALw/wD+Dqb/AORKAOlormvtnjD/AKAXh/8A8HU3/wAiUfbPGH/QC8P/APg6m/8AkSgDpaK5r7Z4w/6AXh//AMHU3/yJR9s8Yf8AQC8P/wDg6m/+RKANmws0s2uWDM73Exmdm65IAA+gCqPwq5XNfbPGH/QC8P8A/g6m/wDkSj7Z4w/6AXh//wAHU3/yJQB0tFc19s8Yf9ALw/8A+Dqb/wCRKPtnjD/oBeH/APwdTf8AyJQB0tFc19t8Yf8AQC8P/wDg6m/+RKPtvjD/AKAXh/8A8HU3/wAiUAdLRXNfbfGH/QC8P/8Ag6m/+RKPtvjD/oBeH/8AwdTf/IlAHS0VzX23xh/0AvD/AP4Opv8A5Eo+2+MP+gF4f/8AB1N/8iUAdLRXNfbfGH/QC8P/APg6m/8AkSj7b4w/6AXh/wD8HU3/AMiUAdLRXNfbfGH/AEAvD/8A4Opv/kSj7b4w/wCgF4f/APB1N/8AIlAHS0VzX23xh/0AvD//AIOpv/kSj7Z4w/6AXh//AMHU3/yJQB0tFc19s8Yf9ALw/wD+Dqb/AORKPtnjD/oBeH//AAdTf/IlAHS0VzX2zxh/0AvD/wD4Opv/AJEo+2eMP+gF4f8A/B1N/wDIlAHS0VzX2zxh/wBALw//AODqb/5Eo+2eMP8AoBeH/wDwdTf/ACJQB0tFc19s8Yf9ALw//wCDqb/5Eo+2eMP+gF4f/wDB1N/8iUAdLRXNfbPGH/QC8P8A/g6m/wDkSj7Z4w/6AXh//wAHU3/yJQB0tFc19s8Yf9ALw/8A+Dqb/wCRKPtnjD/oBeH/APwdTf8AyJQB0tFc19s8Yf8AQC8P/wDg6m/+RKPtnjD/AKAXh/8A8HU3/wAiUAdLUFpbRWkAit02oGZsZzyxJPX3JrB+2eMP+gF4f/8AB1N/8iUfbPGH/QC8P/8Ag6m/+RKAOlormvtnjD/oBeH/APwdTf8AyJR9s8Yf9ALw/wD+Dqb/AORKAOlormvtnjD/AKAXh/8A8HU3/wAiUfbPGH/QC8P/APg6m/8AkSgDpaK5r7Z4w/6AXh//AMHU3/yJR9s8Yf8AQC8P/wDg6m/+RKAOlormvtnjD/oBeH//AAdTf/IlH2zxh/0AvD//AIOpv/kSgDpaK5r7Z4w/6AXh/wD8HU3/AMiUfbPGH/QC8P8A/g6m/wDkSgDpaK5r7Z4w/wCgF4f/APB1N/8AIlH2zxh/0AvD/wD4Opv/AJEoA6Wiua+2eMP+gF4f/wDB1N/8iUfbPGH/AEAvD/8A4Opv/kSgDpa5rwR/zH/+wvcf+y0fbPGH/QC8P/8Ag6m/+RKl8H2F/YWt82qx2sVzd3kt0Y7aZpUQNjA3MiE9P7ooA6CiiigAooooAKKKKACiiigAooooAKKKguz+7Cf89Dt/Dv8ApmgCfNGRURcCmGUUrjsyfcKM1XMwpPNFFx8rLG6jNVjMKQyilzByss7hRuFVDNSedRzD5WXN1JuFU/OoM1LmDlZc3Ck3Cqfn0nnUcw+Qu7xRvHrVLzqTzfejmDkLu8Uu8VR82jzaOYOQu7xRvFUvNo82jmDlL28UbxVHzaXzqOYOQvBxRuFUhNSiajmFyl3dS7qpialE1O4crLmaM1VEopwlFO4uVlnIoyKgEgp28UXFYloqPcKXdTCw+im7qXcKBC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmXtxtutoPCrz9T/8AqrSJABJ4FcZLe+dPLIDw7Fh9O36VE5WRrShzM2Wuvem/aCe9ZSyk08Se9Zcxv7NGl53vS+d71niSl8yjmFyF4zU0zH1qnvppelzD5C4Zj60hlNU9xo3UuYfKXPONJ5xqnuNG+jmDlLnnGjzap76Nxo5g5S55tHm1U3GjcaOYOUt+bR5tVN1G6jmDlLfm0eb71V30bzRzBylvzTR5tVN1G6jmDlLnm0vm1T30bqdw5S6JqUTH1qlvo30+YXKXxMacJqz99L5lHMLkNIT08T+9ZPm+9L53vT5hchsCaniYetYwn96eLj3pqZPszYEw9acJhWP9pHrThcj1p8xPszaWQetSBs1iJdgd6tw3anqatSIcGjSoqKOQMODUoOaogKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3XrkWukXL9yuwfVuP61xVu2a2vHdyVW0tlP3mMjfQDA/mfyrDthxXLVd5WO/DxtTv3LytUqtUK1ItI0ZKGpd1MBpRQSOzRmim0AOzRmm0UAOzSZpKKAHZozTaKAHZozTaKAHZozTaKAHZozRSZoAXNGaTNGaAHZozTc0ZoAdmjNNzQTQAu6gtTM0jGgLDi1NL1GzUxmpDsTebR5vvVYtTS1K4cpZaak8/HeqbPUbSGnzByl/7UQaljvMHrWM01R+eQetLnBwudhaXw4ya2Le5DDrXn0N4VPWtex1LBALVrCoYTonag5GaKpaVKZ7QOTn5iP1q7W6dzlas7BRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUcsixRM7nCqCxPtQB534kuPtXiKfBykWIh+HX9SafbrwKzIHNxdSzMPmkcuR7kkn+da0I4rhvdtnrcvLFRJ1FPApFFPAqyGKBS0UUEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABmkNFITQAUwmnE0wmkNDWNQu1SOeKhY0mUhpNMLcUrGo2apGIzcVE7UrmoHPFAxjtUDPQ7dars1SWkS+aQetSJdlD1qizVE74pXHy3PVvBs3n6MGzn52H8q3q5L4bSb9Bmz2uGH/jq11td9N3ijyaqtNoKKKKszCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArF8XXP2bQLsg4Z1EY/4EcfyzW1XG/EWfEFnbA8u5cj2A/+vUVHaLZrRjzVEjmtPXgVsRCs2wXCitOOuSJ6U2TLTxTBTwasyYtFFFAgooooAKKKXFAC0mKWjFACYpKdiigBtFLijFACUUUUAFFFFABRRRQAUUUGgBpqC3uY7jzfKOfLkMbfUdadeTC3tppm+7GhY/QCuf8ADKvBcSRydZ4hMf8Aezhv51m5pSUe5SV0dETTCaUmmE1bENY8VC5qRjxULVJQxqYxpWpjUiiNjUEh4qVzUEh60hldz1qs55qeTvVd6ktEUjYqCRuKkkqu/SpZaPSfhY+dHu19Lgn/AMdH+FdtXn/wolBh1GPuGRsfgf8ACvQK9Cj8CPIxCtUYUUUVoYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5148lEmvwxg8RwgEehJP9MV6LXlPiKbz/FF8c8K4QfgAD+orGu7ROrBq87+RasxhRV+OqNp90VeSsEdkiUU4dKYKeDVGYopaQdaWgQUUU6gBMUtFLQAUUAUuKBCUYpSKTFACUUtGKBiUUUhoASiiigAooooAKSlpKAMfxPMU08Qr96eQJ+Gct+gxVWAmKTT5zwGdoT+I4/UCm61J5+rpHn5LeLcf95j/gKlYCfw9I8TBpLeTzAQQSCD39DiuGcr1fQraxsMaYTSRyCWFJF+66hh9MZpDXYCGMaiapGNRN0pMojao2NPaozSGhj1C9TNUL0hlSSqr1blqq9Sy0QPULCpmFRsKllo674VybdTvYv78Qb8j/8AXr02vJfh3KIfE0anpLEy/jwf6V61XdQd4Hl4tWqBRRRWxzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4w8vn6veS9fMnds/VjXsc0gjhdz0VSTXiml5LAnqeTXPiOh3YJfEzpbUfIKuLVW2Hyj6VZWskdD3JQaeOlRqaeKohjxS0gpaCQpRSU6gAFLRSgUAwFOoooJCkNLRQMbikpTSUAIaKWkoGNopcUYoASilxSUAFN7U6s/Xrk2ulXDr99hsT6k4H880m7ajSuctd3B8q6uEOZbiUiP15O1f0GaoeFxJpPi+XTpSfLvYMlT0LDnP5BqtSMF1XR7cf6mOQK31wQtJ48kXSPF2k6ouGSNwsgXnjuPrgmop0b4eU3u3cwdW9dR+R02kbo7eS3f78Ehj+ozkH9atk1XuMQa0jId0V3ECCOhZen6VYalB3imdG+pGajansajaqZRG1MIqQ0w0hoiaoZOlTsKgloY0VJTVZ6syiqzDms2aIiYUwipSKaRSKRd8LSiDxJp7np5oU/jx/WvaK8KhcwXMUy/ejcMPqDXuUbh41YdGAIrrwz0aPPxq1TH0UUV0nEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFHWX8vR75/7sDt/46a8c0o/MK9d8Snb4d1M/9O0g/wDHTXkekDJFc1fdHfg/hZ1FufkFWFqvAPkFWFrNGzJFqRaYtPWqJY8UtIKWgkdRSClFAC0opKUUCHClpBS0CCkxS0UANNNNONNNAwpKWkoGFKKQU4UANNNp5FNNACVzviibdPBB/DEpncfThf610VcV4gvALLV74n5VVo4z7KMD9c1hiJWhbuVFGRPreiWWmB9T1WxtL7clyEnnWMnnIAyfQYxVL4lQ+C9a0yPVbG40WTUGZGmns7iNZZARgFmRgx/Guk8O6uF8MwweXGEaIK7yNgdOcDvSatDo1/4La3uIbKW8WM7SY1JzjrnHB4Feq4pwsux5EZONRN9zm/DWm3d54V+2af4j1RJ9PnMYjeRLiPbgEf6xWboR0YdK6ZR4sgjVkn0TVI2AYb0ks2Ix/eBkBPuAPpXEeCND8O3Gqm11DQ9LlF3GBFJJaxlkcdlbGRnPaut0zwboQSW3+xPDLbyFSYLiSLjJwRtYYFeXCSu0etKLT0J21/U7bP8AaXhrUUUdZbN47lPwAYOf++aRfGeghlS6v/sEh4CahG9oc9MASqufw609vCFin+ovtch7YXV7ph7cM5x+FRyeGJtrLF4i1xFPVTJFIPykjb8ula6AuY2re4guohLazRzRHo8bBgfxBp5FcFd/DOCWXzYtTaOYnmZbK3ikI93hSM5/GmReDPFllIG07x3cJGBgxXNl9pB9PmkkLD65pWXcfNLsd41YUviLRBqP2A6zpov/ADPK+zfao/N35xt25znPbGafoUHiSCbZrl5pd3bhDh7a3eGQtnjOWYY+mK4rQNG1zS/FniCaa11hbG+1Fp4/skln5MkZGMuXbzVP+7g/jRyobk9LI7u9mitbeSe5ljhgjUtJJIwVUAHJJPQe5qGN454UlgdJIpFDI6EEMCMgg9x715ZF4V8X3thrtnrA1KW3urKVNOjk1QMLc72ISbB/eMRt+b5gBwTjpHd+HvF4sdHt7H+1bKzhsFhkhiulkmjuQRl/+PlAy4HygsQBxsHY5F3Gqsux6qy0wivNNT0PxnLc6vcwT6iZhJYNZ4vRGjBUAuP3YkKDkcg5BPTNDaX4w/tbVWs3uzHOk7Q3F9cbfJYjEaJHHO6Ee5jUjr7VHIu5ftX/ACnpJXNeyaDJ5ui2DZyTAmT74ANfIs+h+NX066SxfVLUPFar5c+oiSYyqw810fe21cZ4yM/3e1e4vpviBvghfaR4O1G9m8QQq0cF1cXA898yhmHmHADbGZVPGOOR1reilF7nLiW5RTtax3CeMvDzarqGnPqtvDeWNxFaTpOTDiaVS0aKzgB2YA4Ck1vTyx28LyzOscUalmdjgKB1JPavn7TfBfjKy1fW7zSbDWNOhvtc0q4AudWSS4ktYlYTiSQTMWHPKljkcAECsHw3qXii68e6LpI1rUNQ1oPqzao9prIntXHlMLfEaSlYQrkAB1Q7sdccdJwn0fY69o+oTQwafqthdTzW/wBrijhuUdpId23zFAOSm7jcOM8ZrUr560PwL41tfE2g63fQ6jJqv/CMtp8t4+qCQ21/5hKPMPN/eRY2kqocE8lSeabB4Z+J40LUo7V9ctrl9CFvIt1rKzPcal5gJmgfzSIV257p6be9AH0PRXhmseE/HmkCzGjaj4k1hJtGvYJzNqsYkhvpU/dty6LtVj8pXJXtWLfeE/ilLoN+0Vzrf9qxaNpy2WNa2g3iOouMjzdrHbvyXyG9zigD6NorgvhzpXiDSde8WxaxJeyaRJdxyaU11eG5bYY/nALMzKN3ZsewrvaACiiigAooooAKKKKACiiigAooooAKKKKACiiigDI8WHHhnU/+uDD9K8s0Zehr1Pxd/wAi1qX/AFxNeaaOvyiuWtujvwnwM3Ih8oqdaijHAqdBUo2Y9RTxXmPhz4nXGoaf4e1PUtDjs9J1q7NhBNFemZ45tzKokQxrgMUblScd8V0tr4/8M3DyLFqeQsUs6u1vKElSLJkaNyuJduDnYTVcrMudM6wUVxdl8UfCF/HC1hqsl008hhijt7OeSSRgodgqKhY4DAkgYHfmtK88Z6LY3dpb30l7atdvHFC9xp9xHEzyAFF8xkCBuehIIOQcEEUrPsHMu50YpRXH+BfFM2s6Nrd/qq28KafqN1a5hVgPKiP3iMkk49PwFRj4n+EvIab+0rjyxbC8z9guOYCceaB5fKZ4LDgHriizFzI7UU4Vy97478N2N8trcamokPk5ZIneOPzf9XvkVSqbuo3EZrN8I/Eaz16x1W5l03U7YWN89ntisbm4MgU4DfLFkH1XkrxnqKdmHMjuxS159c/FHSDrfhmz0uK41C01lrhDcxQzZhMQ6eX5ZZjngjgqOTxW0/jrw/DqEtldXN1a3UcMtyY7qxuIS8cYJdkLoN4ABPy5z2o5WLmR09FcVY/FLwffxwNp+qyXbTyGGKK3s55JZGCh2CoqFjhWBJAwOh5rU1Hxnoumy2seoy3toLpo1ikn0+4jjLOMqpkKbVbn7rEEHggGizDmRvmmmuX+HviK78SWOrTX0cCNaapc2UYhUqCkbYUnJPzfTj2rqDSeg07q4UlLSUFAKeBSAU4CgTY0immpCKYRQCKOrXRs9OnmX76rhR6seB+przvxPIF07+zV5ZYvNf8A3QcDP4iu18RMJJbO2B6uZmHso4/Ug/hXC3zpc6x4kYfMLezSLPYHJJ/nXDXd5pdjWMbpv+t0Y8FydMZJBAZoJQFZA2OcjBzg10l299PpU/2OxEBaM/Ox3HGOwwK5u750oEdVUMPrXrulql1oEEigHdGD+ldVKrJR5UzHF0o86nbc8k06M282nSK2GDrg+mTj+telyzKNQtb1MeXeJ5cgHRZBxj9MV55eQmCOaEEK0ErKueuAcj+ldJpF0093qenOceZEmpWnsSBvA/n+dc9+WZ1TjzNSXY65hUZFFnMLm0jlH8S8j0PQ05hXSZEZFNxUhFNIpDImrzLSfHUsGs6zYait1qN2+sTWWnWttHGH8tI1ZuSVGADnLHPNemtXMXfgvQZ5JpXsmSeS6a9MsU8scgmZQrMrqwK5GBgED2qotdRSTexz7/E3R5La2mtLPUroT2kt5tiSMNGkRIkDBnHzDB4Gc9s8VBqHxP0W3tZrmG11C6t4LWG6uHhSMCFZseWG3OuWO4cLmuhXwX4fiWFItOVEhtZLNFSRwBFJnev3uSck5PPvXM+I/hlZ6motbKeLTrBoYbeVYklaWSOMjapYy7G6AAshI9aa5HuJ+0Wxcu/Hul2880L296Wj1KLSyQi481wWUj5vu8devtTtD8Zafrer3On2UMwkgd0dpHiU5Q4J8vf5gHPXaBV688FaDc6g17NYuZ2uEum23EqoZkGFcoG25x3xz3otvDmm2mqjUUiuJL1UKLLcXUs5RSckLvY7R9MVD5bGi5767GZrfjfTdF1yDTL6OVZJpY4VkSSFhlxwSnmeYF7ZK4/Suk+HvxX0W31A2N5bajBDdXMtvHdPGhiEkKkuDtcsOOh281h3ng/QrvUJb2eyczyypPJtuJFR5E+6xQMFJHrj+dbHhHwp4eh1/TfN05GSO8kuUDyOwE0gIZiC3IPTByPaqpygmrGdaM5Ra6Gz4a+I954q+KeiW+nRX1n4avtHmu44rqKEG4ZZQqyqVZnVeow2098d6j1P4nXPhj4h+N011b268NaUmnlfs0UJFn5y4Z3yyuylivTcR2GK7Xw78PPDPh7U7bUNJsJYbq2ga2gZ7yeURRMclEV3KquecAYHbrTdZ+G/hXWdaudV1PTHnu7pomuAbuYRTmLHl+ZEHCOFxwGUiu08wwLz40eH7K58QLd6drsdpok0lvdX32QNbmRGVRGrhiCzFxgHBxycCo9O+N/he9kgHl30Ub366dLOTBJFbyOpZC8kcrKVYKwBUtypBxXXf8IP4dNhrdi+mRyWetXDXV/E7u6zStjLct8p+VT8uMEZGKgvfh94e1Dw/daLqVvfahptyyNJFe6nc3BBU5UozyFk/wCAkZ70AcrB8XtOnngvTFfwaTLos2rrA9gDO8ccuzcHWY4DdQpTpyWHSus8EeM7Txjo8+paVazCGMgBDc2srOdobH7qZwrcjhypHcVLP4J0KW5trhbSa3uLaxGmQyWt3NA0VsCDsUo4xyq8jntnFWvDXhfSPDIu/wCx7aSKS8l865lluJJ5ZnxjLySMzMcepoA8w8L/ABuiHg221bxfp7Wl1dX8tnbLA0Mcc+xiDhpJsJsAG4uyjJ+XNaUfx08OXFjFdWGm61eo2mS6rIIY4d0UMUhjkDbpR8ylScDII5BNdKPhn4VS3a3i02WKL7Ub2Py724Q282SS8JDgwk7jny9oPfoKmk+HvhyaSWS6tLq6mlsJdLeW6v7iaRraRiXjLvITySec5HQECgDz74rfGAQeCdXfwUNQ/tO3sLPUDfiCIxWkdw6GMOJDksyNjCq2M84wSOrk+K2hwau1k9vqLWsepro0upBI/syXjDPlH59/sTs2g96taj8KvBuoW5t7rSH8hrSGxdIr24iWWGHHlLIFcb9u1cFsnjrV9/h/4YfXP7XbTf8ATDcrekCeURGdRhZTCG8syAfxbc+9AHN6H8ZdC1a401RputW0OoxXctrNNBGyS/ZsmVQEkZtwCkgbeeMc8VufDz4g6Z49tp7jRoJ44IgjZlntnY7s4ykUruh46OFP64dZfDjwtYx6WtnpskB0sXQs2jvJleD7SCJirB85YHg5yvVcGtHw74R0bw/e3t7plvP9uvQguLq5upbqaQKMKDJKzNgDtnFAHQUUUUAFFFFABRRRQAUUUUAFFFFAGH40lEXhm+LH7yhB7ksB/WuA0lMIK6v4jSj7FZ2wOGkl3keoUf4kVz1ggVBXLWd5Ho4ZWp37l9BwKnQVEgqR2KRO6o7lVLBFxljjOBkjn6mpRbZxOg/DHStJh0q2a/1S+sNLla4tLO6eLyo5WJbeQkaliCzEbiQM8U21+FWhwJDEbrUpLa2t7q2soHkjKWaXAIk8s7AScMRly2K4/RfFPjn7ffPcad4kl006bNIkUlpGLmOdXG0Bvs0ce4qchcSA9ix+WtjwH4r8Uw3GrjxRpeu3lp51oliUsT5iiVW8wsfJh3KhA3HYMZ7jBOjUu5z3j2Oi1j4b6VqnhnTNBnu7oWFhb/Zo8xW0jsNoXdukiYq2B1Taf0xnT/B7w/NqUF693qZeBrYxh3jkKeQAEAd0MgBA5UMAfTpi/wDFHVNb0+206Pw9BqzTXEjq09lGsiQ4X5TKPImbBJ/hUc9SK4GHXfiXe6Z5zrq1ncx+HmuwqaWn729W4ZAhDRn5mjAOwYOOQKS5mtxy5U9j0630PRfC3h7V7e51A22n6hczTzz3UyIEec4IVsAAZOADk/WslfhToYtRALvU9g0Y6J/rUz5Bk8zd9z7+e/THavPviRP4w8QadqVhe2WriHydNmtLSz0xpIp2O1pzI4RirIwxt3L06GvTfiJf67Z3mgRaOb6DTZ7ll1C6sbT7TPCm35NqbH4J6nace1Gq6iun02Mq1+GvhPWJ4dZ0q7W5R4YoTPHHaXccwhAQHMkUgDYXBKYyRzyKuXvwr0m6tb20/tLVo7O61E6qbZWhaNZiSW+VozvU/wB19w46da808EWni7Q/D/h8aboEwvbfSdSIFzp4DxzGd2jUuy7lyOQuQG9KNR8ReKtX0nxLpQe/1i6g0uxuPsd9o0RkS5eZPNHkGEZAG4jIOAMgnrVWfcm8bao9N0v4WaPpaaQdOv8AU7efSrqe6tplaLIMwAkQr5ezaQMYABHY1mJ8KPCmkajFcXOr3sdxdC5tIvtM8AeU3EbKy7zGHlYKW2hixHuOKwYI9e8M658RbmCDxNPcXNyk9olnaRlZlJT51kMDqSudu0AnbuOwkblhspfF+uz6AfEFjqE5sPFMbxTvZuh+y+UxDsfKjyoJxvMa89QOlCv3DTsegav8NdK1XwxpWgz3d0NP0+3+zR5htpXZdoXdukiYq2B1Taf0xm6j8HPD99fR3Mt3qm6NLZEVnikKCABU2u8bOudvzBWAbuOmH/ES88Wp4jS28Ozajb2A0i5uPMtrOOYG5QZiUsyNySMbRgntzzXIX+vfEqTSr+7gXVYLq30mxuYbdNMUiW5YqJkIaMsTgsSqkFfYcUK76jdux6z4Y8O2nhy2vYbGS4kW7vJb2QzMCQ8hyQMAfL9efetk1laPrDahe39pJp1/avZ+WGmuISkU5dckxNn5gOh4GDxWdqOr+JYppUsPC6XCK7KjyalHHvAJCtja2AeuDyPrUO5orJHS0VwF1rXxFb/j08I6PGP+mmreZ/JFqp9t+KMv39P0O3HGRGhkP4EzDH4g0WDnPS1p4FeZrb/EmUZmuLaPPa2niTH/AH3A/wDX8af/AGT4zf8A4+Z9Rn7/APIYhi/9F2i0cpPN5HpJpjV5wfDusyDE+k3U7HAHneLrsJ+KqmCPwNQXXhW4ht5Zrnwf4duFjRmY3OuXE5xjJ+/bHJ4oshpvsaPifWraxuNSvZ54k+zp5UYdwCSBkgc/3jiuC8LajbSeHfElwt5DcTtEjSCOQM2WZjkjPHXFUvFWky6boMcS+FPDFq87jD2053569Ps64HGOtNu5tZsPA11EmmaVDDc3Sw71vHLEoo4C+UMjg85/CuHlUrtdWjtp3VGT80uve/6Edot7qmFG9lVRhAcKor1Lw/r1zpmiwWbWqSGJQu5nPIxjpiuA8OQ6/Bp0bxWmlMrLvJa5kBPGR/B6VUm1nxRPN+6g02JB0Alc/rsrojFnFWq8zt0N3xNpM2qanNf28KAyAFkDZOQMZHHsKfHcva2Gh6qpKyafL9mnznIUMMg/8AJFR6DdeKLl/LMWkDgnLvI38lFRajb68dQutLcaQP7Rj3gDzMeYgJGPQkcVFSH2uxrhq9pJSWn6bP8AA9NslFtf3VqOYziaI9ip64q8wrlfC+pPd+GtKvLjH2uxb7FdYzjoOfp0NdWwqoO61KlFxdnuREUhp5FNNWBC9QsKncVCwpDRFtqN1qcio3pDRTkFVnq3IKqvUs0RCafbzGC5ilHWNww/A5ppphFIrc9wgkWaGORDlXUMPpUlc94HvftegxKxy8BMR+nb9K6GvRi7q54k48snEKKKKokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA878bzfaPESQ5ysEYGPcnJ/TFQ264UVV1CX7T4hv5euZSo+gO0fyq7EOK4pO8mz1YLlgkWEqZaiSplpkseKWkFLTJCiiigB1FFLQAyeGK4gkguI0lhlUpJHIoKupGCCO4wcYNVNH0TStEjkj0bTLHT0kILraW6whyBgEhQMn61fpRQSx1LSUtABSUppDQwGmm0402gYUDrRQKBki07FNWn0Ika3SsXxLNtsVhHW4lWL8M5b9Aa2XrmtakE2sxR/wAFvE0h+rcD9Aazqy5YNlQ3PMfGF59v8Tpb/wDLC0wCO2cbm/QAVR8Zs8GleHdOPDtE17IPeRiRn8OKIFOr+I7hYuftlx5QI7KWwT/3ypNVfFt+NT8aXsiEeTERDEB0CqMcfjmueCtZdj0Kvu0adPu2/wBF+p2Hg+dJrFYSfnQYx6jsf6VZm8OytOWtwGRjkDOCPauS06ZIWUCeNHX1cAg/nXS2fiw2UZFxLbuq92kAI+pzWilY4amHbd4nSaTpn2CJ5ZyA+MAZ4A75NcF4lv3uNXW9tjta3cNCf905B/Oruq+MoNQi8sXlnFEeCFnUk/U5rj9XvrZ1RYNZtbUjOSzxtuHpgn+VOT5tB0qXJrI9U8I+ReX18kI22mrWwuFXskqna4+uSDXSaZK0tknmf61MxuO+QcHNeBeFvE9zpmpJBH4k0RY1k85HnhJG7G0jKyjGVJ9eRXef8Js1nqFwn/CReB5/M/eEnUTAA3QjGXweOmaVOLT5RTqXep6QRTSK8+b4kRp/rJvCkxzwLTxFHIT6YDRrk+1Mb4qafGP3+nytjPNve2rj/wAelUn8s+1b8jJ9pE796YRXBJ8WPDzybGh1NSOSVtTMB6ZMZYVq6f498PX00UNvc3QlkYKqyWM6ck8DLIB175xS5WUpx7nSEYqKQVxvje/1S18b+EbGw1We1tNTeaO4iSOJgRGm4EF0YgnODzjHTB5rIT4lXVzNFEmixpHcXlzp8MpvCSJolJBZfL4U8cgkjng9zkbV0P2iTszv5BVd1rzLQfiJqdv4N8OXOq2g1HUtWeVIXjZhvCE5LrHESp7BVVs9cjmr8Hj/AFC61awsI/C90ks1kL65WafypLWMSmNyUZQWxt3ADlgRgVLpyKVaLO4Yc1GRXDaZ8Q5b37I39iSMt9aTXdmlvcCWSQRk/K67QFJx2J5461EvxCupNPkmTQy9zDKkdzAjzk2YKli0w8gMo4/hVgeefVezl2KVaG9z2v4c3flanPalsLNHuA/2l/8ArE16NXynZ/FSSx1e0fSNFl1WWOGO7lWzaV9yOwBEeIueCeX2enWvc/h74ok8Q654sgY3Zi06+SGITtGQFaMN8qrGhUc9HLn37V1UbqNmefieVzvE7mivEtK+Nl/qMWlvB4WtlGp299NbbtUPW0J3q/7n5chcgjPPBAHNNufjsw0+a+s/DYltoNGg1ifzL/y3CSSCMoo8tgxUnOSQCPStjnPb6K8/8K/Ee21PVfENhrsNpor6RLaoZZL0NHKLlN8QDMqYbHG3nnoTXoFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU1iFUsegGadVbUGKWNyw6rGx/SgDyewYyTvIeSzFifqa24ulYWk9BW7F0rgiz2ZqxYSplqFKlWtDFnJWvxK8MXtuJrK9nlV4ZpoN1nNELgRAmQRtIqq5AB4B4710Xh7VYNd0Kw1W0SVLe9hSeNZAA4VgDhsE889ia8z8KfCibT/CNpa6xf/a9Wsre8is4lcfZLdp943L+7VySGGSxODnA6Vi+IfhN4m1HRdMsYbjQVkstOtreK5ChJY5oyCxMnktIycHG1kxnkHnNcse5jzStse7Vm6Drmn6/ZyXWk3H2iCOV4GfYyYdDhhhgPz6V5lqHwv1K51y81NZNMFzL4gg1OKYswkW3VcSR7tnVuPl6HuarW3wt1fT9Au9KsbTwuySap9qM00KtJLB8+E/eQSLGyBsA7ZBhmxj+Isu4+aXY9qpa8S0L4O3ZPhi38TTWl7pulpdpLFHcyhmEj7owpCrkDHIyB6Aiu08f+DZfFOv8Ahm6K2Ulhp7XJuYbnJ8wSRBVAXaQeRk5x+NJpX3Dmdr2O6rO1/XNO8P2KXmr3H2e3aVIQ+xny7nCjCg/njFeQab8ItetNM0+CDVbOxu10e40+6urV5C8jtIWjP3QWULheSCBwBgVCvwZ1BvDV7ZOumpeSS2k6I9yslu7RZVsIlrH5RZTgkBy3fPUvlXclylbY95rO0LXdO16K7k0q4+0Ja3L2kx2MuyVCNy/MBnGeo49DXlGvfDTxDqfiey1K1Tw5psNrcWk0C2arE8SxKFeMuLfzHGBtU71XCjKD+FI/hZq9hper6fpll4WMd3q5vVmnhVna2JP7ja8DqhX+E4cDJ4HdqK7hzPse1GmmvD9B+DN59o0CHxNLZXul6ebsPDHdSqxWRg0QXaqcAjkcD0GKuWvw11+01TXLqyXQI1voZwFvwuoO8shH3pDbxuI8cbWMg9jScV3DmfY9I8XeI7TwvpkV9qEdxJFJcRWwEKgnc7YUkEjj8a2TXhun/CXxDb2OrwPc6TGl5e2F2kUUm1IzDnzSBHBGqlsjAVR7nIyfcz0pNJbFRbe4lKKSlFIoetSCo1qTtQiWRvXA6zdFLLxDfDqodVPsikCu4vphBbTSt0jQsfyzXnHiCUQeA7tpfvToR9S5x/WubEvRR7s2pRcnZdTj/CEwsbS91Nlz9jt2aMn/AJ6v8i/pu/OovDvhuPVIknNxJHK33jgEE+tJfj7J4TsbQcSXbm6k/wBwDagP4c1H4fv7i5jGl26FHaRVEqMQTnsfx569Kzak7uP9I7aqdWtaGy0+SW/5nTN8PdMLF7j7LcytjczWqkn6nNXLTwDokRDNpdrIR0LQKMfkBTZfFVhpWtTWMUU03kRiFmjwQWA5JJPJ7VaHjKIruFrM2P7zKB+ea5m6z9DlScldIc/gTRmbCWUSA9dqLj9RVS/8O+HNHieS6ijVRgEBQMnGQMAc08+NpZATaWUJxwS027n6AUtzdy6/4Sv3uUjW4t5RMQgIATGCcZ9N1Uvaacz0NKcPeSns2cv4p02yeOxext4UhkYshRQM8DB6V3/h66M/hfSb1lCyWzm3lCjAxnbn9AfxryPTWl/tcQTSO4iG1QxJAGeMV6v4JxLpGsafjJWQSKPqOP1Wui3IlfoKtS9k3F9GdY1MNQ6bN59hC/8AEF2n1yOKnNdJiRsKjIqYioyKBmRqWg6RqV3Fd6jpVhd3UYCpNPbI7oASQAxGRySeO9MTRNLieNo9MsVaKVp4ytuoKSN95xxwx9Ryat61qVno+mXOoanOILO3TfLIQW2jp0AJP0AqDR9Ustb0u31HSpxcWU6lo5QCAwyQeCARyCMEUajVr2M6XwzoX2WW1/sXTPs0j+a8X2SPY74xuK4wT7nmks9G0vT5EksNNsraRIzErQwKhWPcWK5A4XcScdM81DpPimx1jwzc65bRXKWlv5u5HVQ58sndgBiP4eOan0PVINb0az1O0SRILqMSosgAYAjgEAnn6Gk79RxcW9Cj/wAI/o0ZufL0jT0+0qVn22yDzRnJD8fMM881Vfwx4fMCwnQtLMKsWEZtI9oPTIG3rW9OwRWZjhQCSfbrWZo+p2etabDqGmTefZzglJNrLuAJB4IBHIPWpuy+WOxXvdA0e9WFb3SdPuFhTZEJbZHEa+igjgewr1n4ex2K6VLJaWdtb3DSAXDxRqjSsAArMQMsduBk+lec4q/4L8WW2m+OrTw7Ms3najA8ysANg2HHJznPbpWlCTUrGOKgnC/U9Jg8L6Bbi3EGiaXGLdZVhCWkaiISZ8wLx8ofndjr3pg8JeHBDJANA0gQyQLbPH9ij2tCDkRkbeVB529Aea3a4P8A4Wfov9qf2f8AZdR87+3P7Az5abftGzfuzv8AuY79c9q7Tyzo5fDOgytcPNommSPcNE8xa0jJlaIYjLcclB90np2xWzRVLUL+GwSFpkumEsqwqILaSYhm6FginavqxwB3IoAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVr9d9jcoOpjYfpVmkYAqQehGKAR41pLcCt+HoK56zBiupYzwUcqR9DW9btwK4InszLiU9pEijaSVgiKpZmYgBRjkk9hUaVKoB4PT0q0ZM8v034uw3F/c29zZ2UEC2El7BfC6m+zS7H2ld726HGf4kVx2GTxWx4K+JNrr13q1rqsEOkSWL26K807Kk/nKWj2+bHGwJ29CvPBGRXQ23hPw7beabfQNIiMiNHIUs4xvRsblPy8g45B60+28KeHbaMrb6BpMSs6SER2cYBZM7GI29VycHtniqbiYpS7lDx54s/4RaCz8uG2uru6ZxFavLKsku1ckRrFFIWPI6gAdSa4lfjLLcWIurDQEkRdFOsyCW+MZVVnMLRriNsnK5ycZHpXqOraPpmsJEur6dZXyxNujF1AsoRumQGBwfcVWj8M6DEhjj0TTEjaA2pVbSMAwlixjPH3NxJ29M80JxtsDUm9GeT/E34iX2oeH9XtvD8M1itiunTTXwu2hlU3BV1RFVfmG04Ylx3616T4x8UyaFqWhaZZWCXuoavO8UIluPJiQIu5iz7WI+gBzV678K+Hr2WOW80HSbiWNFiRpbONyqL0UZXgDsOgq9qmladq8KQ6rYWd9Cjh1S5hWRVbpkBgcHnrRdByvueG+APiLd6T4U0GbWbjU9QzpuoXszPOrmQxTuAG3IXJxgA7wAOoNbmt/Fa/TQtYebSjYXFrp9nqKSWV+krMs8sYC5kgKg4bn5WHYHoa9LXw1o8VqIrPTLGz2QyQRPBaxAwq+dwQFSACTkgggnqDWH4c+Gnh7RX1Fmt0v8A7eiRzR3UEAh2qdwURRxpGBkbvu5zzmqunrYnlktEznNN8faxY6n47l1t9MOn6TeJBbCe6aPYWxtjHlwMzZBY5wTngAj5hQuviBe+Irzw4sMF1pE9t4oTT7uGOWQCZPLY4O5I22nrtdQfUV6ndeG9DvLm5ubvRdMnuLlBFPLLaxu8qAghXJHzDKqcHjgelFr4Z0G0WNbTRNMgWOUXEYjtI1CSAbQ4wOGA4yOcUXXYOWXc5zxx47uPDmuLplppMV9IdNn1IvJdmH5YuWUfu2ySAcdBn865q++MrxWF3fWvh9ZbW10601GbzL3y32TkDaqiMglSw6kZHp0r1G80vT7y48+8sLO4n8poBLLErN5bDDJkj7p7joaqHwzoJhlhOiaYYZIkgkT7JHteNCCiEY5UEDAPA7UroGpdGW7HU7K+kmhtLq3luINvnwpIpeIsMqHUH5SRzz1rK1Hxp4Y02WSG/wDEWkQTREq8T3kYdSDggrnOeMYrWtdOsrO5uLi0s7aCe5KmeWONVaUqMLuIHzYHHPQUr2No5LNbQszEkkoCSe5JxU6Gmpx1z8WvAts2JPElo55GIg8mT/wFTmqTfGrwRvZYdUaVgSuDEYiD9JNuK70WFn/z6W//AH7H+FWUVUUIihVAwABgAewp6E2kedL8YtAk/wCPdFfOPmk1TT4wPruuM/kDS/8AC1LWQfuJPDSdcfavElun0zsD/wCfWvSVpxPFO6FZ9zx7xH8Qbi40mZFvvCcIkwuI9SlnOM9v3SVx3izX5r7T9N09/Enh/wAl5kVhbwOSgwcsWMnQD2r2jxm+9tPtv+ek24j2HH9a5nxrKITby5+eNW8v2YgAH9a469RKpFWNqd4WkmeP63q6XdxPI/ieFlQCKMQQIoKjgYB3cVe8F63puh2WoanPqdxcXQUx26SxjG8jqNqDtWpqyeRZRp3OM/Wn6rF5cGn6Uh+W3jDy47yNyc0Npx5TflcFyp6vT/PqYekarpw3TXF3umlYsxKMcnPJPFbI1rSmXDTmRSMFFgck9sY28/lWnaSQ28IyQAMAk1bNy5jaQRERqMl5GCKB9aqMHUfuoJVI0VaUkjlHj8KO26TSYH9m0lyR+Pl1a0lvBkF+ouNIjFvICjhdMlAAI64Cdc10K3TpsEsDxl8lCTuVh7Hv1p8iyuOIZWPsDTlCa0aZKnSqLSSOFj0TRzrRjt7VxCrlQHSSEkZGDtYA9D6V3Phzw9pUPiGGCWO8ENyhjAjvZ0AbGV6OOOMYqPWs31vaXkqGO7tG8qTd1dCPlP6VeeUwTWd0nWJkcfgf/rVDlK1nuaOUa0bpa2/E27Dwlp6Xt5aG51xCjbk261eDA+nm89V61ebwnAOU1XXkYdD/AGnKcfgWIP4itbUyIdctbhPuXCBSfU/5K1eNawm3G5zcqOaPhhxzHr+vIw7/AGlW/RlI/Smf8I5eKcxeKddQ9/8Aj2fj6NCa6emN0q7sOVHD/EHwtqHifRtM0aK/C2IuI21CeQgTTRp2VQmwsSAeQACOmOK5EfDTWLW2TT0uLDUNHtdVN/DaXcjKJ42U7klCxlQQ3IwpByeB0r2I0001JoTppu7PEYfhbrEOl6fbTHSbxYEvENrLI4hRpiSkqfuzllz0IHTg1Bd/DPXF0t7W3n0x2n0aHTZS8rqEdJA+5fkO5TjHODXtzjmq8godRjVKJ5jpvgi6tdVvJNTs9I1aG6WNVuLpiZrVRHtKIpjYFR25XPesTT/h1qNnpGj2slvotyLCScz28jsIr3eCEkkPl/fTOACG46EV6/JVdutR7Ro0VGJ5joHw3mttb0i6125j1CLT9PSJG81w4uFmMintlVBwMnt0rS8aeD5vEOtrd4snthps9qEnySJWHyMPlOADg5zkdq7k01qTqNu41SilY5m8+FXi3xNo+jPb3vh/dZWVlDDd4EdyssIAk3y/Z2kdeG24dAOMg12f/CsNa/4SL+0PtWn+T/wl/wDb+PNfd9n8rZt+59/PbOMd63fh9qZt79rCQ/up/mTPZgP6gV6PXbTnzxueZWp+zlY+etH+DXiq1l0G2fUtMtbfSI9WhjvbaaQzkXaOI3CGMBWVmyRvPHQ5rah+F+qDwxo2lxaT4Y027sNRsLu5vrOZy9+sDEu8n7lSHOcgFm5ZuR39roqzI8h+GXw51fwt40vNUuV0uOwnik3KZFvbtpXkDE/aTbwyBMADaxf/AAzPGPwh1TXfFHirV4ZNIEmo6hptzZSys3mwRwJtmG4IdpbjAUkEdSK9xooA8w8D+EPE3hC+1KHTG0JdFv8AXpr5rcmUGCzdRtSJQoVXyOnK46GvT6KKACiiigAooooAKKKKACiiigAooooAKKKKAPINZi+y+JtQjxgeaWH0Pzf1q/atlRUnxCtvI1+G4A+WeMZPupx/LFU7F8qK4ZK0mj2IPmppmvGanWq0R4FWVqkZskFOHSminDpTJYUUUUCFFKKKKAFpc00UtAh9Feb+LviPc6Bret2UGjQXNvpFlHfXE0l8YWZHONqL5bAt6AkZqxoPj1rzxF4lt7y2lGnaeli9sLWymnnIuITId6xhjxjGQAB3p8rJ5lsegUVyB+I3hc21hOmoySJeiY24itJ3Z/JAMgKKhZSo5IIBqhB8S9Nu/F2k6Rp8FxeWWpWRvIr6GGVh97AXYI+nqxICng4NFmHMu53pptcq/wAQfDcRv1uby5tZLG3F3cR3VhcQSJCWC7wjoGYZOPlBrV8NeINL8Tab/aGh3Yu7PzGi8xVZQWU8gBgM/XpSs0O6NUUopKUUDJFpWPFNWlY8UXEcj4iO/wASWanlY4S+Pckj+lcn4tb7TqtrAeQqmQj8eP5V1N63meKLtuoihVR+Wa4i4m+065fz5yqN5Y/4COf1zXnz1r+h0U43aMPVirahArfcDgkewrZ0jw/PqMr3LthpW3E/0rCkzNrCKOcZJr17wvaolpFlc/U4FejhaUWuaSOTHVpRmlF2M+TwjZW3h65klx5qsjeYwJ2/MMnH4Vk3l60WnSrJZ2jWKr87SRM4Iz1K5PHevS7+0+02bwgYDL07dRXG3P221neFJ41AJAygbn0/+vXdeMFrojzGpTfdnkd4fCH2yOd57Gxk80bjby/YQO+SE2EH3PJr0uwg0WS0R9G+IEsbFQ3lveW12hB6ZMil8fRxWpBoF1qEkU95LvJ5UrgLjPOBj19ea6k6Dpk1uiXen2s21eskCt2Ge1F09UPbRnkPizS9fjhe4t77SdUiXhisDQNjrgkO4/ID6VjrqmprYoLrQ7h0C432k8cg/Jih/IV6Z4h8BeGJoXYaBpKvjAdLOIOAPQ4yK80tPDOlKksf2YxtG5X91LJH9fusOOtcWKik1JnpYGTacUdldeNdKk8P6c90b2xmiRAXu7KWJM4wcSFdh5HYmup0nW9M1iFZNM1G0uwVBPkTq+OPY1xHhLwxbXWl6lCt/rUbQHKKmqTlRkEj5WcjqD2570W/w/07WLctd317JLG5w0sdtMVPXIMkTEH/ACK56XLqjZqSuj0amkV50vw1u7R1bSvGXiC02n7u9WTHb5MBM/QVq2WieMbIf8jdaX2BjbeaQOT/AL0ci/1rWy7iUn2NzWNa0rRfKOsanY2Alz5f2q4WLfjGdu4jPUdPWq+neItJ1TUZbHTb6K6uY4UuCIsshjYkKwfG0jI7E1g+O/Duqax428G3unPNb21g14bm7gaLfCHiULhZAQ2SCPunHt1rmvFnhTxgdf1y88PTSl57K0hW7eWOOW42MfMUbSu1jxyNg9CKairasHNp7HqcgqCQcV5TdaD44/4RxLfTrrWE1X+0GlinurlI0toSoyjgXExlXPChiWB9B1ZqOi+MZNPslhi1n5dJaFIk1VVlhv8Ad/rZX8weYmOgyeONopcnmUqj7Hp0q1ka7qtloemT6jqk3kWcGDJJtZtuSFHABJ5IHFc14Y8P+Ix4uvdQ8RanqBghithbxRXQ+zXEnkbZiYx0G/kDC8881g/E/wAO+Jdbn1yC2gu7yznt4FsEiu1ihjZXBk8xC6hicEgkEDjoekqKbtcr2jUbpano1ve2t3JMlrcwzPA2yVY3DGNsdGGeD7Go7m/s7WZYrm7t4ZmRpFSSRVZlUZLAE8gDkntXmniRPEGm31xc6lfz2+iPqqN5f9pJbvLB5f3Y3Mi7RkMduVJ61T8NWHiPX9C0uR7i/ksZ4L9JWmu2XduyIS2W3MOODg8expezW9x+1d7Janr2m3yM1tfWM0cseRLFLGwZWGeCCOor220mFxbxSr92RAw/EV8dWegeJrXQdJtI7TVUigtJYpbeDUljcXO0bJA4l/1X+yG4OTs9fSfAHhjxrrGrWc+sa/rNtYWOlxIps9QEcE14jHKyRjJK7SuSAM+tb0Uotq5zYpuaTasfQVFfOMfh/wCLL6TaW7jW4rq20G7s5ZG1eMie8aRjFICJSSdpXDNgjGOKsax4P+JMdjrZ0q7103K2mmy6cG1skG6BT7UDul+7jf8AK3yHsOldBxH0NRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch8SbUy6RFcqMtBKMn0VuD+u2uMsJeBXq+p2iX2n3FrJ92VCmfTjg147CHgmeKQbXjYqw9CDyK5K8bSuelg53g49jprdgQKuJ2rGspScVsQnIFSi5qxMKcOlNFOqjMKKKKAClBpKKAHUZrkPiVqeqabpFodEt9UlnluljaTT0VjEpByXBhmO3v8sZOR1HfylPGnjkLpVlqtzq1nqcmnXspittKV5p5o3IiJjMTEKeASABjnjrTUbkOaTsevT+BdCu/F0/iK/tI729lhjhVLqOOSOLYchkBXKt75rO8QfDPSNc1HVb66u9Qjm1Ge2uJVRozHugQog2OjKykNyrhgT6VxWpa98SY4mL219BqK2Vm9nbWlgs0F1OxHnieTY3l4543IO+au3mrePo9cuZov7R+zReILe1W1WwRons3X94wby95VSPv5wO/tVmupN49jo9I+FmhaVLpT2txqBOnPdtCGaMAm5QJICAg4AHygYx3zUmnfDPSdO/sc2N/qkL6ZaSWKSLKm6WF3LMrnZxyTym0j1rjNH1r4l3Oo3q36yW8oivVFo1jIUDiNjAYpPs/l43BfvzMGz0B4NK58U/EabTLiSyttZWePw9DJh9H2sb/wC0RrJtDR/Mdhc7RkY5A4zRaXcV49jq7T4K+HbWK9RbzU2+12LafI+YFYxtIJCxKxDc+VA3NkkcHPGPSLK3Szs4LaMkpDGsalsEkAADPHXivJPEd58QNGxbtqWoXv8AxLZLi3u9P0hHM94ZPkglQI/loFIGeM9S2eKmGueNx4w0qO7ivns5jaJPaWFoUS2coGmaSWS3ZJE3ZHyTKQOBzzSab6lJpbI9cpRXz/a6n440rQNMSys763Cm4M2nafpBt5nJuHVGD/ZZIVG3nDBCepJ3CvZ9RGuyC3/sl7CBSgMpvY2kcN6AIwH60nGw1K5uLSOa5ldP8WSf67xDpcQOOLfSWBHry87c/h+FI2g61J/r/F+prnORbWtqnPtuifj9felYLlC3fzdW1qX+7Lt/AZH9K4WyYfZ7mY9ZHZvzJNWbfRWfS9Zun1nWJGDOwAuRHu4JGdir+lcwmg2I0tXle+kYr/y0vpyPfjfgfgK4klzydzrpX7Gl4ehNxrUj4yBhf617Z4fjAiQgDoMHivD/AAd4S0a6US3WlWdwGckC4jEgxnA4YGvc9BggsNNRIUigt4UCqkYCqigcAADgewr2KEeWCR4+KlzVWy3rl+LG2ODmUqcY/hHc/X+tcJ5rSSF34Zug9B6Vpajcm8u3ZvuA8j37D8P51mqQ0p9K8nMcTzS9lHZbnRhaVlzy3Oh0O7eBSrAvAxyVHUHpuHv/ADrqYZNyKQ2fl3BgOGHY/wD1u1crpOwrsYgEdK1ILg20u0n9yTnP9w+v09R+PWrwWJ5EoT2/IVejze9Hcs6ifMjYFgf+Af8A168j1SI2uv3CEYWT5gMY+vH517LIBKh3ZGOCOTg/nXmvxAsxBdwXaA4B2scY4r0MTHmpsywc+SqvMj8E3It9elt3OEuoio/3lyR+m6trTAbfVbq3PAOSPwPH6GuIM5tbm3u4+WhkEg98HkV2l9J5eqWt4vCTAMSfQ8H9DXmRdpnq1F71+5smlFB60grpRkcP468Tz+HvGHhWOS7+z6RcR3818NinesMAdTnGRg5Py4z05qvP8U9GtrC6ubyx1S2aGyj1FYJI4y81u7hFkTDkdWHDEEeldbq3h/S9XvbO71K0S5ntEmjhLs2FWVdkgK5wwK8cg+1ZA+HnhgWN1aNprvBcwpbSCS6mdvJRgyxqxclFBAO1SB7VScbakNSvoZE/xM0mOW6tprHU01CG6t7MWbJGZZZJlLR7SH24IBOSRjvTLH4i6Xe3Vpbiz1CGe5u7myCSJH8kkChn3Yc8c4BGcmtPxB4E0vUFvJrOCCC/upreeS4m898NCpWNl2SoVYAkZUj3zWbofw20qw0qC31J5b+7iu5b0XSySQOssmA20q+4DAAwWOe+aLRsP37mafiloctnpNxHBef8TKN5YVmMMOFSQodzySKmSyngMTjtW34m12DQdPS7u4maJmC4E8Me3gnkyOgPTGASfakl8BeHv7Jg0sWlyNNhXatoL64ERG8v8yb8N8xJy2fToBU+t6BpmrCz+225LWT+ZbvFI8LRHGPlZCCB7ZxUPlujSPPZnJj4kaVNZWdzaWWo3CXNpLeKESMMkcTEPu3OORg8DOe1Y3jT4hqPDN/L4a+1C8itbe6Nz5UZS3WVlwHDnqVOMBT1/Guut/BXh+0hhit9P2RwwS2sY86Q4jlJLr97nO48nkdsVWufAnhyeHyZNPYQmBLdkjuZUDxoRsDgMN2OOWyfehOCew7VWrXIPH+sX+kxeHX053DXWqwW0yIqEyRsG3IN3AJwOcj6iuj8JfGLSNMs4bUaN4hvr28ubiKO0sbRZplkgVfMUqH5OGBBXIxnJGKg1rRNP1q3totRhkkW3lE8RSV4mjkUEBgyMCCMnFdL8LfBvh+3v4L2HTwt1pTSPaS+bISjTKVlLfN85YADLZPpV0WrruZYmMuVvoWV+OHhaTXptJtYr+5uElnt4zD5J86WJSxRU8zzBnGFZlCk8A1U1T41aNP4Uv8AVNBF2RaWNtfzXDWa3CQ+dMI1hdBNHmX7xIDYAGcnG09zY+CtE07VZdQ0+K8tJ5Z2upI7e/uI4Hlb7ztAriNie+V5rPi+GPg+DQtX0aHRY49N1aYXF5Es0o81wwZTu3ZUAgHCkAenJrrPOGad8StH1Lx1d+FbO3umv7WZoJXeS3iAYKWJWN5RK64/iWMjvnHNZutfEO80j4syeH7rTv8AiQwaG2rT3ahd8W2QhpCTIP3QUEEBS+7oCOa6UeCtEfxDBrlxBdXOpW7vJA91fTzpAz/eMcbuUTjj5VGO2Km1Xwhomq67BrN7ZM+pQ27WglWeRA8LEkxOqsFkQk52uCPagDz6H9oLwhLp2o3iQamy2VtHeGOMQSPJE8yQggLKQpDSJlXKsAc4ram+LWjW630Vxpurxana6nDpH9nmOIzS3EoJjCESGMggMclxjHPbOg3wx8Kvo0+jyWd9JpEyLGbKTVbpoFVXV1CRmTamGVT8oHHHQkVa1D4eeGNQnv5rrTmM99dxX00qXMqP58QIjkRlcFGAJAKYoA4LwD8VbqS3vLbXbfUdT1u51y/tbHT7aO3E0cEAVirHesfyA4yWJJ6Fq05fjj4ba1W6sLDWL+3/ALKOsu9vFEBHbiYwtkPIp3K6kEDPqM10KfDHwnHZpbxabPGEupbxZkvrhZ1mlULKwlD+YNwABG7B7inj4Z+EBG8SaLFHG+mHR2SOWRAbUuXMeAw5LEnd97PegCjH8VtCn8W23h62hupbydbeRZGlt4EKzKGQqJZUeT5TkiNWI6YzxXoNclJ4A8OzXmn3E9reTjT5IpbWCbUbiSCB41CoywtIYwQB125zz1JNdbQAUUUUAFFFFABRRRQAUUUUAFeY+O7H7HronQYjulDe24cEfyP416dXP+NNO/tDRZCgzNB+9T1OOo/Ks6seaJvh6nJNM4KybkVvWx+WuZsW5FdHaN8orkiehULgp1Rq1SCtDEKKKKACiiigAqs9hZyX8V89pbvexoY47howZEU9VDYyB7A1ZopALmlptFMB1FJmjNAC0maWm0AKKcKaKcKAHio522Ru/oCf0qSqmpNssLl/7sbH9DSEjzrRVMvh3Uh3beP/AB0Vxl3LjTI1H93A/Ku38Oj/AIp2+PTG7n/gIrg4VNxLYwKM7mAI9s5P6Vw003UkvM6oS5VJ9j0DwbYiKCFWXlVAOD3rsdZuTDax20IxI+D689s+3Gax/D8K28PmSEBVGSMjJ+lO+0GaaS4YdcgfT2/lXq4qusPTut+h4tKm6s9fmUruMRBY1JZh1Pc+uaS1iLtx0FOuJEiiknm+VegJ6n0AHrWto3hjVtRhEzOumQMMrvXfIw9SvGP518/SozrP3UepJqK10LWmRRoFMgyueTWjcqqsNoGxu9Ingu9jX93rsu73hBH5bqpXy6loqj+1Ikns8gfaoc/L2yy/4V2PC1IR1RkpRk/dZp2UpjURnkchT1yPT6j+XHpWb4ssGvtMlTjlcg5H1Bq5HskgAR8hgHR1P45Bqa0dLlHRwFcHawwMZ9vQHr+YrvwldSXs5bnHXpuL54njAJaBo3+8mVYe44ru71fO8NaZOOf3aAn8MH9RXM+L7A6XrUj4/czkkHsDXR6BMt94PMAOZLdmUjv13D+dclaPs52fQ9P2ntIRmjYtJfOtIpD1Kgn645/WpRWdoDl7Eof4HIH06/1rQ71uiWrMcKUikBp1MRGw4qCQVZaq8lDGirIKozd6vuKpTjrUM0iU2qI1K3WozUM0G5rt/hiPl1E+6D+dcOa7z4ZKfst+3YyKP0Na0fjRhiv4TO3oPSiiu48oBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIQCCDyKWigDyPUrU2Gt3VsBtRZCUH+yeR+mK07R/kFaHxBsSJ7W/ReCPJkI9eqn/ANCFY9ox2iuOUeWTPUpz54JmqjVKGqtFmpGbAoEx5cCkEoqnNLiq/wBpweTRcLGsJBTw2aw21BFIG6tK1mDgGi4OLRbooFFMkKKKKACiiigAooooAUU4U0UuaAHVT1hsaVen0hc/+OmrdVNWG7S7xfWFx/46aTBHn2iOE8LX59nx/wB8iuP8MRCfV4c8iOMtx69B/M12Xh9A/hy7U9CWH/jorn/hzCHmup3+6GCgnoMAk/zFc2FXNXfqVXly0pHdSuEto4IxtZ8EkdcfWlVowNrHaqjJPYCordTdTS3BOF6L9KLeyOq6xZ6WhISVt8xHaMdfzxiscZN4jEKnHZaf5mOGgoQuzo/Begf2jMms6kmYFObKBugHaRh6+n5+lehVHFGkUSRxqFRAFUDoBipK9elTjSioxOWpUc3dhUU0STxPHKoeNwVZSMgj0qWitCDz25sToWsLZkk6ZdEm3JJPlP3T/D/9dWTCbW5MiZYlQCM4yM5xXSeItLXVtKmtiQsn3on/ALjjof8APauU0y7e+s1WZSt1ExilB6hh1BrzMRT9lPnidkJ+0jr8yt4w00avpL7QC6ruU9Oex/z9K434cSuut3NpKduYiWU/3lYD+RNd9AXineCVSFY8eme4+h/n+Nc2+mjT/GtleRjENxuic+5U7T+YAraravT9ot1uTRl7Juk9mWNJHkaheW/YEkD2B/wNapFZdx+48SKe0i8/lj+laZNZ03eKOp9xQafmoxT60EI1QvUrVG1A0V3Wqk69autVaZetSy0zMlHNQNVqYVUfrWbNUNJr0T4aKRo9w3Zpzj8FFecO2BXpnw3H/FOk/wB6Zz/IVtQ+M58X/DOrooortPLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMHxo4Tw7cg9WZFH13j/CuKsuQK6n4gybdKtkB+/OM/QKT/PFcxYjpXNV+I9DCr92acS8USdKkiXimSioL6mbdMayriYqDWpdisS8HUVLLiZV3OwlyDwx/Wux0aXfCh9q4O9YjI9DxXW+Gpd9vHz/CKS0ZpUXunUr0paZGeBT60OYKKKKACiiigAooooAKdTaKAHCoNQGbG4HrG38jU4qK6G62lHqhH6UgPPfDWW0C5A/vt/6CKyfBsf2bw3vH37iQgZ+uM/pW14PAOh3g/wCmh/8AQRVLRodtpp1uP4IwxHv1rnw0vZyqT7IjFe8lDuzorb91bhB3Fb/wythPd6pqbckOLWP2AAJ/Uiudnm+zxzOwwUiLL9QOK9A8A2H9n+FbFGGJJU85z3JY5/kQKxy6DlNzY8RLlhZHR0UUV7RwBRRRQAVw2qqNL8XsQMQaggkHoJF4OPw5rua5P4iWpbSIr6MfvbKVZB/ukgH+lY14c0Ga0Xadu5W1VQyCRf4hgisq+YzwhZB++jIkUnuQcg/p/nNaUTrPBE/VDhvwxxVPV4+fl47rj+VebRq+znd7Pc2qQ5lbqjJ1w4u7O6HRiDn2yD/WtM9azNcjP9iWMoO4YGDjH8Oa0FbKg+oBrWjtY6U7xRKtPFMUing1qAEVGy1NikIoAqstVphwavOtVJx1oZSZlXA5qlIav3A61ny1mzZFeVq9U+HP/IrQn1kf/wBCNeUSmvWPh0c+Fbf2eQf+PGtsP8RzYz4Dp6KKK7DzAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkPiJ/x52X/XY/8AoJrn9OGSK6T4hpnSrV/7s4z9CrVzWlN8wrlq/Eejh/4RuRrhahnWrceCtV7gcGkCepk3Q4NYd6OTW9c1iXg5NQzWJzWoDD10XhVv3MY9AKwtRX5q2/C4xEn0FI1l8J2UR+Wpahg+7Ux6Voco0tSBqY5pgbmgpIsg0VGjVJmgkM0ZpppBQOw+igdKKBCimuMqR6g0tFAHnvg8gader/01PH4CnaMA127dl+Ufy/pTPCfyx6hH6SH/AD+lSaJyJGPGWJrzKk+WNRLq1/mE1eoi3NbtqN7b2SZ/0qZISR1C5yx/IV7MihFCqMKBgAdAK818DWwuPEwkIylrAz59Hc4H/joavTK9DL4ctK/c58TK8lHsFFFFdxzBRRRQAVW1G1W8sJ7Z/uyoUP4irNFD1BOx5v4YlLWDW83+tgJhYHsQelSXSvJCQGHynPPXFQyxGw8Z6la9EuCLiM+55OPzb8qvXERiidnPUZrw6sXGTieg979zJ1dvM8MRYH+rYKfqMg0sD5giPqg/lSarGYvDUm7o8gIHpzmoIWxbxf7g/lW9H4TSOxeDcVLGc1RjlB4q5Ac1shlkDigilHSlIqiCFxVSdauuKrTDiky0ZNwvWsyYVr3K9ay7kdazkbRZny16p8Mm3eGQP7szj+R/rXlU3evTvha2fD0w9Lhv5CtcP8RhjP4Z2dFFFdp5YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBieMLf7T4fugoy0YEo/4CQT+ma4DTpMMK9XlRZI2RxlWBUg9xXk99avpepzWsmfkb5T/AHl7GuestmduEldOJ01s4KCi4HBrNsbobQM1dkmBXrWd9DVqzM6771i3h5rWu261h3jdalmkUYuoN1/Gt/w6uI0HtXN3bbpAPVgP1xXW6FHhFqUaT+E6OH7tTHpUUfC08tWpzsjkFVycGp5GGKpytikykWEapBJWaZsd6i+2DftzzSuNxNoNmnCqltIHFWgaadyB4opBSnpTEITQGqN2qNX+agdjhNABTVdXiHG2Q8fialtAYRInRtxwPxOKLVRbeNNRibgS5YfiQf61faAfb/bOf8K8fEpqbRb3udp8OLYJYXl0fvTTlAf9lBj+e6uwrnfAIx4Xtj/eaRv/ACI1dFXvUVanFeR51V3mwooorUzCiiigAooooA4T4iQfZtQ0rVE42v5Eh9jyP03VJqBE2ngr97FdB4p0/wDtPQby2A3OULRj/aHI/UVwulX3naYm45dRtYH1rzMZHllzdzsovmgvIf4suFfQ4FXjfIOPwNZ0reXbqPRQP0qvrk3nTW1sp4XLEehJH+FVdTutoIFTS+E6oR0LlpKWetu1ORXN6Y27muksxwK0iEy8o4pcUL0p1amZEwqtKvFW2FV5RSY0ZlwvBrJuhW1cLWTdL1rNm0DIn716J8J5Q2l30XdJg35qP8K89uF612HwmuNuo39t/fjEg/4Ccf8As1aUH7xGKV6bPTqKKK7TyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlvHGkte2Yu7dN1xADkDq6dx9R1/OupopSXMrMqE3CXMjxq2uSO9aCXWRya1vGHhp4Wkv9MjzHgtLCvUH+8v8AhXHI90ygpBIQenGK45RlF2PUhUjUV0atxMCOtYt7MBnmpmt7+X+AJ/vsP6ZqreaY6W7ySTFmXkhRgY780rMpOKM2MebeRj/ayfp/+uu30ldqCuWs7F4J4HkXaske+Mdyu4jP5rXXaeMKKUUObT2NQNgU1mpu7imM1WZWB2JqlcMassRiqlz0NS2UjMvrgohIPTk/Ssxr798OeoqzqXMbj1BrnUctLn0Ws2zVI7/Q5/NhVvUVsA1zXhZs2y/5710orSOxjNaki0p6Ui0pqzMgkqnLJsarcxwKydRl2gEHvUsuKOf8Qn7L4ktL3+CRArH36H9CK1GUxuJc5GefpUGsxR6hp3l8eah3Rk+vcVN4ctdS1q2W1+xSRAfu5bp+FVemR/eb29etcWIoSqyTitRyaSuz0DwICPCWnE8bkL/gWJ/rW/UFnbRWdpDbwLtiiQIo9AOBU9exFWSR5cndthRRRVCCiiigAooooAK8w8YaTc6Nfy3tkubOdizADIjY9iPTvn8K9PpCAwIIyD2NZ1KaqKzNKdR03c8IhLNKZ5eW5IJ7n1qhfTb5QPevcrnw/pVyxM1jASepA2/yrg/iF4b03S7W1urCNoZXl8spvJDDBJPJPOQOlc0qLirndTxMZySsYWkr8grprMfKKwNMTAUV0dsuFFRE0mWl6U6kUU+tTMiaoJBVhqhkpMaKE61m3K9a1phxWfcLUNGsTCul61f8CXn2LxZabjhZ8wt/wIcfqFqvdp1rKdngmSWM7XjYMp9CDkH86UHZ3LnHni0fQ1FVNNu0vtPt7pB8k0ayAemRmrdegeI1YKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA9K4i+0C5gu5vssPmW7OWTaRlQTkrgnsSfwxXb0VMoqW5cJuDujghoOoydLbbnuzqP61ctfB4lH/ExmBQ8GOPPI9C3/wBauxoqVTiinWkzyfxLtfxPdJEAsUOyJABgAKo4H45qzacKKoXjeZrl+x5zcSEfTccVpW64UVzPVs9FK0UiVnbOEUsfyH50zbMeSUX25NLI0uCECD0OefyxUOyYn5nP5kUAOdZF64P0OKrytlSCCD6GpSpXnc5+rEj+dV5jxSY0jH1H7rCubQESMcHbnAPbOc/1rpL/AKGuh+HelWmr6NqlrfxCSL7QpXsVO0cg9jUxjzOxU5qnHmZm+E/+PVPpXUCuc8MqEiCrkqOAT1x710W4CqiZz3JBQxqEygUxphVEWG3DYBrA1eT93171qXcw2mud1WXMZqGzWCNPwZpTa1qBMwP2SHBkPTcey/57V6vFGkUapGoVFACgDAA9K574f2Qs/DFq2PnuMzsfXd0/QLXS11Uo8sTzq83Ob8gooorUxCiiigAooooAKKKKACiiigArzn4oXAkv9PtQfuI0rD6kAf8AoJr0avIfE9z9v8UXjj7sT+Sv0Xg/qCaxru0bHRhY3nfsJpycit+FcKKytOTpWzGMCuaJ2y3JFp1QvPGnBbJ9Byfyphus/djkP5CtCCVqhemtNIekJ/E1E0sv/PH9f/rUikJKOKozrxVppH7xEfTBqCUZGf51LRcTIulyDWPdpW9cL1rIvF61Bstj0b4V332jQHtXbLW0pAHfa3I/UtXa14/8NdQ+xeJBbscR3aGM+m4cr/UfjXsFdtN3ieTiYctR+YUUUVoYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhOASe1LUU5xBIfRSaAPH7ZzJdSOeSzlifxret1+Wua0tsuK6mzwVFcCPYnoMktyxyHdT7VG0M46SA/UVqBMigxirM+YxXin7smO/H/wBeoZVIXnrWxMmBWbdDANSxpmDfj5WrpfhXciG21rceI9kuPbDf4VzV+eGq34RuBb6T4nbOC1qqj6sWUfq1Km7TuOsr02ix4bGLZfXFa8soVST0FZmgri2FXpetNDerK73Y7K5/DFQPeDvvH4ZqeQ7f4c1UmcEfcxQNIjmuAy5ByKx799y1auGxnFZ87ZHNZtmiR7V4Z/5FzSsf8+kX/oArUrJ8KNu8M6WfS2jH/jorWr0Y7I8WfxMKKKKZIUUUUAFFFFABRRRQAUUUUAUtVuxYabc3TdIoy4HqccCvH7INI5kkO52JYn1PUmu6+Jl75WlQWinDXEmT/urz/MrXHaenC1yV3eVjvwsbQ5u5sWS4ArR2grjpnuKq2q4UVbHSpRoxYoY0HCgU/KDoKiJpCadwsSMw9KjYimlqaWouOwyQCqc61bY1Wn6VLKRl3A61lXajBrXuT1rJuu9Zs2iZscz2l3DcRHDxOHU+4ORX0BZ3C3VpDPH92VA6/QjNfPdx1Ne0eALv7X4TsCTlo1MR9tpIH6YrpoPocmNjopHR0UUV0nnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVFcDNvIPVDUtBAIwaAPDdMOHFdbYNlRXIxqYL+aM8FJCpH0NdNp0nArz46HszV1c20pWpkRyKeVrU52VZzxWRetjNbFwAFNc/qL4JFTI0gYt+/WqdjdmO2vbdf+XgxqfoGLfzApb5+tU9MjM1+D/dGP1/8ArVlc2aurHeaJHi0Wpbtijcg49RzVnToglso9qkmhDDkVokYt6mI82ehB+lVZpCc1qXFkp7Vnz2YGeKTNIyRl3DZqjKeK0biLGazrjis2aI9m8GnPhfTf+uIFbVYfgr/kVdN/65/1NblejD4UeLU+JhRRRVEBRRRQAUUUUAFFFFABRRRQB5b8QbkXPiYQqeLeNUI9z8x/QrVWxXgVn3dz9u1q9uc5EkzMp9s4H6YrWsl4FcEneTZ60Y8sEjVgGBU2aii4FPLVaIFLVGzimMSaYaTGPL00tUZNML4pDJGaq87cUNJVaeTik2UkVLlqzLhuDVy5brWbM3WoZtFFGfqa9O+EM27RbyE/8s7jI+hUf4V5fOea9A+Dcnz6tH2xEw/8frah8RjjF+7Z6bRRRXYeQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4lr8RtfE+oxtx/pDsB7Mdw/Q1o6dNjFS/Eu0Nv4jjuAPluYwxP8AtLwf021kWdwFAya8+XuyZ7VN89NM7C3nGKnM4x1rmV1JUHWkOrA8CrUjN0mbV3cDaa5y/m3E80s+ohhWVc3O/pUN3LjCxTvWzmtDwral5A5H3ju/DtWPOxkcJ3Yha7Lw5CI0Bx2qUrlSdkdLENqAelObFMVuKVjxWyOYikArPuQMGrsrVn3LcGkyomReY5rFujWxdng1z+r3AtbSa4ZSyxIWIHUgDtWTOiOx7b4K/wCRV03/AK5/1NblYfgr/kVdN/65/wBTW5XoQ+FHjVPifqFFFFUQFFFFABRRRQAUUUUAFUtXuPsulXtwOsULuPwUmrtYXjeTy/CmptnGYiv5kD+tKTsmVFXkkeR6X0FdLZ9BXNaaflFdJaNwK89HszNNDxSk5qNDkVLxWiMRm00xwQKmLACoZGzTsLUryMarsxqw5FQOwqWikRMxqvM3FSSMKqTNUs0SK07daoymrMxzmqUh5qGaxRUnrvfg2D9t1U9vLj/m1cDcHmvSPg3Fi01Sb+9IifkCf/Zq2oL3jDF6UmekUUUV2njhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcd8TbD7ToaXSLmS1cMT32twf12n8K83srdrmVEVsbjyeuBivcb62S8sp7aT7k0bRt9CCD/ADrxvTopLHWmtZxiWN2Rvrg8/pXLWjaSZ6GEqe449jTg0GLHzmRz7nH8qlOiW4/5Z/8Ajx/xrWgYECpmxUlubMI6LbY5j/8AHj/jWBrFolpJhM7GXIz655rt5Mba5LxYQEiI65K/pn+lJrQqnJ3OdtF8y7z2H867nS1CRAe1cfo8eWDH+I7s/wAq6+0bCipSNpGoJlTG78+tSbgy5Ugg9CKrKykc01o0bkHB9Rwfzq7mDRJKetZ9yeKmkicD5ZX/ABwapyhlzubdUsaMjVJ0traaaZiscalmIBJAxknFcKHju79YG1C4vIJMsYJF8t0xyCwwCV4x9fWtHxNehNTm/wBJmt9qhSssmxTx95BuBI5/ums/QBJdXbzLJHOir5UTxxFN5YjIJwMkbVH4+tTayLvd2Po/wchTwtpgPUwK35jP9a2qr2FutpY29uv3YY1jH0AAqxXelZWPIk7tsKKKKYgooooAKKKKACiiigArnPiGceD9Q+if+hrXR1z3j5DJ4Q1FR2QN+TA/0qZ/Cy6fxr1PJdOPArftX6Vzdg3Fbds3SuBHtNG1E/FS781TjbipUbn+VaGTRaAyKilwByad5M7jKo+PfA/majk0+eTrgfU//Wp6kXRWldP71VJHT+9Vx9Lk/wBg/if8KryaZKP4QfoaVmUpLuUpG9DVaRjVuWxnQZ2Pj25qnIGU4Yc+h4P5VDRpForS1Ul4q3IQelVJRUM2RSmNex/C20+zeE4ZCMPcSPKfz2j9FFeN3Geg5J6CvoTQ7Y2WjWNsww0MCIfqFGa6cOtbnDj5e6o9y/RRRXUeYFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwfj7RWW4i1m1Vi0ZAnCjJ2/3uvPHFd5SEAjBGQamUVJWZdObhK6PNrGdJ0Btpoph6BgG/FTVqSV0HzxyL/wE4/PFW9c8C291K0+mSLayNyYyCUJ9u6/hx7Vjf8ACJ+IITtjljcDp5c5H8wK53CS6HWqkJbMneckYVZGPoEJ/pXJ+LJAQkbMBJuB2ZyQMEZPp1rrI/CGuXHFzeRRxng5kZzj6Yx+tZnjPw5ZaBpFqELz3s03Mr8YUAkhV7dR6n3ocXa9i4TjzJJ3MHS0AAx0HSt+3zisfTEJUYrUVZ2JWCMvt6ngAVmdci6p96duwOtUWhvwM+Vn6EVWkmuIv9bE646nHH50yNGaUk2O9VZ5QapG63DrVHWWL6XcqqGRmjICAsCfxUE/lU3G42MrxDfTW6K7TPbhQWJNqZUxngHB4I9cgVY+HdjLea5pwuQTNPcC4lBAA+UZIA7DCjrzXHWUlw0ghuoBGrHaVeGeNiPQsoCn9K9c+Edkp1m4lRAIra3CKP7pJGP0U04r3kjOcrQcj1qiiiu48kKKKKACiiigAooooAKKKKACs/XrU3miX9soy0sDoo99pxWhRSavoNOzufPViw4rZt2xiq3iGyOmeIr22A2oJSyDttbkY/PFED9K89qzse9FqSTRtCTEfFaeiJvDSNyc7Qfb/wDXWErfIBXT6GgFnGf7w3fnz/WtY6nPVdkXwtKUqQClA4qzluVWjGaaYhVorzSbRQFyhJCMVQu7dHUq6hl9CM1tSKOaoXCjmpZcWcZfQeRcOg+794fSs6bjNbuuLiSNvUEH9MVz902Aawlud1N3iWvClh/animxtyMxrJ5j9xtXnH6Yr3yvMPg/p4aS/wBRYZxiBPY8Fv8A2WvT67KMbRPLxk+apbsFFFFbHKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnHxaJNxpa/w7ZDj3ytej1wfxWty1jY3SjiKQo30YZ/mKip8LN8M7VEcto6A49hXU6VCBb7scsS364H6Vy2iyDaT7V2OnDFtEP8AZH8q50d9Zk7RDb0qvJbhu1XT0ppFUc1zndR0uKRS2zDeo4NcDrH2aSZ4HcNLA5Vj9lMwHsSBwe+MivV7lcoa821Nv7K1O981HNpNL5okUEiNiBkMPTPOffFZzVjanK+jOMsmjGo3JN3bKyzDCK7ISu0Ywu7pnPBr3z4W6f8AZPDn2hxiS7cvn/ZHC/yJ/GvG7WGPWtfaK2EcyTCKEMQCpbc2PrgNX0dYWsdlZQW0XEcMYjX6AYq6KvK5nipcsFFdSzRRRXUcAUUUUAFFFFABRRRQAUUUUAFFFFAHm3xY0077TU0HygeTIfTklT+rVxNrJkCvb9c09NV0q5s5OBKpAP8AdPUH868K2yWt1LBMNskblGHoQen6Vx142lc9XBVOaHL2NmNvlFdrpK4s4h6KB+lcBHJ8or0LTTi3QewohsVXLuOKXHFA6UvarRykeOaQ0pIpjGgCOQ8VRuGq1K1Z9y3WoZcUYGvEBEPffj9DXL3jV0PiBv8AVD3J/T/69U/Cum/2x4ltLdhuhVvNl7javJB+vA/Gs7XlY64yUIOTPV/BGl/2T4as4HXbM6+bKO+5uSD9OB+Fb9FFd6VlY8WUnJtsKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKoa1p0Wq6bPaT/dkXAP8AdPY/gav0UWuNOzujxBY5tLvprO6XZLGxUjsfQj27112lXayxKqSIXwB5bHac+x6H9K6LxT4fh1u1PRLuNT5Unv6H1Feazw3mk3H2fUYXifqM8hh6g965JRcH5Hp06irq2zO6aYIMSgof9sYH4Hv+FO3gjrXKWepyxLiKV1X0zkflVr+1AeZIbdz3O3B/PNJTQnRkbdw42muJ15gt1JjuAa0brWEVSVtrYH1IJrCEd3r2ppb2iB5pOMKAFUep9BUzaeiLp03D3pbG78L9KN1rEuoyKPItgVQnvIfT6A/qK9YrO0HTItI0uCzhxiNfmYcbm7t+daNdVOHJGx51ap7SbYUUUVoZBRRRQAUUUUAFFFFABRRRQAUUUUAFeW/E/QzbXa6tbJ+6mIWYD+F+zfj0+v1r1Kq97axXlpLb3C74pVKsD3BqJx5lY1o1XSmpI8Fhm6c16Lp0wjhQS/ISBjdwD9D3rivEvh660C9KuC9q7Hyph0Yeh9DU+j61c2aBI5cqP4H5H/1vwrkXu6M9Sa9qlKB6ErgjrSlh61zsHiKCQf6TaRk92jOD+VWP7W09+R9pT6sSP5mtOZdzmdOS6GszConcVmnULD/n5mH4H/CmPqGnhcmWV/bkUXXcFB9i3NIPWs6eQMxVcs3ooyfyqKbW7KPPl2zufVyP55NZl54mnIKwJHEvqOT/AJ/Cpbj3NY05vZFLxGHjmjWRdp2FgD1wT3/Ku1+F2im1sJNUnXE90NsYPaPPX8Tz9MVyPhzR7rxLqoeXe1qjgzytnGP7oPr2wOlezxosaKiKFRQAAOAB6VdGF3zGWLqcsVTT16j6KKK6TzwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqnqWn2upWxgvIUljPOG6g+oPY+4q5RQCbWqPPNT8C3EJZ9KuVkXqIpuCPo3f9KwJtD12OTYdNmJ9VwR+ea9iorF0Is64YypFWep5NY+CtZvnH2oR2cR6mRgx/BQf6iu/8OeH7PQrdktVLSvjzJn5Z/wDAe1bVFVClGOxnVxE6uj2CiiitDAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK17aQX1s9vdRLLE4wUYZFefa18Ppo3aTR5w6HkQynBHsG/wAa9KoqZQUtzWnWnT+FnhV7p2p6cxF3ZzRgcbtpK/gelVPtjL1yK+gMVE9vC/34o2+q5rB4fszqWOfWJ4L9ubsacj3M52wwyyMegRST/KvdltLdPuQRL9FAqZVCjCgAe1Cw/mP6/wBonitn4a12+I8uxkjX+9LhP58/pXTaV8OlDLJq135g6mKEYB9ix5x9APrXotFXGhFbmU8ZUltoV7O1gs7dILWNYoUGFRRgCrFFFbHIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41077=[""].join("\n");
var outline_f40_7_41077=null;
var title_f40_7_41078="Sarcoid granuloma with Schaumann body";
var content_f40_7_41078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Well-formed sarcoid granuloma with multinucleated giant cells and a Schaumann body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 366px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFuAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDQ8QaTquoXEt1bXIiMgx5LVmeHbG70y4la7YefHjiMnBHqK7vwfqFlrlkrSxnz0HUHGfxrWnfw9bzMt7PbRsBkpu+YexrZ1WvdsfVusqb97Y59NXF+iQTxgDpwORVq0tJ9xW2glk+buMYrsNEuvDt1EfsJgdhzkHJ/lWJrniddOu2it0RmA5C9QPSsI1JTlyxiSsa7csI2Mz/hDt1x9odWjkJ3HDYwetSeJdftvCmnmW6ZVY/Ko67jXAJ8Tb681ko5KWxZkxGORj3qHxdpepeK9HYAtuj+aJnGNw7iun2Urr2j0BynKJxWtfETVb65me2ZYoC3CqOtelfCPXdT1m0uXvVzFGAA6jGetea+Efh5ql7qnl3kXkW6k7pGIwa9ctr/AEbwnZR6XaThpAf3zJ29qqTuuVbmdN1Jblv4iXSeHvD7aktrbyXzkJCzLnr1Ned+G/iXq9nqcbaqsLWMhG5Vj2gD1Fen+NreDxr4DEOnYE8TB4wOMEdvxrxvQvAOu6tqSW99C1tZxtl2cjj2pUuVwfPv1FzS1TPUdb+Heh6zerqVuZYo7n96yIww2eeOOK6XSbbS/CWjsyultbQrvZiR+Zq1b2629nDbRsyxxIsYJ68DFeE/FvUNVGstY3DuLEgFVGdprOEXWXLJ6DaUI2Pe9C8ZaVq8ohs7qOSUDcFPBIPcCtjU7uOK3aQIWCgsdvbHWvnH4PaRcXviSC8hWaO2tvvux+914Fe9ajrFpp1u73RAi9j371hWw8YzShqZezV7pHA+JdVv9TDqpJsWUjy4iQy+5PesDwf4bvrC9i1a7mEFpES5eRiCV7fhXTeFPE/hvWPEbQWsTRyyEhN/KE9SMVmfHfVZdNsYdMtyP9LXLADHyg9K61JqXskrGqqR3O5svEukXKSNBfwSbeTtccVztx4viutVW3T5Yg+zzc9TXhXh1bm6v4ILUEu7LGVXPAzXsemeCbwazbzXEsf2eNtzqq43H1NHsqdPVsuLi9TgviHqN1/wkcogmmjjiz91z19q3PhNBqD6i15N54gjAZnfPNeg6h4A0+/vnvblyx3ZZR6VvyQw2mltbWioihQoAXrj1pSxEWuWKM7OUjN1+fTvEMQ0jUGzDMN5CcEY6Guds/hN4dQ/aIr24Lbum4YwO3So20y/fUJ5VURzyDmUnp9Mdq6SytjbWgDOZGUEn5vvGoacFaErGzoLdaDreGx0mzg06wdIIM7U3uAWPTqepryn4s6nq8PiB9JtpJIbeKMSbYyVLg/xE9xWrr1g19qwu7qcu/SOAZwrE/KB6EHvXXeMfBI8WWGmtNcG01GGERyzhdxkGOQatONKSlJ7k1HKPu20OK+EPie88m9sJJ2kL4KtJyAfSu40Tw5ZX8815d2cE8ocjdjoe9P8K+CrTQ7NLbb5zlstLjaSf6V1ls8USokKqmecbSCfr71nVrJtuHUhWUbJamhptxFBGkQRVVFxt6YqrrV6qhWiIJ756daqXEwWU4ADEduxqrJuYKGwWPXmuWNNc3MxQorm5mM+2RWceUUlnbLEY5/Oqh1G5unxGCEHTjA+lSz26vuXjPUdqdCoEZIxhfbrXQklqdUYxWok6SNCpLcd17/nVnS4lBUTHLD8M1BG4aRSOQepzwKvxRRw75cHBG7qf8ipk7ImpKysSTQM7HbyvbHX8altYgiD5gvc8815F4i+Kl5I9zZaNaYaNyBKSM4Hp61Y+G2uahqENxNqErM+4bc/rVPDT5LyME3PQ7XxVo89+Ymi3HbkMo9D3rijFF4TlkmuYVJc5G85wM16JDcTzHqAB0x29q434m6bNqlmsdsu6RRywNVRk01CWxtFtKzNLRdf07W0aK3nRZSuCmep9qkhjis5JDMxEpOAGHH1rxfStN1PQrxbqUSIFO4Yr0zRfEEWu2rCYBXjGCW4JraVLl1jsUnzHYy20F7CgaQsWz92qdtpqj5WU5U4VqqWxfcAOEHHBrprfYiIrHJI5Jrnk3BCu4ann/xOt9RfRPsNqC0MxBfdyMg9Kz/hzps9raCzkbaCMkr2+temX9vHeQFWUFQeOOlZSRQWTiOOMBj3qoVLw5bErV8y3OU8Q+H763nnubSBbyGZf3sZ6g+q1z1mdU1KeOx+xzRxAgD5cYAr1KG4Mk5RDjjJz3rC1Txjp2i3MiHy2kXqOmPbNaQnK1rXZU3LudXDaiK1hjALGNAvNZc6AzPFKqmNzk5rS0PWbfWLFbq3YAdSoOcZpk9uLmcsjgMvt3rmTcZNSFSnbcxLLQNOi1WO7fzSVyRGz5Uf59K3Z7u0UyTK4XPBO7p7CsLxAkkemXLlirAArjtXj3iHxZcPIkMJZDFnOD9/3reNL2urY5Jc12e/w3aXe3y2DKvHynrWs0FrqelT2spUebGVPPtXkPhjxVZWfhy3u5Z1WRvvLjkH0re0/wASwz5ntplUNyENZVMO3ougqlFSV4s838T+Fddl1oiO3kmt4TshRTwQD6V6z4B0ubR9DK3pxI53OBwF9q0bS9iuf3jAbx+g9KtXVxGthJIdpVVPQ9fSqq1ZSjyNEOPctx21hOf3siIzcDJHNRGx8t2FuWEf95uQa8C8e6hrDeIYp4PPFvHjYEJC/jXtHhbXrzVNGhN1FsYcE96idCcIqSZk5SU2kdBoujC5uRNLkxqevrXZxosUaogAVeAB2rP0LYllsBGc5I7VneJteGno8aqWPTivPm5VJ8qPOq+0xFXkXQ6IkBck4HqarWqiSR5iCMnAFeZHxTcXdzGrOVi+6Vzya9D0C5Etoq7huxkD2qqlCVNXkFbCSoQu2aMsauhUqMfSsu501ACy8Z7dq1zVaedQSoIJrDZnPSnKL904iX/R711lIEfXPoaZKCm6WI5Lc4HIp/iu3l84k4APPHWsDS4L0SZk3GH7oyelejTSlFSue9TtKKlcvWytNksG3A5/+tRU1q6x20rMM8nmiqd29DXVvY5n4eWtoYmijZUkC7cda8V+JOlahpnivUDdLJh5N0bEHDLjitQ3V3pN48yvLEY9pQr/ABZr0/SfE0GsaXCt7FFPcIgJVhk/rXa4ypvmWqZzTg6kro8M8PXepWMyPbTy2ykYaRcgAV3HhXxB/b+pm2njaOfZgzg5EvPeu71nRrPX9HmhaMWNwinaVXjBrzOyszba5FvuQxsmwqqNoYZ71pGSmvMuKUVY9J8PfD+10+6e+ukZvm3Ko+79at6vr1r9peIOi+X8inPHHaugstR/tXSYzABuVMMAa851rwhNeSs6tKG3HJH8X4VzQ95v2j1LptLVmJ4i8Uz2puIoG25AII61w9tLNdXSCVS8rtkccda9Xm+HaGxjlurqGJwuWLsAPaul8H+EbGymaaQxTcALnBFbOtCCuhOdm2hvgCykhs2leSRllK7VYY2gdhXR6lcxWQCgqszc8+lQa5dpYH5SFVO3cVyU8dzdT+cZAY3POD0rn5faS52aJX95mjqniZIAyWsUlzOFLbU/rVO6W61G1imuIIJ4yQdjxDgd/fis7+1l8N3rKtr5jTYjZlGcHPrW4uu50/c6LFITxxwRW3Ly/ChNNm9plzapaCOCCOJEOCijGDXB/HWyuLz+x4rMt5czMGGcDIx1rbt1ugiuU2+c2R+FXtW0xri3Mc8hnUKCyY4GaiKUJ8xlUhF6I8f+Fvh25k8ZWzWu6XyJCzlei+9e5+MvAVh4rvYZdQkljeIbSIz1q34LmgtrJVsbJI1QbWCLjvzz3q7qWoKJy7lVCnnJwKwq1Zyqe5pY5+RudkZ/hfwBpegMHtIAWTJ3Pyfr9av6zdpH8sDxIxHA4rO1PxM0XhzUbgsHS3hZ1C/NnA9a+ZtS8T6tf3clyXkAZtydRgelOjQnUblUYKLjL3z6AsWvLjVQs0rLH3PrXQau9vFGEZgWXjA9KwPhrcz33hOC4u4z5rDG7HLYq7NbyAAFcH6fzNVLWdn0Oqmk3cjMjy8hSFzgUjrIxCK2CRnJFWorWQqcDAH86aLWUbsHqOM9qE0dHMjmfE+pJpWh3t2SiXSoVjcr1Y9KofBXxBf6pqk1rfSySI6BiWbJGD1FcJ8R7i+1bW3spCYobd8LEeC59a9D+CejHS9PudSvJgry/JEDwQvBrepDlou+7OavPn2PcLixhlj+RO3BHauP1iCaGYmM9Bn6D1rZtPEcEaeXujYjp81QXcn2yUscBe5FeVS56b1RxUFUpSfPscnJqcEVwsU7ZlYcnOMVbt3V5A6kFCMCsXxH4faS+e9hG4qPmXNJ4cM0alCDuzk59a9C0XG8T0IyvodG6KGYkZJPaqUiSNKNh/CtGYmOyknK5ZELbc+lc5pnjC0kJF1bvbHOFx82azipNNpbBGdjsvDWmhpS8wAQDntVTW1LrLHEODleD0HrV/TtZt7iwzaMssUqnBHY+/oa5zxFqBRJIYXCykZOe1YwjKU9TnhzyqOUj5z8S6dd6Pqc8aeYN0hILDrXrfgHT3ttDt2kUqZxn5uuO9XNMgWRRe30KyRxZJ3L3qnd6vDet9pW8hijbiNFOD+Vek5OS5Tde6z0iwhygHA4x05qO5sN0mQvCjpjA5rF8G66uo28kHmiSaE4JHp9ak8XeMotC8oTRmSSQhV7c1wOFT2nKjK8k7or+L9PEullfKHQbhjkCuK03Slt7qHyspGXwc9OtddbeP7a5uoLO9gEczDJK8gL6mt5dHsZYxcWyoYj6dCT3xW0ZypK00XCqlpJGJ5RjACk7RgEen0rR01trbWBJzxmqmsCaGTFtHgLxx3rBudels52ht491ywBYn7qj/Gmoua0NXqjvpSfukHBrn9Zvo7e42ONkg5ViODUWma5fSBBebJH4+UjAx7Va8W2keq6XLPCrMUjJVR1OO1Zxi4StIyjeL1IdHha+s5X3HLAqGHBrwfxLD9i1PULfUS+6OUkIep9OfSvcPhtqsC6RFtAxnDKx5B9Oa6LxB4c0XxAgmv7aJ5AMK2MEAfTrV+39jUaa0InKUXZnjvwS16cag1m8Za2cYOecV6zNdeTMWwME8GnaZpumaPxZQrEpGD8oBNJeR7t3IC43DnvSnNVJXsOkrfEGp+TJbLlchuue4rzvx78OodQ019Q0gmK6jUs0RPDdyB712OtXMtvp6yuo/drl9pz+VcDZeM4Z7h1kkkEbEhVPU/WqpQlvF7Gzgmir8OdKlvdJuNOvbb/AEfAcGVRlWx/Ca3NL8MG1naFSdq8jnnFXIb1p7oJDC4ULuDBetbVtNPaQMbhPnONr4/StZyd2xx0VjW03TbeK2G3KvjBJ9KVgbV1WVd0JOCO1TWkoe1Qn5mxzmq95cHzl6YXr7VyauTuTG97MR9P03b5vlKyZBq5Lc21rbeXAqhwf4f5Vz95epE23IBJz8x4xVS71IEKY7cE9Qc1apN7sXs1c9B0/VFhsSWUiRhwcjFcrrMj3hm5wX6epqnpOoC6ZYpGKyAY2sMVsRW4BwM5zkn3qFTVOTYQpxpycluzlYbdxqAUR7XHT3r0Tw1dNaJmVcL0+lZJgigJkfAYfxe1cf481+7gWCDTwWjZ9rEDqKuS9v7iFWSqxs9j1XUfEkUcLlRwv45rF0zWbmSdpZI8dgvWuJ8MyyTykXbvs4IB7V6DblY+I4VIxWE6MKSta5h7GnSjZLc858W+O72TUpIYIo90Mm1o3wCQOcius8P6rBrGjx3SjZkhXjJ5U968z+Nuj+ZqFlcwIyTyNsYjoT711vhiBrPwzYRKwLFMsOeT3NdThB0k4qxsoJ2jHRHY/ZknARSqgc5zRXF69qU2laXLckHfGOgPJorONCb2kTKMl1Nrxt4MspdMa6s7VWwwyo7r/SvNE02TTtWWTTbdXViVdAefavbrfUM28kbN8jdj0qilhZG5Li3QMx5KjrU0a8qcWp6mdLmgmpGPoOi3Nxpkn2gv50mT/exx0rgtZ8F3thdz3cgY7cvkele/WPkWkIYYGRkZOKo63JbXds8Ywc8HjNZU8ZNTfYwVeUql0tDzTwNeAxNu2xlRhl6ZruImhkj3BASPzrjptOa21LyoF+UqeR0H1rSs5HsJAjOGY8iIGumrHn96J2yimrnz/wDEDVtY1XxDdRXM8sSI5CQLkAAd8frXp/w3bVI9CtUundpQvVzzjnFdfDYaXqV/LLPZW/2zrukjG+thIbWxkICBSfu4HWqqVlblSMqcVF3Ocu9JvLzcbgZz79PaqMunXsMXlxx7lDA+lX/FPjvTfDbYu2826blYl5Jqt4e8daf4ncRwbop2UttIA/KlF1LXtobe0bfKzMTRbq+mIkkjiJ+8NwP4gVoweH4kvraOYmSNMHc57+wp2k6PdLrLzTHCbiQ5bJY10l7aNNCHi/1y8fjVTqWdrjnI57xheT2FkDYQ7pFcBeM4HakvdYex0Zb/AFZVglkBJjj5Z+wqxKLrCLcxO7ISwUjNcH4q0LXPEdxBKgZUi+6kjFAc+lXBRaSZmlfY9D+GfiGy1LTSLaUGVifkf5W//XXj/wAX9b1F/Gt5p1xcTQWsDDakRwCMA5P512PgjQLjTNeso5A3kiTe4ZcBWA6g/pW78RvhfbeJNWOrW900U0qjcnrWfNCjWvfc56vuSOG+Ft82oaRq9nqEudO8sqXY8hTjiup8O+CPCMxigurt7hlO9dw28HoPpXN+JvD3/CH6RZ6bbynF0xZ2GMM2eh9qZ4WttV1XUI57JQI8+UzuPQck+3pW8vfi5xlZM3tzx1PdNGtIbdRDbIq2yjEagdqL6xId2xhexx3qWxnOnQwxk+a6KASBVu7vRPGylAB14NePeSlc5uaandbGXZG1DbbqXy1HSpvN0xrgATDJ6Z4yK5Dxnf8A2WBnLkMp3dcYrh7HWr/U762g8o+a5U7hwMf3vpXZHDc65rnT7By9656B4s03RL69+1SWEUtwoIDY5x/WsOWR0WNIYyIguML2rpY7dFdISC5PO/rg1mX6ixv9ocbHGcZ5rSm7LlNYcsFyowBJb/bH8yUqSAxyeAfQV0PhjUZzcfZzKZ4yuQw/h9qyWWCW+DmwVgw5yMjr1rp9KENgn7q0CR8ZAWqqtctrDlrE1/3e5A/BIzgVXmtYYpVKIqgegpi6lauh3TrGT3zkn60rvGxV4pw6DBODXKotO5ilJPUvmyW80y6ibHK7eOpB/wAmvmvxDFq+j61HbASsYJmWNVi3bkzkHOK+gBq88UjBIv3Z4J9Peql0I5n814WMueGA5rWhOVJu6umEISTdzF+Hjt/wj8Uk0EscjuWcSDad3sKn1jTDdaikyuTuxuwelatlG5dklG4A7hWpZ2sT3OGxjPQn9acqnLJyLk1DVmXqGmxv4engjwHKEDPNfON74f1G1n8xcZD4CdCK+tNQjgitxwMelctqGiWF7IjTQKcHg0YbEct7mUJc/vHG/CjSJ7G2uHmHzO2c96xvjJHO+oQsgYhSHA+let2sEdtGViUIuOw5FZXirw9Fr9vGsjeVNEcpIOmPQ1ca/wC95mWnbQ8itZrJLVL5L/8A0yRAjwkc49D6V7R4FUtpNmJmBVssufTtXG6J8N7ayvmnvJ/PG7cYgvDexNegRosMQS3AVFG0KOOPSliakZx5Yky94b4okhsLUyqAxGRivG4rllmuZJLkJPJklGGc88CvU/ENza/ZSl8+FcYX6+1c/oei6NdStMUSaZMDDdRRh7U4alwvGNjGsBe30Md3ZmXzYcKVKnDfpyK7zTkkWwjEy7XZfnXtzVpTHDAu0LGinAXpWbcatGLlVRgxz27UpTdTRIu7kQ2miWVlPNNCGRWySg+7n1+tbOnzqLYKScKepFI/lOu8uEBGeTjmlhhjwRkFT9Dms5PmWpLd1qYerTFllMZwkY3f415vrXjSeGye43ttSQgKD15xXrM9rG+9ZMbG4Of5GvI/GHgq7Et1b2VsXRz5iyDnOewrooOOzHKSsdp4O8R23i3SWty3+lqOjDk1yer+FEivw8luYpEkGJE5X/Jra+GHgefRJRqNw5DsmBH3X1rvbu23rI7gCNRuIPSh1I05tQ2JpydtTH0S5trdBEQuQowSP5U64ujeXjRbFaPGR6c9a5a68R6Wt6Y4ZVY5xuU8Zrp9Kmtbm3JifeTg5GOTRKLXvWNUlui7paS20Jgu5vNIYlXCBflJ4HHp0zVgR8ncACao3Gr6fb3kNpNcoJmOFXI4rSRSyYQB2HQZz/nisHdasWxyHiWxubxriG1ZVm2jAzip/B2lvGYoNSdZhGuce456/WtHX9NeOWLUYleVovvxjPzr9Kh0LU4C8138sQH3VZsEDHpWylen7pMnzB4miEUouokCNGR84POK6O0Pm2kUi8LIgY/WvM4dS1nWfFMloySHTlO3eVwuPrXoks6JGkVuQAihdvpxioqQaSiKzehW8SGWeyaG3cI54yOaq2OmI1tFFe7ZH5wfSprV3mumjljAx2HYVoKpXBH3R61N3BcqK20F0HQ4muiVwsYOdo4rtJLKKKPOAAOeOormtJ1D7OX3D5Rxj1qbU9fjkXZCWLflXJVjUqS8jirwq1KiS2Ev9LstVjaK7ijkCNkhhkexqm1lHDEUhjQIo2qB2FTWl0yW5Icc9T3pZ3HkyMoPqB70Lmj7tzWKlF2OS13SzqVjcW0rKyv8px2FFaOnmT94sikru3DPUHNFdqm46HTKXcq6VfC806KUE+Y3ZfWtwSR21rJLIwCou4knHSuX8L2zQabDuHIBJx61reIYJL3w1ewwgvPJHhUDBd3+zk1NSKcrdCahwd78V7ifWFtkgiW1jk8tmbOdueuelelaZfR3VsJEIZGAZWH8QPSvne10G+XXjFqlpJaozfMXI2he5GM817n4emtoxFaxyIdqBQB0PtWuIpQUVyoSinAtatcQwSLvxuZsDnn61z2uRy293DcoRIyAEe9a/iFXgnhmeMGLdwSOK4ufxbDq+uRaSkLRhjzIOlFKLsmiVJS0udxos/26/glVPLkQfMR9O9ad4HmujKR8saEDnv8A5FYuiX9nY3RtN6rKeua67SrZLtijFsdM4HT2rnrPllzESap+8z5e8VaLrmqeLbiZLK5n3uQGSMlQPrXffDXwFfaXOup6krRFUKxRMOpNfQNtp1pZoAkaBB329PrVaSe0mlKbgAp7jIzSlj5SVoLQ44V3zXitDkNTuRpmnyT3A5HRcdTXLeEfFc2pa2sEgUIx+7jp713/AIq06xvbKRJZscdAckVwfh3wq1lrpvI1eNMY5HLD2rSlKEqb5lqdEZyqa7Iv/EPxKfDctosUUbNchjukOAAPSsfS/HWk6npn2q+litJEOGiJwc+wq98VNAk8RaPCsQLT2xLKBwTnGRXiLaERq32e98y0ZVzifhmPoD71vQpwnTXc3pNpH0rot3bXdgtzZypJCVJDoQaqW+stc3zRqjC3BIU9zj1rkfhZb3VrplyJVaO2d/3S+gxzXbQ2Ue4upC85zWE4RhJp6lOK3kZPizw5beJDbm6eZUjGAF647/StXQdHt9OtY7e1QJCoHGOvufU1fWHbGWU4HueRT7SYRvyCTmspSbjyrYhy918pqQWa7Q+3ryCTn86o6rdW1jbO87pEFHzFyAKvPfhFKg5z2x3ryT4qXN5qqf2XZJI5OGkKjliccfhUUKTqT9456UZSleexy3jHV7nXo5LbTz5oWUR5i+Yt7j2rqvB2htpOnRS3rl7tk2/MfuAdhVDwH4T/AOEeVri8LNdEcKTkIP8AGu0kUyRquAUHK4PNehUmrcsdj0OhbsopGtZWDbCckE9c44rlr2wnutTjae4LGLklTjNbQurkr5cUZ443HtViKxjWPzpVJk6E1knyttkWtuRRxxiSNLWMMNvLnkfnW3GrCEbCokX7wPQ14b8Q/Gup2utTafpkws4IRt4BBc9yPaqHgvxl4i+3/PcNKkGHYStw6nt75rR0JSje5lOab0PdmWxZz50arIODvxxRBDA3MGwgHtVi8himiEpiU7wCAeo9qp2GnuY5wGZMnAA4x71zJq17lKatuaNz5EMHmM8RHoDyax7jXrAT+VGxlkUfME5I+tZniFpdLj8i2YPqEqlQz8qidCT71y3hO1uLNbmO6bzY5iz+Zj+LvWlOiuW7Y0kvM9QtJkuLcSRDC9CCORVq3/dsWJBA4981yH9sJoXg8ahcHLysfKz0Ydv/AK9ZXhzx8b61BuY0BDlfk7Y9ql0JSTtsZtXbR3+sTmS2whBb1HWoUcfZ1D4yB1quG80JJ2YZpA23cHPA6fSoUUlY0jG0bItoSFyvf1pGu1VcuyhV/D86qPcbodvYce9YWuGS6kjtEl8pSvmuRxkelVGnd6j5O5sSa9Zx7wGLAHllBIqO31e1vJD5UqgnkA8E/hWZ9mcacotPuIOQ3BbFYdzq1gshWRRFdrgKTxgjvWsaUXsOMUafjieGG2gkn/1aEk45rirbxB9hvB/Z6/u+HyR1FdxCbfXbForpNxHBOMDHrVL/AIQxS6BZQEU4C47enStISjFcshPR6GhNqEmoWUUwGwOoyF9ap2dlLkymMnbkg4xnFa1xD9hhjt7Vd7AYAx2H9akiWe3t0Dytkgkg/wAqhNW90u9keQ+NPGV8988VtMEWFsCNARk+9dV4F8Qy3GmwuxcTvJtEZbKk57e1WtT+H+na7O90plgumOZEXG3J7jjpV/wv4JtNFu0d3kleJ98YblQfU1o6lNxszLW52D8khzgN146GmrIYwQ4DbfUdvWnQs07Sfdwv8Oec1m3mqJZEm45A7Hoa5Yq+hVmzaikDIPLbch6gDIqORY7hZoZMhXUjk9iMVm+Hdcsbnf8AZ5EPByD2Nac0T3UJCgeaBkH29PaokuV2ehm9GeZXngWy0y8d7IyypIdx3ENtrovCWjmwhk3A4JyC3UVrRRP5jbuueQauROLdmD8o3auiVSTjY05FFaHkl7K0fiG6fUI2jRJCI5G75Oflz9K9I0TVIUt4ZLmcRh1yGkO3PtzTb7TLTUbiM3EKyKpyCedv+FYXirRWub+1myfsijBj7Bh7Vbcalost7WO6bULS5xFFcQyPjO1Wzx9KyrnRbe8uEZoEDH+I1zfhS2ng1SSaVf3MZ2IxX/CuzW4csSqZ9GHSsZQ9m7QZkrp2Rah8Pxm1xA+MdlwKpNpklpcDguOwx09zV+w1S5tmk+RWU9AR0rWt7u3vVZpFCyKOhrmlOpB66oxdSrBu+qOfjRhMGZVB68VDdSO03yFcDHHep5pBFPNswYh0Pp61j3s7S+W9myurcB19a2gru50LXVmlErMVAyMd6gSN5WfchG04yKhja7juSDLuUDgHnn/9daETFyxkARsAEVTutQ5iusblxHnCd+1a1ocKQ+Pl7Y61zV9rK2F/5d5GED8RlTndWxaXiTQ+bk7T17EVFSLauFRNog1K8S2FwzgbQhPt06UVHqkS3lvIIeQwKkY9qK0hZIpRTW4+1tvs8caHhgOTWhGVL4Q7vp1rL1XU0tNMur+bCRQxlySOgFeLWnxPlj8RLO2/7AXAxnkA96I0XUTZlOa2e5tfFKw1Mav9pjRvJ46H3qr4Tvb6xvRcXUbshIKluleheK9RhvvDkNzYBJjOnmp2BA9a8yt/EK3TSWS25V9u4nI5b2rrpNzhZoKdz2/wj4o0LxPazW7PH50ZKyRsRlT0rH8a+ErHQ7K81TR4ovOEZdcjOeO1fNMaXtjrLvC08TBy2UypIzXvvw68SXOqqLW7ke5gCn94w4HqCa5pUJUZc8Hp1RyqEubnR41otxqN14qtXEsry+Z8x3Hp6V9eeD4/+JeC4bcOhNcfpvg7w+Lx7y2tVhud3zY4Ga66G/hsbPaG42+n8q58XW9taMURVjKUeWO5T8b659kCWsPLsCTXHpPqF4x8vdGuMEjii5M2palJcSchugYZwK6bSbIMgx3HA9aatRjbqehCEMLSS6lLSdNk3iScmSVR7459q1GR1B6bgMVuGFLWIMQBxk59K5zU7lS7FDzjgjjNYxqOpI5YVXWloQSqrKgUkKc5Oe/1+tZup2lhM8S3cEcpXJyyg4PvXQaZZm8jLJjheSeh+lYOpQq10VBBHfHatqbTlbsb05JycewW6Ksa/Zl/ddNo9K0I5DlQDhSO/esG9uY9Ot3luHCoBkkjgCuTi8aJfzTR2NyHKdumBW6pOexpKzdj1CaXZG2T8x9Tmqwc7PvcdBUfgySDVtI8/O5/mUjPcVeRo4ZdpAIzkVz6KTj1RipLVIyWuZ3m2qrlRx9acy3Ej5VAD0yRmtGWVEDbBkNz9ajgugr/ADAehNWm3sjXn02MsQXWGWXaSTkZHWn24YA+eDGQcbcdRW3lZArFQpP+c1Gtuqybm53Dd60lU7i9rfcLUebb4Me1iOenFV51BdYn+VT1x3oQSozhzgbuBiieM79wOSB37UluJLUwvEXhLRtbQfbrfc68b1+Vj+NVdD8D6DoUwntoppHAyvnPuGfoa6NcsRng569qbdxnkF8J1GDWinLa4+RXHzSvgMuMHsfSrkOowptBUoT2bnmskPtcDt704qZFBGTnODipcE1ZlSpxlozJ8Z2F7eS7tPwpkXYzjtzWPaWl+ttHBgq6nDuRjHqa7axvDbOVkjLj04zWheXlobbMwjiPv0xVqrKCUbEOTi0raHj/AMa4L0+H9LOmRu9patskVOwxjJrkvh3pst0Wedjyfkw2Oa93sprecyCMxzwnggYI/WpLbSbHz1kS3ijwcgqoFaxr8keVomSs79B9ghjso0dThV5plwVCfLnk4rSkCqpUD5c4x6j1rMnG4Yxx047VzRd3cumVJpVWMk7dijkVx/iPWkEiT2yNKy5jfbj7nernjaeSG1RYeruFLDoB71lC6jl0lEigWOWLHmSMAQQK66ceprLQtaX4gjvLbYZArqvyqDjj3qnqulwXsiPJB5m7ALg42+9Up9P06S4WSI+XdoQ5YcBxnpXbafpaNFHJI7NlQVAOKuTUNUQVtFjW2tR5IwFIUZP3gPSuqgkM0alRznjNc5qrC0kiRSGbn5RwK1dF1KI2pSQDefbpXPUXMuZCnorjdVkeK6t2iAL8g8VmXQu7q4kSH7hIyeeO/Are1W2E8BdMFlO5Py6VgWl7crL5ZiLIThj3U+9FN3Wg1qrkq3c9le2bPnYx8uTP93PWuju5oowX529VPrWc8YkTecMPXFXLSMyWXlybevA9vWoqNaMh73IkYAF0PDHmsHxTpzXul3BjB81Fzx1NbMMBgXYz7h1H0qVQV3FhkH8aafK7o0tpoeA+fNosAlaSUSFsYB6fWu6+H/jWQ3Qj1R2KTEBXJxtrupdI0m5m3T2kbMw5GOM1Tm8B2T3Xn28oSMnOzGdvtW0sRTkrTW5hNtOzRtXUllHN+8nVXboAfvCq00PmKRkhlyQM54+tSPa20aIGQFlwNzc5pjOIoCF4aQEgn1rnXkaRRz91rpsldLeJmwSrMRxmreja1Fd4jvIxHIx4Ixj8aw9EF1Nqj20MSuu0liwzg5qx4huba1uYrUhUmIA47H610OMb26jerO2RESNSycHkBemP61KEjWMY556e3rWV4XvGutO2S58yL5Wz1x2rUEqFTuIBB4I6fSuSaknYzdxY8DIQfLnjmnKARx8oJ64qkt1bLOsS3MXntn92SMk+tW1R967+nt6//XpNPqMrS7I97Odq85PoPWsXULywt4oIUdY/MbaAoxk9al8Uwz7P3Z/duDn1rgraC5W8lW5JaNRuj7muilTur3KXc7Z7tTbN5km0g8YPJpftTIqvEkhO0ELnmszT7KeUD5SsaDLK3Oc1fjs3uJ1YJIjYAH4Ht7VWiLTRqX9naa7pcbSBkkT5gyYyh/z2qpoMDQIYDJ5sa/JvOcmt2OFYLUIhUqPvH1PrVeKIIvyDrz1rFS0aWxEXoR/Z3t7wquTC64Izgg+tFWInHmBG53DqKKiTMZPXVGRqulrrngq5tsDfPGMNnGDnP86+fbrwLqVrdstwbdYw2GkMoOPqK+jfG10uieDL6aA7TFFtXb2J4zXynf3d5eXPmxmQh/vZP3j3rrwrbg30uS7NuR9DeG7PTb3w3FptvOwlgi2Kyk8ZHSvCdatLzRdYmhQMjpIQpz0966b4e38lnrMPkXJYjAeIdjXqfiXw1ouoQNrN/GwkiTe+CQG+vrWifspWezLnF810ZPhOwsPFPhewi8QQNHdsWETjIZ9oGeg9D3rtdM0i00q0NtpkKRRLwe5I9a4S18S3GjNp+yS2l0tl4gUDcvpzjtXoFpqsGoyobQttkXPK4A9s1hVU4u/QtRsRz36WUhJfK9/r/SuUvPHFu+oSxSShgmB6irHiXwlrMv2idLqMxyHKgN0HbivIJ/DWr2mpy/bYZDg/KRyHP1rSlCnNXTCFWK1sfQXhaa31O3861YOOn0NdjBttF3sRgDGcd6838BRvo2gRrMoS5kbLLu711sl1LOgy3ydRXFXpOUtNiK0ZVHrsWr7UzcZjUk88cVmSiPeS0i8ZyCaxPGutLomgTXqL84O0Z9a8Pn8S61ql6scM06mRsKsfc1vSoXV1oaU6cYqy0PpOx1Jo4zDb8r7etVJIR5ryFS0jDBPbNYPgG1vbbTo/7SLCZuWDNkj616FMllZaLNeOokdImkHPt0FYTapSsupnWnGg9FueP/FC0v8AU9OihsGGFYM8YYAkD0riPD/hzV47iVoLZi8xx8y4KjpVa21LW7zXmmgvHkDSB2jUjAB7c17vpkJhtITONjsAevrXoTk6EVEtWauHhOxbRdFjtxw+csAc81PMxaYtuPHIB7UtxMoRgvbkZqjHOJD9/A75rjSu3JlQhbUfOzODtJyDk4qELufuPcn9Kkdo334yvp71AjlCwZW6irRsloakEjIw+ZsY6EU+aSUvhD8gx0/lWcrFpCQcmrKuyZJ596hx6mbjqPNyxQjOSOxqFmdcjduJ6+1CkEfL1Bx9aD+6JLYyRjI7U0rFJIQTccrz0zSo4ZsMMjqKY7qWXA478VE+VfCHr6dqdh2TLM0tvbwtcT/JGo6n1qbTL22urfzIG3DdzkYIx2rm/FLCXw9ewyTiAleGPYgg1jeBNbt543tGleS6OMuRgNxVey5oNicDuZ3jeUlRwTnArm/ipDdv4OE9iC7xyDzFXrsxya1Ed7diSSyZ4PoDWnZXIaJ1kUPERyCoOR3qdYNSXQmpB8uh438NNRvbHWYBJJJLa3JKFf4R6HHava4pTn5SB/L615rfeOvDulaxNDY6bGlzkguvGT0rqvC3iOy8RWhntBtdGKsDWtZOfvctiFrudFcM2cAYGOvqKqMwPPtS3BYgFeR0PNQrgKx6YFc8VoXCOhi+ItOXVLGSIYDD5h25FcrCt5p6Lb3Nv5qLzkgYxXdSYZdx6kenX2rC1GeU3PlriPb1bFdNOT2NJIxbG1utU1JGnVY7VTwvfGa9Ah2paFSBhRhcd65C1mkinbaS+5sEmun0lzKnlspI3YzRVuyHZLUz57fzbvcUJA7nipnlgt2SPISUkAMOetbk9kHkVkOMg/8A6qoxaVAJmlkAJPTcCayVRNE81zQtYt8AQuSx6ZPP4VSv9OAn3xvtkzyOzY9q07IqjLtXgZIP07VdeK3uHUybDg7hx0OKwdRwlcyc3B67GBBbEnMrt5YboDVwv8oSIY/hX6VdMcG4oAFU9eOaZabVUmWFlPIw5BOAcA8evX8aHU5tbDc12KVy4iVgy546g/0rPRzwIlfy/wCEVc1R/NcIuWUjoOuKdDJD5IB5K/Lgc4q4u0b2KUrIpCdC4Td+9wSM1dsboh/LZs54NZ5DtIxKKqDgFeM+xqpHN5Uy7jukU43Y61fKpI1UVKNjqFtxL8zfMufyFQXFuhiG/p0Bx09KLK7E6Yz8y8H/AAqxIA4YDBbsCa57uLszBtxepxhgm0fWJZSVW1nGBIefwrL1W1tpL9Lu6BUgjBznFdtf2iXEZgu4i0XXryPcGud1Tw7Ndr5bXYe344I5x6V106i6l3uXPC0oOo3pQt5ZVcDscVq6+s8tlMLI/wCkFG2cY+YjAqvp1pHp1oIkfaAOZG61SuvENjHMLe1YXF2RkYPyqfrUSXPLmiCTvc8Aex1j/hI44J4rlNSD4bLHOc9c9K+mLOeeKxtRcHfMsSK59wB+tc9KdTlupJZmh2gDkRjj8arLrdwsjwzkbhwCehrao3USXYUKVndnY3Ea3EeXJKkZAP61kvpVuzF9pUgcMP51e05nuLNWJwxGMdQKnbHl7sDZ29T9a5ObldkNO2hmsZYERbdATuwS/GPetSGEiVQmQQRncetQW5yCrbWI/PHpVuEF8swGMjGfT61MmyZNhfALGcttHY57Vi+a4dQ5O0nGAcZq7ql1H5e3nrg5/lXPnVrYXSjdna3QitaUXY1px90662tNkZlc9TyT9KKo2uoLMVWFsoT81FYyhNvU5+SXVlfxo9ifB2oyakpkhWEF1zjvxXzP4d1RINX8q3topI7o+Sglydgbj+tfR+t26+KfhjdPYMjm9twyBTnJz0/Svnvwh4R1S98SWtobSeIxyq0rspARQck12YWVqcvJmKqWmzvPB/w71G31iKa7ihgjgJcupPPtj8K9Vnt7a8hm0+fLROuDjiqXjfVG0mBjbBnYrhefvE9K4jw9rOorO1zqFuAC2GIY5U+p9qXv1o8+3Y7ornjdl+P4fKNSvBDdmWxlfaYpFxs9cGuwsrFNF01ILZssvRu9XIrrzljyoAKhsg5FU7iQXFzsX7vXjms3Oc9JCpwa0ZNMshsZrqeRljC5Cgck1labqN1JaTxXESB1PyqAeldHpCXF1aSLNEY4hkKCayZrq2g1dIWdVPTZwOfUVMJauNtiIy5m0R2WnylhJMvBGVAXpW/Dps4j34btyRnNaWlBJ2UEfKOpHIrpVAC4HQcYrmqYiV7HFXxbg7JHk/jKwt7zSJ7PUUZoJOMAZOf6VyujSaR4ehT7FpysN3Jxl1Pqa9b8VadDcqQ5KAjOF6/WuDk8PWyzyyRO7s42nAwRXXQqxlCzOyhVVSN7GxZ6lHdf6rBPGRjAFbIBKlXyy4I2t0I9KwtH09rfHAyO9brkLEOMgDkE8VjV5b2QqqWyOO1HwFpJvkubczWjq+/bGBt65/Wt69wIlUE4UAVPeXUcQJfltvHvWO167YEaRkMMhWbnH0rWPPOzk72KpxsipfyymA7WKjvxWOureXK0IOZFGR3IrdudtxbyyEbWVTwPaubsLi2tNPlvZIVnmZiSR97joK6Iao6LmtY6hvkhWVsjb97GOfeo7jV3mmMenxpKckBi2M4rB1S5B0i4kgXy2cBvL6EkmpdJZksEaMbXxg+oz6VXIt2I6Gx1FkcJfwCFs4yDkVsyhcYBJHUEV529/c2Gpw2dxC8u/P73PQHsDXUafqqtG8THeIxjIPaonDqgt1Ld3qMVhGWlkAXGSc/0rCl8VxCNpEhlkQd8YBqIWLeIWuZpZtqI2xAO3vTJ4F0rw241CUTQOxVSFy5AHAq1GK0e5PPfY1LPWkukDR7lZcZjfggeoq69+UZG2gDjJPU1wPhbUhdXgktYWjSJSG3elbcmpxSXXloDvGchRkY9zRKnrY00tqcx45+1y6jeNcTttcjyUbhccZ5rofB2lfZI7eUsHaFSIwRgnPU1O2qQLsjuYFbfwAV61biuI5FHkqEC4BWrcny2FodEpE5V1B46EVes1VJCGO5SMN6isrT5Sse0Z+grQZgg5zyM1yyT2FJdDyrxT8PLtNXubywZJoHLOgPVc9jTPhv9q0TVWsZAWd3+ZV/pXr0bBxtPI9WrHg8LbfEDX6MNjENgdV/xrVV1y8szna5Fua9z8q59ag3jYdueDz71oX0JEeVXjpyOtZMTMrEHhQefesItSVzaDTVyaHYpy4OCOvbFZGqWqzS/ujtJGfu5rbkIVWdmUDHUnpUEDxTRFUAMn94Hn8KqLtqh+ZyUkc0Z2RxtkNluO1dZoZfbl0CkDjir0VvGSrNtJxgqO9WbeMI0qlQqZzx1NE6nMrGUpEsbjYH6HPQCmyOsgZdp44+tRecOAoOB0OarSliWIyCTwexrFRuJQuyUnyWORkdRz2p6XJK9c8cVBEytuDnjvk9KRyBDvBDKpxVWuVyrqW2ZmWPqExlif8abORJChVgYzjGDkEHvVNphLDsctzkEA4OKQYMSRowVR8o2nGAO35UuWwuQt/ZRLMiljuVeucZqCXTWhYEPg9frVyACKQEYJIwG9Kmfc65JxnrUOck/Iht3MGfCyGEPwP8AOayntH+8QfvYyO9aepRKk28Rks3APoayJ76TyypVkTrj1I9K6oarQ0i7bGxZo8axySHOTwfQ1tRzhyCMbiQOfSuYh1iCS3VAuCOG9vetfTp1lADAEg8EHrWdSDe45LmVyXV9Riswm/knjnrmsuz1LzJSgORmsf4k6lFpFtbTbHkLMVAA4GB1rK8Bag2qajPGQcKQ6Pjhhj9Oc1pCkvZ8wQSSOi8TO09t5XmBVJwxB/SvPrdP7PulS2l3s7gqFXv6GvV73T1djgJl+CAccVVg0iysAZUtERyckHnP406dWMVYpS00MoXc7LGsziOXPKjnFRvpTXLmflYweqjlq6RrSzmDSJColI4Vun4VJpSiRpM4BUAbQM1PtLK6Jd0ri6VayWkQyXIKgBG6A+uOxq7MCY2GB7e3vVy0j3fIzEAgfjVW9hwCrN7gjjvXK6ilKxippysUoIsFC+7PoKmmfJ2A7eORVrSVjErPIo6dexxVa5txJ5k0IKktkAjoKrmXNZl815WZzviSUx2EojJ3jv3rzue3uJY47qJndt+QuCCa9LvFVxhgDvbkHvUN3ptlp9ob+UYWNMhM4xXVTqKKNpaaGT4cuzY2T3F2pi45j7misOzvbzUdSvk8oCJgFjZeCv0/xoq5QTd5Euy0LHwjv7rS/B7Wl4sm4OzRxMcGMZ9K63w3rMQvHV02XB+YnsK486Zpuk6I85uJv7QlHyyPJnBPqKn8FvLf2H26Tmf5lbI4yKU6cWm+5nGF/dOk8dwPqNu8tpgvwQAecjniuM8PRvFcTxyM7STP85J+7+FdVYwTec8skhYDoS2als9KjnvBIqjg7jtpKShHlNIe6rGlH/o+m4UZw2F55I9Kl0yxuZZBIiep54q1FaNLMizBBEjfKFJHB/vV2enxRLbKEAC98d64qlbl2Ma2J9lGyW5zMxure32lCF/z1rlbnRvtmpxXC7sqc89BXqtxEjD5hkYx0rktT2W9xlQOTyOlKhWu3bcxw9b2mltTc0mERW5LZU+3apptSa2k2t8w9R2rm7jWTbQfv3wg5ySBWLY+J9J1W8Nvb38cs4yMA9fpUrDSleTRP1bmleZvarqj3c7bVOM4AHpSWIiSNuO2SKzZyIHyBx1x6UWV6JJ8KCvqTW/IlG0Tq9mlG0djorJUjiZyAhOdtU7iZUUkLgc44p8kriEYbt0A61kahMZYQo4POQD0rKEG3dmdOneV2Zus3FuWBmZs4yu3vmoTsWS2EabGI5Y9cUt1FHOFLbmKYHqT7UznG4xO0gyisOi12rRHUloWbhleN1Qn5tw46e/NchFaxuAh+RImKvubAHpiujIMKbHLb2GcgYHpxXM69ot3PdqIJmjjkxkrkfnV09NLg9CheWk0lxBGjFzMxDAHsPQ1o3dncacVSFD82OQePp9al06we0uoYRIzvGMg4zxXYWaxzSsLhQy8de9VOpyiuc3qN9A4gjk8vzMY5Izn0qPQdKla4njbaA3I9QK2da06yeQSJFh88kD1qTSwIyflIP3eDUc/u6DVzmoNUbwtc3VrJbSPLIx2kLkFTxnNR6nLe61am2004xj5nX5U9q7sxxzkmRA/bBA/rThbxxDCxoqk9FXFL2q3tqQo23PNYbf7AI7JcqmMSytxya2NCt7KS4lRMSJt2lj3+hqbxBpqmedZULW8vcD/ADzVPSzFbWDwwsYpAc+xHvWt+ZXG2bY0m2kSKR9qKoKjzOdp7H2rJ8hE1HyYm39R8vQYqaT7XcsohDuvuTzVzS9PFgrByWdj1JyV9qm9t2VBE9gxVmjIG5Qeh6VoRnzGIcdO2ahiT5+Mbhzuq4VXZleMjqKxkWxYmUTIN2CfujPWnX2vf2TEkeA80vyqlUjC8U4fYWQHIIPPuTVed1bxDBMYlkVVAIYZx9KXKpPUyqRuiPXNf1WziUvayyqegjXrVvTr+PUbXz1Ro2PDxvwVPvWr4nv4LTQXlmC/Kpzg968+8DaxDfT3Dqrqsq5w2Mcd6qC54OVrWJps6DWbkmMqqs4VeEx1qO0vLextBPcuqMzBQewY9ql1Hdv3xuQzDBXbn/8AVWVe2zXEex0UW74IU8t9f/r1UUmrM3aOzs5hMizgenI71alcEnaRnt75rO0WKS205EJ+XHTnkep96tGTHCgnnjA4rna1MGtQZ/nCkncTjNQTM7ZVPlH86fGA8v3uQfXioZ2ZpiVJJHU5xTS1NEtSBQzSfPjd2wCAanMZfBUsMHkDpmoBl1bcWODkbauCNmiRhIEJ5I7iqehUnYGXMfOEYnP0pk0alcMmMDO6pC6MgYBmYcZHP51IskaoVfLZHSpuRcgSR0RGDjOcEYq15jBwjKu4nOfas5mkfIAAYHODUsMoMqsI2ADY/ChxuEomo0IYMWGe4rm9QtxdXTIjbQp9M/lW/JP+9j8tThuvYVianHc2t0bmHHl/eK4zj2opXvqYq6KD2MUFwQCQp+9x37VHorPBrDQTPiFuUI4Gaw9a1p21cP5savsyMnriuk0Zn1S1N5NFs2LgcY5/wrokmo6lx0LfjPQRrlhGiT+RJExO4jOeMYrl9P0l/Cis0HnCNzwp5GT1x+dd0swnWMlvu/rVXxHeaaukyf2iyCJR34NYwnKNoboFdFvTLtLm3V3OGUYYE9DTdSf7QI1hYcEZPfFc54e8QaLI4s4Z5klY8NOAA2enNdaLMRKWyCD0OKmcVCWpN0nczZIiqBdpHt1rX8OwAHzM/O3Uen1qndplFdCxI4PHUVY0q7ClBjaR6nrUVG5Q0HUblDQ0NUNxEGaFSR6DuawIr2aaQi4AUg9q7iG9tjbrvKliMEEc1zOqW8Ml1+4jOMkg4wPyrCjNL3WjloVG3ytWH2QV2aJG4Y9P6Umog2/7pWUkjgdMgVHaxtab5HViegx2rM1e+Z4Nw+V+oYrz7/jWkYuU9NjeEXKemw1Iy8wZyEAfGe9afiLS47/R/JygkfG0N2I5rHsJzPGGIA9R6itqJxJCqyDIzxn09KqrzJp9i60ZcyZjaN4aWwtQ87LLMwI8wcY9Bj0orXnlfa3lAkYoqlKctWxQ5rbnFf8ACuzDKInuikKjpJklR9TXS6R4attK08WlvkRqDy3BJ9a7K9jgS1uLq9KBEBY85BXtmvG3+MGnprMtsbV3s+i3AOSfUkelKE61de70OalWc3pud3b6JHIQ7ZIUngcZ96sWUDxymN0AHriqekeJLW7jLWUqSxMMqR1FWhevNM2VH0BxUyVR3TN+Wd9S07owTJK84Y56j6102nhFt1cEHtjNcNIszXGUcFj1z6VPLJcqwwW4AHy1nOi2kkzOtQ50kmddqNwqo208deTXFX9yLm5AB+6efTmpLy+nmiCv8mRt6dqpD92MgFQcDPUYrSjR5NXuXhqHslqeVfGnUbiKZLNWeNSASOcGuc+Dtk174vjJyEhVnPPBNe0+ItBsvENttvYwWXhWA5FQeH/DVl4fRfscWJMct3Nd3tVyW6g4z5zWvn5dScEE96r2jBCSgDD+f/16L5twGDk1FHMMBQQDjGR3P0rJLQ6jXeYgBVxzggDnNVbhjvwMjB4GcZqvBcuz89hjNShNygE5Hc+lSo2C1iluBPB5zzzzU9sVJAzg46k06UqkgIwV9Mda5jxfrT2Sx2kBWKa5yfMxnaK0S53ZDvZXNS7vbcXyJJPHkHG3f1NacFxDJBtmCOp5BHGK86u/DC21iMlriac+YCM7s4/StbwS99IJ9NuE8to/mQMckL71coK10yLqW6OmiggLsY925uN2ecCtG3jCg9SCcgMe1MtLZbdf3p5NWI324Vj36YzWLdwexX1AcbwSUHYVmIQzNggHvg4ArWuAJIyEb2IrJ/s9i7Oq7cnoO9OFrDRo2spKhAwIxnjsavo7AgbgecZ9Kyij7AqECTHJ6VaRiIgjZcsOfWpkrjcS35aHIZVI9+aqfYbV5MrFEH6ZK4qRWDkAHB7CnggK3X157mlqibWIliEYVVIXnGMUySMsSSDv9fapwPM+ds+1QsxVGKnA6c9SaLlIU4UE5woGSaEbduV/4uaaxKQgsQEYcnFUhqFuZRGJoi2Rxuxj61aTYWNDJCgKORwMdhWLqbyQzm5jBO05ZcZyK6FU37Tgg+1Zt7a7ZGbAbjIJPBojJJi0ehJZTrqGnMjbDG6kNvGccdq5rTbGGz1RIrVY/JQEYA5rXFgu5JIsxsxywB4rRsNLW3LSyMrzOeMjjBquZQTsRblZRvyyODuGwjOCOarWKQfaEk5LE5IB/nWhqVv94E557DtXPSXT2lypRCykZJPTFEdUb7rQ9DigUp6hhkelRXG2FBt2/Uc1S0LUlvbAOjZkADbSMVZdd6sT8xHO30Nc3K1J3OVJ31KQICzDIDE/pUDRj5SCWPTA71oJFGSAIxj+LFQtE/mHHCVombxkrleNfmIQDA/zipgWIEjHJA+lQ4AGyNskdRmjhV+9lTztHJB9apq5T1LSMCGSP5sHcxHGDmnXMSthlwHBBGDjNOsR5lvwp69emKvhINoMuQ6YI9DWUpcrMJSszEuIpVPmKTyOuM5qCBpDgnAAPIPpWvdT+bu8hsyKcHHY1QGJCxXhgcNgYOauEm1qaRba1J4Wk3owGVHWi4uxFuXllk6k9asRlVWME7Qe4HeszVrd5ZmVGYcY3eh9KlWb1I0b1Oc17w6Lq4a4QRhTk5HG3PerWma5YWdilkJxLKpw5RT+JNN1yO8h0RnMbFVwGK8YX1rzW+gv312OXT55ZCCGYqOFHqfauyMfaK0mCta57ho11bXDHynSRSMcda8/+K9rLFfWV0qsbRX/AHvPA9Ca2NAn23sJVGQOuGye4710uoWkOq2bRyKNrfKQea50vZVOboD3ueRatZwXRtWtZ1MhOWER4Y8Yr2HQrpxpES3xKsFC7ic1h2XhbT9PbdCCpHJy3FaMcbSTIhXFvnLf59KurOM0kEop6s2Wghd/MDnGO3FYsOqQT30toqfdJGRVt5ljZhHIAu7ABP3qxreGAXs88KHzCe54/wAmueELJ3FCO9zstL01rh8AnyiPwHtXU2lhBageWuTgD5v51V8NoY9Ji3Ahn+bGK1M9O1cFSTcmmeJia0pza6IingSeLY6qQfauD1vRWW5wMlMkg5616DWfq0HmqjccdaVOo4O6HhK7pSt0PNYBDa3IifOQM5rcjKSRleCoGC3cZrM8UaWy6hDJATkEbvcetXrV7aaMLBcRO4PzKrZ24runJSipLqezKSlFNEssfkgAMH+UYJOTxRXN3DXo8QEq7tbPtRkxwB65opqnZb3JasdNrxfUdHurJmMSTReWxzzXzTqfgjUdKvJneOFrKPpK8wXI9TX0b4jtrq1gchfmx2zivnjxlqo1C9u0uWlSKJ/lROjHHeunBfDpsYwUF763Ow8FJGmkN9ju1mkH3o1O7Zx+tdzpTzLbrI3BboPT3ryT4ZR3EGpPqVtaFYhCVwx4Y+1dBD49kfXVt7q0jCZwxRj+7/xrWcG27HbCV1qeo2Ykabdg4HUk1fKkr8pO7p04PvVbTiphWQY2soPzHtVgSNsZ+q459PrXBJ3ZjN3ZTureOFnm2nzZFCluTwOgx071RWQyfdyF/iq/d3Ia3JwCMdj+lZMRUyluTk9COTWsLtamtNO2pp2wDIwz+PepXIVACR7k1BCVCn5R83emzSEQEfKwwcc9/rStdie5lXsoLMGBJPbtUUYV4wQoGOoznmqd47POFz8p5znFWbJlXkHJI7V0WsjRF6NFiIZWH1J6U+OYnLd8DocVRBMhIP3QM7lP9KsuDGq4GFPtUNajKl7cytNsVscZO0VwfigzQ63Y30i77dDtI6kDPQiuyuVMchaPqBwQaitNKe5nIuH82FxyrDp71tBqOomYPivXwNFgOlMVu5AVQqPugn+ddD8NtMu7fT5Ly/kLTztk+uK1rfwvpsHlmOPoeM89K6CO3wp6KgGB7VjUrR5eWJi3bcq7WnlZC20KMnA5FRuhjLKCWA6irUrLbKG++56Gqhc5LH7x6Emsk3fyKjd6j2G6RQCApU/hTHjKAY6rxTTHvjKHJHGCvB9cU8twy44z69qEUKsQkIJ+XHqOakeHc37v5VA5GeajOUUkfMucAe9LNL5kbYUA9N/eh36C16ELAAnpx0BqbcflAUeuBxmoMHEZdQBnAAGal3NncoUL0z3NNjYgDADByenWoJiyltwOV46cGpnLHGANpzkepqGcuFbGMdvyqkNHK+Ib1572Oyd3itgodyGxk54H0qhb6ro373T3XymX94k2etLr0JlY38iGQRZjZB1K+uPauY0wx6mDaW8CkgEEdMc+9dUYqwuY9P8AC2qLKjRiXdHGvysWBOK255klI6s3sa8ftEaw1hNPsJDDP96R+u3PUCu3h0e4WzkmS/cSovmYxw3pWVSnFO9xNrqb4ZSTvK4BHBPFaaneuQMY7VyHhvVBeq0cyCO6UkEYwHA7111scwqScY4PHWsakWtwkVNQi8xAMHI7jiuTntJo79pNpfBwCfT6V2V0AY8jPXJPas54yZSTu6cnHAqoSsio7FLw/FIkzy52oc8HjHvWy05SXchypA69zVQqN2MfLx261YeRDtVI+VwcUpe87jaLqMkmWU7PUDvTZYkbftZtp71As7Mh2jC4/Oks5JXQkfKoHA71mkzPltqIIduwqdvb/wCtTZIli3DdtBHTH6VPOMlSrbcc8jioyVeVvNIIx0BzVXLTZJZziJsLt2gYIq1eF3gbZknGeO9Z4KruIAU9uOlWIbh0XJOeNo4zmpcdeYmcdbofp8mYCPLKsRnB7Gq6B84ZQXYk5XpU73bOPKZeB1z3pV3pIoTB2nOKWqJ1Vxs8bRRglhtwD+NOWUzOilcADBz3pupSGVdoBBB5Pf8AKmWCYTljvPU0LbULaXZomFZFWNFzEQUOe2f51hy+DIbeVns5XtQ5+dQvmKw+nauhiIaOOPI+UdR3qG+vBG2x+UzkE5OKxhOal7rOdc17I5yPS4dOKmNjLMeC7nt7VpWsjBjGeRjIz3qvLMk8xZADg8D0qdgY5oweAQOa6W299zqS0sXo+6EDeT3qtfslpC0gOMA554+tTK/Rfu4PWs7xAsktrMIxuO0nHr61mleREU7nBarqM07bo5vm7L7d6u6JdujRvK5IPynPHJ7VlQ21vLcqzyfvAQNuMYq1FcJc3rQwL89u2CD/ADrva0sa6HvHh+9jmsIgGBZUHGeta55HHFeOWV7eafcxxxNtDj93x0Neg6Pd3DQKnzNgZZm6k149ei6bunozx8Vg3F8yejOhDgHjt1qpqUiLauWxxz171E7St97HQce9ch4n1Mw24S4kEahjvwe1YU4OpJRRjQw7qSSRV8WRXWqWM8OmyGO6ZWEZHrivnjT9P8V6R4kjhIuoblJMO3JQ88nPQivcR4ot47hbi0bfHxzjpS6l4iGpOix2qhicFwe9erQ5qT5UtD050ZStFbE0GpSz28X2s4lK7AwHOfpRTtO5IEwUqvOfSilKSi7WNtI6Hf64FaCTdjp0ryfV9D083Th9OilL5Yybetd5rd9vkwHIBrmNTlZLdieTj8awwilFepz4Snyx94wZYY4YUitkjhBHAxwPpXAeJdBuLbWI5IGE0kyjdtXG4+o9K7W7mLMmw7cHAyeh9K1NLt1lmjaeNJJFPDY4r0FNw1O6UTW0PfDpNolwG3iNQQRkjitaV0ktnDDgcHAxzToogoDuvGOp4H0pL3bBbFi3ykY9x7GuFy5pHPKSbMOVwiMoO0HqT2otSokzy49Tz+VUbxmmVg3bv6Yqxp8hRGREG4gc5rp5bI6LGpCgI5bA9cc1X1DZGuyE4J446U55v9HCg/NjnNYd5eK7YJIOep6VMItkJXJFAcP5hG7Hp0qzbx/MQcZYjGKzrT5pW3EEZ4BPtWrb4Mg/hI5AIxmrloaIsCAbNynGDx61DNudc889uOlTgFSH3YGelVrw4ieRcFVyeR1qE7k3MS+1m0spzG75A4JHat3QtWsbxV+zyRv6AEcCvMJNCvdRjDQyeYzbmfe3LHPar+k6Ld6NtlMnJXdtVuhNdEqUWt9SXK56mxzwgO0kE1aQO0KpvbAPTg1gaNdyz20QmJJA+8O1annMG2rkEdT6e1cc4taENC3XC7cksvT2NU26hW+XHUmrbXCoSCN7HrxVJjhiO57ZzVRvYuJZd41IIHy4+tREZI4HqMDpSBW2A5Az0x2FNwNxCuRn1NNaD2JMjcuOPr3pWO7gnHvjGajZiHABzt68d6GkYZGfm7jHage5YjK7lIJJIwSe9PeSOMhcY3HkmobXIcnHA561O0McrAhuOpxU9SX5jJQC4XcQG5z0FRtHlT1IA6mppiS2Qw4459Kq3MxD4BO3jnpTV2NHL6rZ3dvM8luA6v8AeBFczC09pqss62DID9wngf8A169HkdSFdvTpnNcz4guh9rtYtrDzGwW7D1rqhLowatqc3pMnk69eXVwp82Y5Ukd/StjV/FUGnWYglDtNI2dqjP603xk0Nh4bjvUKqGf5GXBb8a4IX9zfGOeKGJo1OPMm7H2960UVPViVup6rpr29yba4tV2yNglehFdvZqzQsQQdvJWvM/C2pS208UN+iSJIAFmjHfsPrXpekygOySj5cdB1rkxCcUKfw6DZFxCcHHHBIqqF3devTpWnfES7lQBU6YrOa3aI4GcYB61hCV1qFOV1qRPCBkdGJ7URIvmN8xJx1zmpTyckjng4pyxIGZgM7htyPStL2Lb0JvIGBIQAoHQ8bfrVVri1WUql1Dk8FQ4rD8UXs7ulqhZY+rFT970zXIXs0kEk6PCUU7TuznOP5VcKTa1ZKTe56Xd749qZBY9CBUUzLtURckH588Y965nwv4ij1CN7SR382DhWI4+hrcWPId3clnOAQe9Dg4uzKWxYilSJGAJbdyMjmplnY/vVbCeg5xWV9hlSSNkmD5HHJq6gaGMxFst3A5H0pNIbSL0cZuS20Y9wc81OY3QB97KR06VnmWYJH9mbaPMAIx169famv9vfBkdG5+7nANZWbe5m027F2YrhmPzPjqfWpLfBQFwclePc1C0WY8vjIxnbU1ojrguOARhSP1qZW5SZbGmnlxIWUjPTFZWuvJbl3jIaIDJx61cuMBy6Mu0tgYqncyfKd65UHPtWdNe8mZQjrcybBxLIHSFkzyQOQT/hVy4LJdxGTIXIyMZA981Np6L5+WBxjoBjFP1NR5bK3RlyvHNbyleSRspe9Yoa9fQ2K70YNnqoHftTNKumu0Am25Jxj2NQ3lmt5ao7YLjjJ75rV06yWCEMoG8cHPSqk4xiN+7oc7q+iwLet5TkSNz06mjT9KhtgZ/KO9xyQvU1t6kkMlwjTIxwONnUVdsUZlCeUTCMYLCj2zULshySRQuGEZhdVGQB19a6/wAMTCeEEAHbncD1rH1iw8yyPkgeZjK+tLHu06yguIZcSY+Zf8RXNUkqkNNzCtatCy3O1n2LEzPheOp4r57+JaalrWpBdLlXERIKk4yK7zxB4jmmthGkjFjwCpxXO+G4Eu5Lne+JVJB4zzWmEoulepIWHoSoRbe7MfQ7ZhYfZnXY4T5sDnNN0aR4pp7Z92VzsyKq+IG1mDW0htdqxg5Zl4BrbC7VR0iAmUZYnjNd71V+51p2JbTV5IYpVbJIG0EiirsVgky7wAoPzMCPaisna+iKUtDfmkzA0o2/8D4/KsC+nkbcqx7t2eQOV+tauqyD7OI4Ms/cDvWDiWNSCSGPUHris6SsrmcV2Ma2g8+6VgRtB4IrsdHgBd1P8I5BHv1rJ0+0HmhihBzkmrOqaxZ6FbT3Fy5Vc4/3qubctEXOVkdGjuJXZmGOAqZ6YrO1i4MoEcYDA8sTzXnJ+KMdzeCKGAiMnBZiBg+tdZoOrJqgl+U4jA3BR2PvUKjKHvSMoJJ3Jwrsdpz83cinMFifCY3Y5b0q8qRufMUY7EdxWZcrsuTuPOe3fiqi7mydyrNetgrz0ye5H1NZjITId5bJ5GBWm6JuO7nHJxTZoSzjK8+o7itU0gG2ayCQMrjy8d+c1sKcMmAfr3qtaxCKMNkFsA7e+atu2OFAA/L61m3cdxWbcVCnB6nPes+/ucELbrtDHadxzk+gqXUJHWGLy4JJsyAErj92MfePPT6etUZ2EbeaQG/ug54pwQHNta3theTtH5vlEZHzYxmrmm3F3qUDCaJsxMUZyPbip9Y8RadbBBPNEjNjd3wadFrOmx2CKrs6O2fOClVatne2xCTNS0cxxRwAlEXrxjJNXUvVYlIwVA689azEuIlVXRtysMqc8GrEc6IMhMsfmwKyauVojU2s7HAIcc03lJSHONxoiuIpAFxg4xjvSvCTKrMScg4Oaz23FewgkwQdw2jvUzRoIssPvfdA7D1qvHEVUEqMY4Gc96ZPd29uoSSeOIDAAY5NG+iHctq4XbuALZ3dOppQxLElQCOOlZy6rYSMQlwhIOBz1q4kgxksCTwCKOW24WJC6rkMwDd1PekE2MHITPbPHvWVqNpJcSeYkpDBuucEYq9GQQoO4nvxnPFFgsWy44bjB4AzTTtYjcCCOSTUMxIIC5AHGRz/AJNNVv4XBH170IYjIXZiVGeTzxx/jWRrmkveQFYiA/UEDtiughiG45wfWpwiYYSAnA6Cmp8rFJ6WPNvEstvqOhJp7W7fao124YYG4enrXL6BoX7u4ec/JD8zwSNtI/DtXql5ZBX3qgJ3EgbenvVefTLO/jDXdtufoSPlJ+uK6FVSWglFnNaEpvdSto7VN1rC2WweEx05+teo2YVF3qRvz+FY2j2tvaRqkESpEP4cVsQxxFyY+BwCCe56VzVpqQp6bjZvMV92fk7571YMqvbryOnNJNs2GOZl39gDzxTUjLwMwx+ArDsRe5myBy4YFhtyCF7iprSYuCHPOeM9qWQ4wXIwBz2OahiIEhIOAOevatd0bboNW0xrsLJEqMwGHU5G4e3vXHa/aG5AR42ZVU7UU4JPpmvRLcBcuMiSUjJzxx0xVDVb7T4ZlSZow3XpzmlSqSTtYzU+hxvhDSrTTLlrjySrNwwJznPUfWuiubqJxMYSqR5yvb65p94Y7iLNogbAJBUdff6151rgvmurhUfyycAru5UeuK3inUldmlla52UP2mNNxbfDyeOw7VtQv5sCMWAVenuPWvMvD+o3ltILOa682IYB6+uMGvTmt2i01CmckZHPQHvRVXKF9bCQttaNFxIVfgZzkAGtNcvJgBSuCSSeh7cVjWUTxSxk4PzEg++DmtgFiuAfTk/41zT0ehE1ZiMMHAxknv8A0q0rKqDI9uvf+tVnV+oXa+eN3enRpkE4Y7uRzUOzRDVyywwMoCoPPHvULQGUZIY9ycYxTiQPlyePQ0hnU7hkY+7yep9KzXu7Eq5XeUQLvDkdOcZJFU7ybzyWJOAOBn1pb+SN3aEjeeCwAxwKx9SuZdPtJ55oyRglQGxj3rojG9mbwityp4k8SweH7FpLmMu6gYVR3qx4B8Yr4jhaIxsjg4yRx6/jXF6T4j0bV9Nuv7bliR3JUq/GAPSt34cDSJdTjTS5dyxkfLk8/SuiUEoNtamNVtq62PRLmNI5AJ8eq5Hf6083axxDcSuB+dL4xuVKKFAVzyR0B9641rm5WNvmbb6nkAVx0oe1imwpQ9pFSkdJZanLJe/PwhbjGT+ZqF5pL52Yj9yhOQR159KxNNnkv5PKj+RAcOSccetdRFGIbdY14brz3q5xjB6bmk1Gnqjmdbs/MuIzbhlX0HFTGzazRbiy2pMwwU9T/wDqrYnjwN0qtvA4FZ0lx5aN5kUhI4GehrRTbWg/iRnNMBv/AHIV+sjMvU+1X5VinCO6gNtGB0zUUrLO2NoV8DjHQe9FtFbxuYd0jsp6knjPJ5qrjcLFiyGY9rAjPcjp6UVZtEDKFOCA38I446UVm3qRexl+O9ci8LaOLoKr3LsFSM469yaoeH/EcHiTSVmjjEU6nZJGxGVPtXO/F+2XXNMur4ztGbKMMiY+8MjJNc38FNait9QuNMuUz9pXzI3/ALpXqPqc1soWp36kwbi+WR7LHCVtQ45GMg9jXG+NdJl1jTXAUtGhzgHGa62bX7SEGCRAqqMKc1Tn1KGOGOVCkqu20+g9zUU3JO9gac1Znk3h3wvLqAMbROHSTK5GMD+te06JpK6VaGKNRu6uevNWNItonZpLZVUMAxwOCa25bV1gZhkdM47VFfEtuxnzcrs9znj8mVb5QWPzVRlBW4bGD23egq7qTmJiFUcnjJ/Ss21dZGdSMYO4nHerjtc6FsJNAE2DIGeev8qLVXlkBQYHbNab2xztYk8Dj0FWLS3iifzDkuRj8KHOyDmsVltwsylvlODkHucUkqneMNxjOB3q1Jh8Mpyq9OOgph+fhsLxuxipuFyACMruKg56Z71zXii4xMLW3YRx4Jmmxn6AV1i8bfmAOcDjp9aydT0x5JGaONZFfqmcH8KuDSd2DZ5TfaHJ9rimgkjMH3mR/mNa0iLdaVcRFGVgpCq3GPTFaf2Se2mlMlkSW4wGACj3NWNL8uOZJLpT97B44Jrrcrq5N77EHgzTrqz0Ex3Cs0hYkBsnCn61v6dC8l1+9CrABtyQck/4Vpx3MBjJ+VEzn8KwfE3iYwq9vYQrPMACew/HisLym9ETqjY1Mw2yhoyCQBhhxV+0ube5iU+ZGwI5Unr7V4pqvia4N04vXabaM7VOwL7V3fhO0s9S8Px3Nq8iScFgGPH60TpcqvJjcrLQ6/UybSwkaMAMcAY6DmuTt44HmBlHn3DEgnJ55rf0sm9tJ7S4l3omCG7+1ZdzA9lI7mBzIeki9MfSpp6Xj1C9znPE7voyl47YOWOQ3X/OK0NC1W4j0+3mJZg/3435PHUg9jU1xdLN/wAfiYQccjk/hT45vMBgSAeXjnA/wrXdWY1dHUQyLPAsyEbXAOB/WhgMbt231I6CobBBBZxozAkDnsB9KHuMIcDAJI4rDroaIlDH7/GzH3iePY1LEygKHXdjhj/Wq6sfKyzE55wRSKxOGJAJHJx1pWGjQhdQxUnAPGP7o/xqcOiccEdAfaqlvnODjtz/AJ6VaOBhgo6Z61EtyJLUq3wAYtx0A+gqmIsA7TuxzwentUN1dvcGSKJCXH3WzWVZrfrOGkLHcSfl5xWsYaajU1E6SCMcBCSD174rXs5lkUqWUleDisG2uWKMGA3D0rnbzWJYbmSRGcInXb3qJUnO6FOzO8nt90gdSDGR8xzTFfYBGM8jG4+lc3oPiOO9TzA48scYbvXRbjOoMQyMc5qHBx0ZFjM8QTG2sWeMcg/XcMVmeGbuS8WUsD1/DFdLdWaz2zLMMKepIzzUWiaOli0hhGd55FUpxUNR89ie2l2oschYY/KuK1mxeK6laYliWyCM4FdtNAYZlBI2tz/9aqupxLNAYwBnqDjOaVOai9A0bujJ8NzoYmhbAHqar32lbrx544kZW4J25/Wtiw0lo4tzYBJ7dq0VCWyktyT0zxVuoub3R8/Y4DTdGYXUxVvNgZ8j5eQfTNdO0k3k+RvOFA5xzW2g3RABVUZ3FsVpWWjC6gaVse3HWs54hbyIlWUNZHOwjaEyAzAHn0NWI7gqnAyRzzUtxYCC/wDKYnyzg4z0Na9lYRIxMmGI5AxxWU6sUrhOtFK5mu7bPm5B6Y7U6AJ13AjovvVm8gEU/BwpORx096pJCWuwkbAq+AFbsaSaauJSTVx7vDCDI0irCFLMTWbpeu6ZqUjx2NzFKfvbVOOPWud+M10+m+Hkt2Lr58wSRl4wvOeleR6Frd5Ya5DcWyk2ccgGQBnHfNdFCh7SPNcE9Lns+p3G/UAEkG0981kO0sxEMxMkO4qdxJPPNaN9ZPdGK4hbO8b8EYxnmoF0+eWQRNuH8ROK2jypHQnY5GX4WvdXrzW0220fLeVnB/D8a2vCOm2Xgy/WW7L5UfKWyea7yzU2kQiVcqmDz2NYHiqCO5kWRsEEbSo5+lKNVzbg9jndJSdy3qmux6uGaA71+8OetZDwtIDFIZFQrkMD3rFvr1fCmjyX00XmlnCxx5wAegBP1rI8O+PhrWrRWOpWsdqkvyrIrE4PYVUadlaOxako6HceHQkV8oRy6twGPNei6Z5TbQyA47kVxVtpv2YmZXEozgbR0967HSraSe2RkxggD8fWuPFNP3rmde3LqUda2R3alBwScnsKzLy4gEDKkqM3T6djxT/Eck9vI0ZUMFBJOf0rw/xjrl3Z64Ps7tswMqG685rTD0+eKuzSEUoJ3PWZPvlc/MMjIq5pduduXwUPOegrH8KzS61pW1laKRUBEw5Nb7SCOOO2Vt8xX73AOR39Oaqd17pXPzKyJLu6isUOSoU9BnoaK43xrf6raTWltaW8dwJmxK0hAC5oohSurtkOpGGjG2VoninSZbefKrJgFQOuDWHeeHNP8DGTUkmaW8kykQYYCZ9K9I0DRRYsbqNsxHOAOhzXKfFbTJ77TGeJSxQ5CL1rWFVOfKnoTOz1XQ4KLV5NTuYpZZFIH+tjJ4IPvWj4O8y+1m+gQFY48sEB3KOnWuLisb+aa3ggtmD4+YHsD1zXs3grRhpOjoZY0WVuDg8V0VWoxBWclY7LQFMEKJB1Xk/Xua1r66kaJVxt2jisbSwI1ZCvy8Yb3q9Lho23DHqSeteVUinPUU4pyuYWqyOMng+u09Kp2EYDgMcnrknrVzUioxtUHAyKowhvMQvwAcdOK6l8J0LY0dTvo7GLzJGI7e+an06aO+hWRCORwOg96ztesHv1jMeeCM+la2mWotLNYwOE681DsoruZXsOKhWAILDoOe/pVa2uBJudASoYgMeM44Ix9RV6U74iYyATyM9aijJ3DcMHH5VKfcFqMVN/ICkdfrUbuyRSbR8wGQ5NK6OCpRgPUUsylYz/AAk/KT2pl2MKN5XYxMoGec561XuZPNEsTRqpQhSfX8q05rHaTNGRkDGCKgNiIgZ5AWH3wo6VupLcLCWVmvlZmIEe3JJ4HtXNRSWllqd7E5Bjl53kZB9q07ySWd0llVnd+EQtgKKJNMhu40E0IfHyk5xj8KqOm5Ekmc1440GwGlyXGnhGn27woHOOP8aj+G93Pc2P2W3tJRs4Dr0Y56e3rXfadoNhEgaWIGVBzuJ4HbirUr22nQbIlSJAclV45pe2TXLuSovoW9O0xrGLMrb5ZCS7j1pbpFVQWdD7bh/kVf0y/gurACJhuIHU15v44d9BEzyWzSySksNpz+PtXPTcpyae5Kmk7M3tUlhtQPOEeCDms1dcsN6Qq6gt1UGuZ8H+CbzxzZyzT3r2kn8CM33h6ipNc+DOv6TbmawdLtgecSAHFbXpxfJKeoPFwjLlaOwgu0YKytvAOSfSpmfdlgBgcgnua8T8OeL59F1FodRjYxIxRwBypBwcetev6fqtlq1stxp04kRsbgRgg+hFNqzOmE4zV4mpazeU+WUsemM9fep3PnK7D5RkYWqEHyEAuCSMjjsOtXQV+YJvYMpLDtUFE9qWVTv6N3zn9KsXbE2rfKOV6+1V7cbODzu6HGPxq06gBtueO2entWctyGtTl7JhLc+TCv70E4JPT1Nas2p/2TeLDKobzQFO3t71lap5umXf2iAYOc9BnFTmGGXT1uVdhg7tuMnNbtJ6vYzlFj7k+XfB1Py55PpmsjxZjRxNOIXkiuQQNo6HGMfStNJUkk2QjCE/jmtm2ihuY/LuwCBwNxzRzcthtO110PKvBpnN+LdIdkLkEkV7RDGY7dVHJ2jrVW20y1tpd0EQByDn2/xqbWLz7NZuykBiCF7Z4/nWNWqqrSWhKu3YeGIUq2GBPOOKlifYcscnp1rg7qa6vVU21xsb+Jwen0rR8OarPcSyWV/lrqEBlcfxr0/OlKjZXL5U3Y627BuoSpycdxWPHIwwZyVAJxnqK0refZvwMLt7nA/OobxBPGxC/KB2HWs4aaPYUdNGNF6QFCYbPbPaqF/dRk4MoR1ONp9azYg9vMQucHse1Zt5fQfbpYLiMvIDlSeA3oa3jTV9DTltqb0GsOqoG+bDZDA8j2rr9I1WJtOYEE4bcBnG2vEJpb4axIsYlih2ghlOR9f1rr9H1eS28uC6YMGHysRgn60q2GUkRUpRqKzO7uZxcS73wAOME1LbXwRGOCY17DvXPJKZ1M1t8yngH0qrdXsnlGE8J04rn9grcpHsU1Y1tV1I3EbtA2GAHFM0RmaVY2QbguD1+Wuf06ZormN3UiM5HOcAV02mLAI5Htx5Tty30q5w5IcqHKMYxsjk/ivp0mo6BJHgs0Y4IycAV5LpunolhaW2mnz7iSQMWwcjPFe5XV88N1suot0ZPTtz3qxp1jpKXJubWKJCepAwa3pVfYws0KUXFXSCC1W0061QklkjUN78dKtWzI/zkMAB+Vcd4o+Iml6VcNBEr3DKxQqgyQRWp4b8SadrVgzwt5dwD80LcEf41k4TceZoelrdToAYzHhFAUdOc1z8sCNefMRuORtHTFYHjjxTHocscMZIkYDK5+97VR8PeJmvbqOIx4Y/vMHqMetaU6LS5kaR93Q7PU/Cljrmny2FzuSKUYDDnY3Yj6V4XrfgW/0fV5tNmilkKMfJmjUkSr26dDX0JZXEhiR5Gy+SBWnFOGTdOo3JyCamNadJ3aujnqRkmYXhGxmsNBsI9QYl4ogG3ckcf0Fd0gggsVaOT5D6ViXFwHUJGh5PWsPX9QfTNIuJ5CFEaFjk5xXLNSrS1I9k6iSbNfxEUEMrlRg84Ht0rxvxHo73d5HNAoZSGyduK2PDPjuz1W8aK+n2uGwqsP5dq9AtNOjl82RQEVl3bSOg/wAiuqH+zL3jVNQjYzPDFo8OgxW6BkJUdK39I0eKxRxsG88licmuU8XeKoPC0SkRiRj8oUe9cnb/ABXlVw11bN5AOCR1HvUyp1KybjswnGVuyPRtZ0xbx22soZOBkdqK8s+KXiC6aXS0sbmSKyvIfM81TgnJ/nRWlOnJRV2Fr7HrizC30xYzIcIOCf8APvXOtfhrljeHEQOOT1qtf6uph8tRv7Z5PauGvb6a81uBUvt4EgJtwMjaCMk1VKjuaqKirnqsFnpsgEtvbgPJ8wbbjI9KHMcsqxoGUBsjt+FZ0V/ia2AKspbAHfH0rTilaW5IVFOCOfX3rJxa1M4xsX7fHP8AF2GKk2As6g9h15rO0+7R7q4RyAUbLAGtWHZs5wDz2xXPPR6kyVmZ97BHJJu2fOeOaxjASW+8Nv6V1F3CWQGMHcO2KxjGyS4mYtzknGCa1pTbRUJdBIiyRsoY5HCnOce9Tif5ApfPHUgcjv8ArUrJCsJUY3dWx1FVEiBbsOflqtHuXvqaAj3RBy2W/hxVkwmOPLBd2OOM9qht1aONePbnNO/eM5BKk/06gVg7vS5k99CAKpGx0yetRvCHQkDnPcdKsKh3lpXG09CD1PfNRzlkZ/l+T+f1rRMpNhFCckMOSMj2qV7JJYnRxkEY54qtZ6jayzNDHIDInbdx+FXmPyEnt2zUylKLsgbZg3GgF3RInUxgg/ewRirf2ZIlBlIzjgitENgLIHjIGMkevvUV86yNsK9epAqlUk9xJsoG7DR5ChWPGT6dq5q8guta8QW+n253Rr+8uGBxha2bkx2+4u6hACcnpVb4OTQavqeq3F0gMk2FOegUHj+QrVy5ISqLoKvPkhdHR2thb29kohiQBT1xjisTxOpuIJEPlliPTNdbdKtr58bY3eYQufSuR1L92XdjgEEZPX6VzUZOUrs5oy5kcPperXuh6pAl0XS2eRdrRfdUk9/rX0bp7m80+N5v415I714a9umpzQZ+6jg7SOvNe2eHSP7LhQD7ox1p5gk4xfUwxesUz5j+NngJfD/iiLUI0YaZqDldyj7kvX8jXDQnWPDmoOtk7Ak4wjcEe4r6y+L+jNrPga+hiQGZMSxgjPIryPw14Om1OKS6uY5F3D5VYdTiunC11OlefQjC1XH3bk/g3xENZgWO8/0e+j6of4gK7EqSse3C5POBiuUXQWsbuYXCgykARvj5mH/1q7WGIiFEPJ4B/rVVGt0evCpzIrLlRkZI/WrEa5YNuw2OOaVkPI28DPbpVWckMAMlhz06is9zS9yzeRR3CjciHj72K5vWY5N4gs2WJF5kPcg9q20mKvg85GcDtWBqRCa2ZXkRIpANpPfHbmtKejE9EZTWF5ZXLfZrh9y5ZQ5BDe3NbWg6m95ZmSSPyplbbKjZypqL4l3xtdAtX0pUmIYfNGM4Hrx71V8DStqcl3esJP3hUEuMZIGDWl+aHMxU5M7SzlJUtnIPb2ql4jjeWyZ1+dkG7b04qSaaOGIBB8/fHWs6bUX81eflHDA9/esIx1uXy31My3uUh0pGVF2MvO7gj6Vi+Eo57jxNc3sFxLLbY2AP256Cup1HQ7K9iEm07WGSqEgHueKn8N6SbN22xhI/4UHHH9a254qLZGxpXUxiUblDJxwamS5LbXJ+U9PpTtUtmdchSVbg47Vh26yxJtkRm54HoKwglNXBWaNaRIZAxkCnPOazL/TLaZj5kYUgcOOoq9qKBrBtgO7HTnJrG0e5naRo2y8f3l35ynqKqF90XHUy72wuolEcU6KiHGGH3hT7K0V2iS4DM6A5kzkAH0ra1GZIgW2Bl9+1S6eIpIg52ox47VrzuxWiLEE5tbMx24JyPSuJ8S6zNYXyyYLqTnCAnmu01Ei1092RzuHbv9K46UDUnlWNMPjJ3Dr7j1pU0r3sKyUWyey8XLqVy1g1sY3RQc44rsvDN3HcRvBnlG69Qa4vSfDjahqxh09WE+wCdscgDtxXsnhjw1ZaRZRxxxhnUYd2HOe4rHF1KdONupxYjERp6Pc5TXI1S2kZuSF+uK4KPU547lQodoW4JPT3r3e+0q0u7YqYgMg8YxXnlx4XjindWXaAxwuMZ9qyw2Ig01IKGKjUVjwLx1p82k6pOUiK+cfNjk9c/wBau/DK1v7jxTayTGRI1IMjAcMvPBNe5X2m6fNGi39vBMIxlfMXOOPes/TbawspXjtERXY5Ze6//WruWIvF6GvJKTutjzj4gaFc6nrYms4vOHQDn5RWx8OfDM9oZby/j8twe5/hHpmvShD9lhykKh2IGPXmtl0tZtKZGRd7KcsOTWE8XyxUUiakmndGDpTR3cLvb/MoOOeBWdf+LtOs9SexOZplwriPDBfY15/4z8U3mhW82lacixFmKtNuwQPQfhXm/g+6m/4SJWeRvKMm6Rt33ue9XDD8zvLboXJ2tfdn1NDco8QkAwCBxjkV5X8YtauQ32K0YLGq73z1YGut07UPt1qklsQMcDaeT+FZ/inw6mt6csrOiTW5LiV/u4HUMR2qIRjTneRajynheiwpeuAGdJo3DAgffOfWvrHTojHpPmZYL5ajaevTPNfPmizaHFriz3OpLcLE2VhjTau4d/evcRqpntkSIh0kICsOARirxic1GMTBwcnoeWfFzTL25t01CJfOSJhvjU5ZVPGfpXLfarSPw/ZR2mno/mAxzbzli56cDmvX/Fd6vh6xe5uUR2IIy5wMenua47w5r/hLUriHzrRbTUWOUYx4DH1+ua1pT93a5pUWtzR1HwTJrHw+02BDi9gBdVPbP8PPSivRbIKsIEZJTPTrRXL9anFsxVPucTqMK29k7kiNlHcjrXJ2pFtfjy9PSeWU/LMpwcd67fUPLlVw9oGQt0bJGKo2tsk0yLBAqR5+902//WrojOy1Ozk0NzQNLUKs87q1yqkIqnIH+Jq7BhLkKWwT81OlEGl2vlpMWlIx1Gaqsi3EcVxG/wAy/K3uK57uTuzNJfIVkEN602F2scnHcetaSX0aJmZlWMf3yBn35qG3YSo0W0ZAIzjpXA+O7a5muksi+YmwIl3FTnGc0401VfK9BSatZnpf9oJKA8DLIp4+VsjNMnQOuWIEmO/SvJ/hXLcNrUtsHkeDLht5OOB+nNerXcoidFAXjgjvUzpKlLlQkl0K1vEpJLhsnoxGM0+4VYowTwxORk01Z08pjnkfpWPqWoiHPmFRg4PuKcYNs01NRNVWLHmNu2ngClk1nePkHAOa41r9bhnMbE4OcCprSZs/N1x3PBrT2Mdw5UdLPdkbGEmWJJx0qeG/zuWQrjA5x1zXOvL5gzGTuAyc81OPMaJ3Q4fHAz19qbgrBojhvHA1PRNZF7p7lLaQ5WRRxnPerln4h1Oe5gfVbxpbMrhpIwV2n3A/nXUz2EWtWBs70MSG3Bh/CRyD7j2pv/CO3EUCQgwPAV2cDD1qpxt725lyiabeMkscsUrNbtLwpyQwrpriQscKPlArGXS1tGgLONyH5F6Y7VPqlxLtQRMA4HPHvWMkpPQ0S6nPfEG+Nv4fvtsgD7BgdMDPatT4GyWdzpAkEqxyxgF8nGa4D4oSb9KUG4UMW5GfvCtn4Oaposnhu302e/jtr+SQiRWOCeeMHFFaN6Lic+I1909k8S3NkVCxTI0ikbsDNUrzwy1/YxSQSFg+DxyPzro7DQbSKONmPmttxv7EVsRRRxrtiQIvoBgV5PtvZ2VN7HmSrqKSj0PNLHwjew6gu7mFeRx/OvRrCAW9tHGBgqPzqwRxz17UL161FSvOrbmMqlaVTcZNGksbRyLuRhgiqdvp1tZRt5SgA881fzge1ZmrahHb2czu6x4XPzGs029ERTUm7ROE8SSLc60MAAJnGPWlt3WSJWU528EHpmuTsru41TU7gQzKYtxPme3pXXRQxxW6JHuOADjPJr13Hkios9ynFKJIwCK/ORj1rNlJ83I+YDjHWtKRW4O7PoB0qrJHtww78n2oizeDsUoyu07/AJfTjpWJ4hEN3JbWV0xWKUnbKBllI9K3ZgcEPgKec4rmvFYliNjd2g3vBJnZnqD1FdENypbMzJdKn0uRra7v5pLAPnK/eA/lXb6Lb2sNr/oOPs4GF561iazq0Frpou7qD5XA3L3BNM8IXo2mLAVHyyLnNOfNOJMUdBeJtTczhB6t/OsCSeN3KLLGQc89zSzyy3t68LyDyVyMZ5qx/ZUAYA/dPGQaIxtuXzW0LOjXgeNI8ksDyK6ewmjklaNsA+4rndHsUa5HkElYzz6it3Ykcu4YAA/Kueryt2Im+bQtTn5iFIwBg+1VAqOFbhQpzkDrSahcRQWyMuSzehzmqy3iyQiPrkZJHFZwUrXREYuxcgSMwupfcCcjdzWNGhjuXaIZBPpV6J1gKBQzRN/ER3q5sjba0QBZupB/OqvylqXKzE1W2SWLI+VsZHHQ1y9vc+XcPFu5Bx15r0OWx+0ZAPPIBrzDxlo93ZXpkgyqv0ZT3rWjOM/dLhOLOhhvY7iPZISH7hhkZFVY9JvhOJrOWIIAeGyR74ql4dt5ZNO23Q2zICBIDzXX+HogYfLlz5gwOD29a0m/Zp2Bz0On+HFklrZvLOym9kO52xjg/WuvyighCACc9a4uJ5LeQsHOe2ehHaq8viuOOZ4p2AKdz0+leVVhOrNyR5NXCyqTckzsZLtVbGMkcVzOu6vaxO5d41JPc1l3fiRbmIi2O47SdwGAPrXlviCW41iOeNrhlukfK7TgYPQY9a2oYRt3kdWGwSi7yO51a68xgyMDnp9fernhrTZBL9qdM7snpyO35VzGhwyCwgjnO51Az82cV6JoMyt5UasrA8HBBGa6KzdOFonZXfJT90leSGC1kN8Cox1xj8qy11LT7m22QThivLFWxj61o+PYpF8OXgtV86UxnaF5xx1rwn4eWuotrUroWltSjEu5Ppjoayw9JVabm3axx0XGav3LvxD0yaa4lXTUhuYLhg770G5SOwPpXndppU9pqDQiN2lPJZRx1r1+WIx3O65dQpz/APqrs9C8Oaclmt9NArmQZUkDGK7nWVKKctTer7iXc5X4badNBbS+du4/vDHvipvitNNa+B9Q+xg5ceW2BjCk8msX4m+ItR8O6/ZtpzCGywGIA7jqK2fD/wARdJ8SW8WnanCguJcxtlBsb8f6VjNSk1VSuibyWiPBvB2izaxrEEKOeZF3KvJIzzX0JqevWXhuwhF40Ubkt5adDgHoKt6f4W0nQbie706zWOSQctnJUe3pXjXj9pNd8WNbWrl/s6bVUn7xxmtlJV2orYiEfZpyZ2XxIe88X6Pp8+mxyTWasTNGnLA9j7iuJ8J+ErhtSjn1HzYLa3ffvf5eB061618PNGvNO0OKGZ8OQAQRyKrfF/Rbs+E5U0lZJJy6tIkecsnekqsab9lElcsknLYof8LF0iwv4bGGRrhNw8x05UfjRXg9rbXa3aJHBMJGO0DYc/lRV/V4S1aF7eDPYfE/jFbe+ksbSfypfM2hyuQnqDW34H1K6vpbm1u5EeSL5hKI9oYYrjPiJb2sGp3iCJhJJKHRwOBkDNdd8Lo57gXDEEwBRiZx99sHOPUU6iSp3R1KempB4i1MyawtovmIgTcSvJJ9Kdpt3LZPvYSG06Mr9Qf61W8di+03V7M2lsJJJ8ZJ5AwaZq/iGS2WO1uIRJLOvWIfc96SjdKw07notu+GSRVBBXOR71BrOk2mp+TLOGE0RyjqOV+tReEZBNplsWXcQAOe2Otbk0UU33AEDccVySlyS0InZuzOe0vRbTSJZmtWYyynLMfU+natWWMeUXlZm749Ko3VtcLIVjkzjBDY/lU96He13LLt24yGxjNU7yabZdkkrGNq90sFsxJBbqpzx7VxWp380Nsb66Vim4DA561seIV3zRQlmVSTk1xc+tH+1X0y8wIovkGVyG9DXXTWlxOWtix/bMS3kVzCR5b8lV7Z7VsWVxqH2qOUBI4G5UMP09qxYNNgm1eJoF3WsOGI7Fvauum0+4ubmGUfuVwPLXGAPr61crbCuO0y/N1e7iNhBw6HsfrWrqkpRlW0Ksw+8TWfa2og1KeeVUZGVV+UYGfarrzLa287Od+AWUntWUtXoPcXTNRgtLsebOqSEYw3rXRrds5zgEMN3+TXmemyrapsvYDLc3OWQnkIM966Dwte5vZ9PaXcI08yNv5ipnTVrgmup0N7cqJg0n3gePrisXUdQiB/1gOey+tSa2ZBA0QJWQ8ZxjIrlPFcTaV4eluJdzu4+Uj5Qv41MYobkoux598T9UkvLiWC3TzIoCMsOcH3rqfgN4Em1++jv5JdlvbsCyhcl/b2qH4F6VF4g1m9t72Fri3lXmIHAJyeSfavpjwR4NsvCIu49OZhbzkMI2OSpHXmscTXjSTUfiaPHr1nzuXfY6N1EVsEiKptG1Seg44FUtIadbZzeALNnJGai8VadJqmiTW8NwbeUFXWQeoOcH615X4x+IjWSPZ2iNJfAeXKF6BsYzXmUqEq2kNzCjS9orXPZEuYX5WRODzz0pUkjyR5inJyOa+ZtKu9be7WWSWQl+3IHNdnYanqdtNHLOwaNcHb3xXTPLnHaRv9TT2kex384tbOWZyQqqTn0xXyn478Xa3P9rjSdlspGLYbrjPavW/iJ4lE3gq7lVmjmjj3gg8NxwP518pXniaSeWNbjMgRsjd/KtcDTVNOU1qVSiqKtN2bPorwU32XQ7aWRQWmUSOcYx7V2EMolUMAMZzxXhXg7xZqNxCgR4GjUf6k8Hb7GvXvDF159upfcHHUN2H9a3qL7R6UXGS0NxgArcBu4zTXkJQIV+XufSpNo2MA3Pv2qEjcTjOe+e9ZLUpFWQ5YcjA+XNYniSFhp5c8BCDwetbMpCqSQO+BXJeIrlp2jgkYmEtk4OOBXRTTbNG7I5vW/EkT2i2TsBu67l6V0/haG1kht/snzLGMEjk1Qm8NJqlnHNLHGqKcoQe3vU1iG0R4mIHks4QEA8ZOK3dnGyM002dPPpQaY3duAZMYZc9feoLnS7m5kSUh1K84BznHt61esJFiuXQlnYncT6V0Su7oCmAOxHeuSVRwYp3jsZ2nW8dnaBi3zsMk4wRUay5clOFJxzSXkUhmLSAlMZGKeRm1jOAhH8Oai9ve3KiklczL9i0WMqCh6Z6iq9gcOWZSx68/4Vq3Fp5hGTt7gAZqSC2McwZgMAZzWnMoormSI/tJ3umMAHIJ4FQyXAtWEirmPO1+CeT06c1rPGpYM/HbBFZD5hvHxzHnkVEZKQotM0BcMIVI+b5s7fT2pt5AupW7xORyOMDvUVon2uRTgoueg6V0Wn2OxGCJtXtxmsaklT9TOpKNM4L7HJYkhRlM/MQMgmr2i3P+mAs64AwOK1/FthPFZCeIN97BAGK462guyxBXIByAvBz9a6KclVhc0puNSN7nZalKy2krBTlR8pH615m11LcX8sWPnLYNegWD3UsaxzxhRggluv41HHpttbyG42qp6nI6UqbVO6ZDi1ojmNWA0+xhgibNzNgAd/pXN3+nXNjf+fdW74CffU5BHv8A411mrQmTVoNQCtLHGcYXsM5yKq+JrubUSr2CP5ZHlupHb1rohK1vMrmkpeRi/Dqw1CDVLuS9IMFwvyknOeeldRoFk+n6o6yGTCsWB5/p/WrXhvRZLWONSwaNBvyBjJ9K6yOElGWNTt6HjrWNask3YKk9LF+2u4UgU3EgLngiuP8AGN9bWRkMCxRxkbm2gcD8Kff2sxuBmR9gPQ+tYPjbT5p/DcrxAmZRuKYySAcmsaNGKle+5FKkoy5zlYNSlvvPmEQRC21GZsAivSPCGpG50kWxcb4wFx1x/hXimhXxu9Yae8UpZRYxEoxk/wD1q9R+Hlrshu7nLpDJNvQnuO1dmIguR36FVJcxnfHHSWHhO3uD8rrMCDt65FeefDvRLq91qG3hKy2wZWm28bADmvonxXp1nrujfYbwgo4HzDjB9RXIltK8HWEqWMeWKgv0Bb3JrDDV2qbjb3jBOU0dZewx+SysQBtCDnOO1Y6eG9Og1X7W1uhucYLgYyfpXO6F4nOrXcWFAiMgUA9B9a6bUtVtLa8VJryCM/3WbBaocZ03ZGihf3Wcn4w+IEOjzPaaaIrq+jfbIXbbt49AMGq3gf4mDXNXWxvrRUlkUhHRiQSO1ef+OvC+tJrU00do1xFdSbklhwwHscV3fwr8ATaQyalqwAdl+VMYKZrodOlGF2ZVKtpcsT0qZEUtIscIQLy5X5v89qKuTxxSRlY26jBFFcEZR6mkGrai6l4P028s900CO4GVL9DWAk0enzG08oKF+UBRwBXb39xutHGcEjIFeU+MvEUdnJJHvEcrOE8wjp71WG56nut3RlhOaV+Yv+JrNtWsphbEfa4VLpg9CBnFeRy6hKII7q6R98jlXYDcVr0jR76PMTxyGYOMb/7+e9UPEehySxPJDCkm9ssu4Zz616FKXJ7sjraa2Og+Hjefo8boMh+RXSzg2wJA6jlu1c34Xb+zrSKBsbyBkDt7V008nmRYILgniuSr8fkRK6aKaSJ5weRTzxgn+lY/iDVoLdDFnej5V4SMhhV7VI3htGfnPYjvXmtxd3UuozfL5j/w56GtqVNS1RenQ0byfzXQwytMEztDj5l+p796rr4SGrXvnqoGTl3YY59B60/QFEev2McofE4Yum35V+v9K9OjitkR0iARD02+tazqezdkZuxzB0OCOGNbK1Vo1Gz5VxyO9K9jctiQAiOMZIYcZrca8ltYwiIChHB9ael2bu2be23eNu2sfaSKSZycZwsoYhVB6djTtVWB9BvCQpkMfykVHNEIbiWM9FIIXH86beFGspkOAWBGw9K37WKsYjanbXdvBaLOiTmMZyPmOO2a09JijtbyyjWIJOdwZupb3rC8P6Mft0+oPiSOL5VjUDOcdea6TQY5JdUM7l5PlJVSfu+1VOyvYlK5Y1OcNqkMUsqK27JJI6V59+0FqSx22nWcN0XkYeYYwchVOcf/AKq1/FttDe+ONPtI2aO5dQ3P3SuePxzXHa34WvdU+K1poV23mPIyZbOQEOfyrHlWjv0ucmLq2i7HsH7Mnh21g8OHVJopBeSN0cYHsRXugHzFuckAVQ0jSrPSLOG2sohHFGgQAegFZup+K9N0/V/7NuJlS5MfmLkcYrxas3WqOUVf/I8lp1H7ovi3VIbXTpYRciO5ccAcnFeWWHhyzuLozMA0jnO4jk+5rirnxhLrnj2/8yfzIN5WM9OAMcV6Jo90UtgUAOATwf513wpvD09Hqz06dFQhZM1Y9KjhA+RRtPBHT8Kiu7eCFC+0bCOw/WuR1TVNeW9byJYfsxH3WHzZrGuvFmrNGYZI4EmHAkDEjP0pqlUetzSMEWfGdobzTZ4Ig211YbQev/1q+a9aga2vJFdejHkfWvXNS8S3YVk1C6LyKfkwBge3Fea+Kr6G9LyLGsbk/dHrW7ulZmOLp3ptvoZ+javJYTKwPIPHGa94+A+u3Gv+IUtb2ZmgRTtboR7fSvnGvev2VbdpvF0jHG1UJxUSlaEvRnFh8RNe7c+g9W0+XT5Rzuhc43EdPQVSbAyoOCODXd63bLcWUqueMVwa/uywJzsO3BrloVOeNnuephKzrQ13K8kY6dAT61xni2z8uaF1yY1JWQrxgHoa7V23Ngj72efSqtzbq6FHRZIzxgjrXbTly6nXurHO2LtcWQhhlDRfw5bHTqKfeQnU7m3traQtECGkPYYPSteDw7aBNse5EPOwcVr2tjFaII7eNUHdgOTVSqxWxmYtzBLDOGjAwOcelbWl3pliUSHa/fPGKiu4WjlLFvk28CpIYPOdV8sccl/WspNTWpTkmtS1cybQA2GUnGBWW10Y518xMxg/KD2963YrVGhKHggdcZNYMsLpcsAgCg84FZ03F6IdNxeht2yxybWccNwGzV9rZSoGMDHJ+ntWJJcLFAu0Y7DtU9xqFwiqkbZyOAOprGUJN6MxnTk3oOv2CylMsfRQM1n3kXnQOYx85PQtir1hp99OxnZdzN0GeMf41TvVubO6CTpx/FkZzWkGk+VO7NISSfKnqM0G4DTiFk2tG2W5r0SwQG2B45/lXnelwmLVWkV/lkAxz3zXpGnx+XaKNxOSWyTXPi/iVjz8e3oOubWKa3eN1BVh9a4m7tYrYNHsAHPH9a7md2UEKCSR+Vc3fWclzKFUrk8E/wBKxpT5WY4Opyt3ehzK7CG3N8p7Zxg+1RR263sgjeQlOm0mtO90fy4nG3LjowrK0qJjeMu4echwQBXfGcXFuLPYjKMotxZm+J/N0W4tobGOM5OZMnquelbCQxR2m9oVjVlywznFT3ZtrqTdPEX8iQpl4yOR3H+NU9Unk8yMKhaOT5WUqPyojJySS36mfO0k2UYruf8AdSl/JgViX5zx6fStrTNQa5R/K4wQM4xXIXdw3nSRbSqht2DyRXUeGbSS52tt8uFjgDrWlWMUuZlTSjG8iVpmWZldAwJySR2qvqWq6bp0H2i+kWNCcYc5PpwO9dkuj2slu6kcqeDnFeE+PNHjbxkz6m83krxFtHyrwOfzrKg4VpcuxlTrQqXstUdumgaFfWy3tvZoVY78jKhvrXjvjfx5dS31zpWlMbLTomMQEfBfHU+wr6F8G2lvceE7aFm3YBVj6ivm3x94NvtJ8aX1tCjS2ssheJweApOcGtsPUUqsoN7dyFVWsUtT2XwLfS6r4Dt5JpvPnij8o7jyxHT8cGvHtUvb65upom84jzWVtoJIH+FeqeELa30vQ7ewtMvJsBkK/wAbd63rDRRBDM728aiXP3uua2jONKUn3NYxlGK1PJPhzKqzEvIzNE5ynQqQD/jXK+J9fiubqZ7q386ZnLGRifk54A/KvZdL8K6fZanLcx3IVZAS0RGAx561514o+H12t440qWF7J2LlZDgpnqK1VSMpXRTvFaGF4V+IGrafdokM+bcn/V9RX0Vp2r2+s+HorpZx5zLhgSPlI7GvmDT/AA5crr6afb+W9wTxiQbfzr0HxbPdeC9AsrCN/wDiYXBMjupyFHcipq01JJbMygnf3j2SwJJVjMjAjBAOaK+fdE8XyrPt+3XTXJA2kgEE0VjLBuTumVo+p79pGqSajZFpgY+3U81zPizw2urymWOIS+U4fYDneB1FSeDNYfUPCOnT3xxdTp86qMHOT2/CtmaQwRK6EDnPB5+lZwThJuJsoW26nL2GnGCSAW9s9tBCMlOgHtitdZCGbgOjdiM1H4gvJBGtzC52nlsDg+2aoaNqi3Bb91gqccdzmtndq7NUa9ra7ZQzOwyeBnkV00Max8KCTjGT0xWFBOsilerepGK0I70hNjg+xrCabM6kWyLVXzbvnO4Zzkda871Kwu47pmtQ+08qorub2YsR8+FPBPY1kTOT8q4Kr0I+tbUm4IuMNDltKhnGptPO5NyBjnrXWaBq0dzeNbzN/pC5256n1xXLW13NBqsyou/DEYPYH0qnrt82nGGSPZHcbtyE9TzyK2nDmdmZNWR6yyxyr+9+R0GS3SqrtC3EVxGFzghSM1zltrY1e1zvURrGN+04Pvk1MbSJAksDxhW6jOSKwVO2jGlY05tPjlmEkfLgYIzxj0rCmtPJuHS5TD9UyeGFXFmlttohcsh5POQPpUd9EFVbhmaQRtnDHse/tVxut2VYgtNGiu3Z4Z2hcHt0I963LGxSyicRks5OSSOv/wBamo8NrgQFSXAOCecVainEsQfb19eDUyk2HLY4nx1o8sl5a6rZErOihGA9M9veu6+HXgb7Lq8Pia/lkmv3j2Avg4XAxVG9VZLc7SpKnd9K7zwRqUd3o8ZztCkqSe5FYYqrJUrL0PNx0GldHS55FfPv7RujzxSRaxZmRJkBV2Q/w4FfQJVW2tgZHQ+lc7418PR+INIltJMncuPz/wA5rz8NV9lUUnt1PMpy5WfEHhDUvs2tRySEjaxBwea9sn8URWWnqodX8wZG6vFPGeg3XhPxNc2k6uFjf5WIwGHY0231Brhow77scDJr2Gk3qenhaia5W9Uela54huY9NUxTKJpB+Q9q4WbXrlf9fIS3qeTVe/uSAVEm/HAxXO3zyS4C9zTlLlVkb1avs1dF3WNX80bi2WHHvXLyO0jFnJJpZldX/eDBplZN3PFr15Vn7wo5NfT/AOyro91Et1fvA4ViArEYBGO1eKfCjwXc+NfFNtYRBliyXkkH8KjnrX3d4S8P2nhrRrfTrNf3cYxnGCaxxE1CHL1ZnTfLqa0+DE4PTHSvLdSeSK6um2t5e8kDHWvSNRm8qIkHDHgA1kTaLBJbESBizgk5Ga5KFRU23I9DB1FSu5dTi1nYANkNGVyQTyD9P61chKMVkGCRwRVW9gNnM8RVzsJ25qXTkdW8xYx5ZOW47+td8tVdHsOzV0X2hf8AiG3PQ561UvLyC0lxcSxof9ogVi+KPEMtrFMtiFkkiUlh1IIHTA5FcN4DnPiv7bL4gR/3TBlLEgdO2aIUG05S2M157nqkd9Z3e1lkjd1465xVvTJFZ3jUjavAAOcivL9U0+40ZftVvIRCxCgbs8Guw8NtPIlvIW2sy4U4+93onQSjdPQJRVrHYvbsyBlOMDn8qwo5o57iWJwMq2OfStK51R7WBkuE8vC8kjrXALqsbeJElaVo4QCzFuBgetY0KbadyaMZWbZ115bOYVaJSzKc8DIxTbVN8y5OAOPfNeeQ/Fu2t9YKNAwsQ5XeOSPfHpXof2iFwl7ZyI8MwyMYIIrRwnFWkXdv3T0DT4lW3XpnHauf8YxxNLCcAvjt1xVGHxDcw2zJDGNwXAYjr9Kxre+uL2SRrzcSTjI781yU8PNS5n0OOjhJwqOpJjL298i+iWMrGyIHJI4610GleLUWLZc7Bxhc8GvPvGLzf2tbJApJYdhx9KzJLq2hjnOoXBt5IhtHmnG70x6j3rulh41Iq501KcKitJXPb31WNo1LkZb+EcYrC8eeIk8O+GLrUYIxK0XQHvz7V5/ovia8nsizoJY4/lEjDGR61sX2p2/iDSJdNv02qyYZMdR7Gub6k4zV9r6mMcGk00cDpPxl1WbU1i1G0s2tpDg7Mhk/WvSkZY75LqNX2zAE46GvN7T4d6TZ363IubiRFIKxuwIJ7V6hZofJVhGNvG3jj8K6qsKcVeCOmEHBO5dntpLrbO3zhF6FuCPcd6wfEOptaeWtsgMpJOPQmtLUrqO0t1aadYUx8zs2AOK5q11rQb27ZYL2OaYHAwQcfSsqUXe72CEOrF0nSp7ydZp92GbhuwPpXq9rbW1hpyRhlG0ZJOB+NZPhiIyeWpUFFAII7+9SeObwWltHtQO7DCgdz6VzV6kqs1TOLETdWqqRzninxla6LG6SXSAk/Ku4En8K8S+Jnj251CKK0th5e9dzyjr7AVR8YWt1q+vzsEmM4cIqj6dxXQ6Z8PP7T09Rq7GOdBhZAcEfgetejTw8KKTe51qKguWC1OZ+HfjLW9K1qGKC7mmWVwDFIxYEd8V1fjLXLvUb5/nKYYqAvQ5NXfCvw1XSdV+2famuXQHaQoCjPeuuuPAltcuJpZGVc7sDHJ96uVSjCSk9xUlyXcyr8N7V7dEuJnYqVwSfX2qfxZ4wS3ne3BC4PQnkn0rYk0qTT9IO1gsYGAT6V5l4sW1FpJLdI5G8FZVXnJ4xUQUK1TmLXLJ8y1NSPVo5VYyYZ5BuAzjNVddvBaaBdy+c7AocEep4FQ6bog1KzSRZCFRRtY8Yro5PBzav4LuLVJC0xA2EdetazcKerZUqkYnz7Ffs15asg8lojt3J3OfWvaPE3h278Y+ELO7tismowRgDtuHcVwNx4QudFS4uNRtZIrJSvJ+8x9BXpfh/xnBpejWETwxC3KqqhG+dR9DVVL8qcNWZRjKWpw3gj4Y6jJfGfWYJbWGMkhWGC3rRXt9nqdlqC77e9jl4+ZA3I+oormeIns1YiMFDR6nn+jRS6XNHDHOPKjJ8uNumP8a7m0jiu7eOW6JVWwwxx0659qp6B4Ju9RkWbU5ykK/wJxW/qGmDTBDEqEJjahqKtWEpWT1Nvbwk+S5z+vLFPaC2tscncx7AVyOm3CwzBLVQ4J/1mev+NdB4pkMUEyRgj8fXrWdbyQx2yxW0arJtLKcZFbwVom693Ym0nWYJrp7fzdzqSrrjBX/GutSIyxZbofXmuH02bTrjVAsgja5ztyhwSf8AGu/stqRHbjaPU5zis63u7EzlZFPUdPLW5KyA7R24xXJTQK94DK8jKhx5Snapz13D+Ku0mvIzczQJJ++iCl0x0DDj69KwbxF8wMq7mGcn/PtTpSdtQhdq7OM16BrfUIblXEasCG4wDVTxbpcuq2the2AM/lMAUx1HrXVahp63kbwXCDYemOx7YptnpF3ZCMxbnhRQEUHrnua6VNLW+opq5ieG7S4tWu45Y2jgfA/3DW5pGnQ2duVnuHllcnAHSuj0e0EEbPNgSy9VPOPrV2aOFRlUTPstYyra2Ero53ZM0MQ8p1wxyR0x6msq5lmhv5A9yj28iBWjfkZHetjW755Ly3sYw32fOJmUdM9BmuY8VzWtpJBZxRKzuxxjqvFXBXG2b/2qA3AUncoXAx15q3YsI52VWPz5AUdjXLxeZHJGvLFBggdfatyKAKBKSSzYbk8rSlGxSNhw5BTnPYD8q6r4aQbNPnjfbuErEfjiuSyOXbgHBC+n41v+E9UFtqTxsp8qRQc+hrkxMXKm0jmxlNypvlPRCQB9PWkHJ46UyGeK4XKPkemaFjKSEr9015LPn7W0Z4n8f9L8H6ld2ttrl3/Z+qSLlLgLldo7NivmDxPaabo98q6RqYv4/VVIA/E19I/tJeDm1mW31K1aTzwoTZt+Ujjoa+W9U0S7si3mIxwTzg5+lexh4N0U1qXL3UpJE8d+JgW+6emDUlsgnc7T05rC8uRTtKnpnjvUsC3AH7oP9RV2bZrDGO/vq5Nq0ZWQ4HGaoIhd1RRyTiuy0DwD4q8SqGsNNnniY/eAwPxrc0f4aaraeJdLs7pYzNPOEK9QuOuaqMLvU5ptVJtxPoD9mfwFP4Z8PNq2ooour5R5S/xKmT1+te2Hpk1BZQi3tIYBj92gXjpwKL6ZYLWR3PABryatT2kuYFG75TJuJ1udaij3ZSL5jj1rRurqOGHDuC+3OfWuM0u6kF5NM7Z3t97NXru6Mq7BnK+tVKk00j0p4X3oroitKi3spYcfNnB9qsppzCMYwV+lZ0bMzhckH1xT7u/kttpDhgvQZ5HrW1pK0UdjjLSMWYeu6I376WEfOSTnbzjHQ+tcDql5BaRR208qQ+amxB05/D6163JdCaAOy5G3Oe9eY2sVrrmrTtfWwMMOShIzn3FdtCTaaktjSN9nuc3oml6hJcwWd3dSy6erfM7EkAZ6CvYra4t4lVLMfJEoQAdsf1rh9e1iO1szDY2rSMgyDjHGOta3wwvZdSs2+2IFZRkFh1HrV13ePM1oNpR1Z2Nz5epaZIkwbeBhS3HHpXl/ifSzDOJJW+QgxuVz0PGa9htP7OUujy+a7Agc1y/jHSyluSiiSN+cnjqK48PVSlyk0KivyPQ+erzwfq1lqaxywSSxyNkFRkSL2x+le86Bpsml+HbKymBLqCzKOvNJ4dvZLaAW52yGMfKSOlXNQuTFC12oaQ9GA6111Kkp+7YpUnCZG96seQ8R8tcg8/hWnBCJYkZFJDAEY6Yrj2DXkzGMnJ+fYepFejeFIw9tbhhuGwZP4Vz1/wB3DmCtU9nG5njw6+oSIxXCqcg+lQa58OtMuU+1zkLNHyC3Ib2rrNX16x0iNlJDygcIv9a8z17X7rVLt5PMdbYDG0NgD2+tYUZV5tNOyOajSrYqXM9ImZqUJig+z6fGSicNKThVYcc1V0kNLK/mXCu6H5wvb6e1dBobm+YidAYEHyx+/qa41tXjm8YjT7eyNu0VwUTj/WA/eJ9q9GLcrx6nfGcYOx2em2H2mYPJnylOc+tdFPdQrClvFjIwM+lc7fahs8yCL5IkO3eP8KztKvFtbq5eXfJErAhgeh5rCVNz1YqnvO7Mb45SSxeHIlhyY3lxIw6Y9K8j8D3Qs9bt7iXd5e8BvavoabU9M11ZrCZUmUgh0IyRXG2vgDS4Lt9kmAz5VSeRzW1GSirT0MnCTd0e0eFr6GKFHaVSJI1wM9feqniS8jmk3n7qjIB9utZ2jaQ2mwiRrwSMwwFxj6cV5P8AG7xBe2l5HpcDvFA6biynBbPbNcEKMZ1m4syhTh7R1GzurRrLUbprqxW3e4Q7fM4LZx2rhPFHji7sdTa1t41jK5DNJ3x2Arz3wZDqlzrlqumecZ1lDExkjAHXOOvFfRVx8O7bVryHUb60HnKOVH8X4V6EuSjZ1Hoa/WoK/LoZPgDxrb3kFrHOv7xgRyMc+9dxrl8tpAJ3UrEcHn/CsfQvBMVjdmRYtiE5GR0rqb/RlvoxBMGKqAN+K4K9Si5px2OSVWPNzSOM13xdEmiTzJh9kWQuMZx0zXk+h+KZdXv49J1JIhBM/wAuVAxk8V7Zc+D7aBGXYJYSuGU8j8q8l1bwRf6b41srqwjSWzWQSDj7o9668NKjZqJ0U6keX3TsYjb6RKbZmDDhtoHGBSJ4ssorw28cwgYnARjjAxTtf0LUwILywt1nRvvRycMuO+e4rivFtnLqOnu1xpRiu0U4dcYP0q4qNVau5up03sdJqt4uv2c1obMSrnAYtgH0xXAav4b1KMqLSNnt1G1h94rk9Qfarfw/1HVbWDbe2zyWQGwsRjH413dpdLPcR28AkdpW+VT0A9TWqvS0WxLnzK6ZmeF/Ctz4a0C+1a+uVMbRbkVh8xwMg/SivStQ0s3mkvaTpuikjKMFORjGMiiuSOIU25TOdVXBWWp01hexTwxmEEoR97GFPPTPrVTXgs9uVBHHII9a4H4Sa47eE4La7mZp7U7S2Oq5+X9K7C4umnU4BOD0FcEqMqdVrsYRoOM+Y5TXdNF5YS8jeEII6ZrzqDVHhujBcxkLGuFB6H2r1yUbmk3qdpFcb4i0QMPMWNWKksp9K9OjNbM9JXK1pp1qZ7e5W3CEtu3KehPU16HaSKIFU5JbgHHXFeYeGdbvH1F7SZD5MfyngAZzXoVuvyAKx9QCelZ4iLdkx1IqSKerFkyoJ24646VlLKIjkgEkZBzW1eTb4pAMnA6YrmbxWEjHG3uQe1XTWmpUE0rF3ejQrsKkE9Ae9a9mwEKYBz356msHT4y0+JSAgGemfetyMfMDF064/wAaJroU0WlyxHTj2p+DuwGyen41XtxtVVQs47Fzk+uCe9WgMZXPPpWTumZO6OUvNsGswu7TZ3t+7BIByMcjuMdKp6jFa3WrxXRhwijIYjGSK7C9tYbjYZFAcZCsOoFUG0uDCpMC0a/dXNbRqK1wSuYugaYXku72RPKSd/3YzkgDvWkbBUuFy5Zc4yfT0rSeSMRkIeQOAvYVx19rl9Obh4LuG1t4mZQSm8sR9aa5pu6LS5dzpT824AgjODiq7gwTrMSSqHr6A9q5/wAPeKUlkjimjRfMywmQYV2JxyK7EruUeZ8wI6daUk46Mpq6Oj8MXMgl8tH3ZG5c9SP6V2EjNHA7sQWC5/SvLtNvJNOuIc5+99729K9KDJfWeYyN2OpHSvKxFNxl6nhY2nyyT6HC+D9bvvFN9qL6hFHHom4pbeYBlsd8fXNdc3h3RLiDyn0yzljZdpzGDkVwGu/a9KgeK2jIUNxtGAK5238capp7gOj4BGDjNbOhKfvUtETOjGaXvG7rfwH8KahcyTWcUtkWOSqSEr1z0NbHhr4QeFdGtVSSyF5L13ykmul8Ha42u2DTshUj8jXQVjKvWXuSkzilDkditZ2trp1sIrWNIIUHRBgAVj22gWlxrzatL5cpHMKgcKe7fWtnUGCWUxxn5Tx618vzfETW/D+t3VvFM32ZZGxGcfKMnoadCjOpzOD1N6NLnTSZ9UE4yfauL8W6qzkWsTfe4OK820H4s3+sXP2dUdcj17fXFdCt1vQyykiRjyfX6VvSwsoPmmejhMDyvnlqa1sUjCqSAR2xViI9ick8ntxXJXmuR283kjdLcschF6sKbHe6lcwu6EWzKfuths10Ok5as75UrnWy3MUSuq5LDnNZslwjO5eQEk9K5W6fVY0a5a9UQquWUoPzrP07W/7SYRscS9gO9VGhZNpjjCMUek2ZjO1ZMIMYHtXJa7pj6deOU3JC+WUjkfQ1tQ6itnpH2y6JVEBJYjPArkLf4r6Xqd79kuraXyHbashGR1wDUwU1JuKujF6SuVI71IROsduJWkG1Q/Bxnk10WiGW2sruYeXGQMqu3OcCs/VLUWOpt5AV4y2cnqBjoK6nTbVZdHiWYbfMQ59ea3qNcq8zRtHnWhXWsah4juxdyvEFG+PjrzXqcs323TlEvJaPYcevesiz0a4DsJlQRKCqMeD+FascDRoqKuEUcjOayqyjNq3QzVm7lLTNMaFS2wbs+vGKbd6N5qP9mmZFbllzwTWwZH8tSh5J6UAHbtYgDqR0rH2kk7lOberOf0jSZYZ2adUAGckHP4VpXGuxWcRitpPmUYyozj6VKHjd8GQk4wx9RWDcWEPnS/ZAdoPBLYx+FafxHeZpThGb98q3hkuJvOkkwGGQSMk0l7p0IFr5kn7ggvIB3Ncb438SHQ7hLWBw1yy7mJ6KK5S28b6mUaO5nSaLJ2qUGMV0KD0sbTmvhR2mg+JLnSvEuqrbQPPYyACADlsg9vatuytDDqt3r1/GVv5PlhiHPlA/1ql4C1O0voflCRy45KrgA12EumXNwMwsGUnI7UTkovsYqEVrI5+K2eW6kS3kL3M2WIx0/wAK6SHQ4ItJFmT88q/M567vWrOj6X9ijDRRqZ36hj3+tbs3l2gV3OXYZ245B/8ArVy1a7vyxMalTWyOMXw7beHdKubhIx9pkBbfu5Y4ryPVdQ1SzvxK80qxsc7kAyfb2r2rWna+mjg8wkFhla5zx+mmaVZxR3LGCdidjde1b0ajT9/Vs0inFJPqeZW3j3WbXUIpRdSSW6MN8b85FeytoOk+M9MtbnULQToRuU7iGHqPavJNI03wxLqAe5laWEnJ+YjvXfy+OLGG4jsdJPCALuGQqDH61VaDdvZ6MbpzqXXQ9J8KeHNM0iMDTrNLcE/NgZJ/GujubyCy+SRhk9sV4cfH9vLO0MGolb0/diZSAx9M1S0fx1Nqt/8AZJmlivVYjaRkfnXDLBVKkuaTOWeX3d5S0PfpblZNNluExtA3A1yVv4x0nV7xrG3mU38IbCsT16Ej3qlq+rXWleFrqctzHEzgjkHAr5e03WrqLxCuoQTN9rM3mIw/vE5/rSw+EU2+b5GMcNGCbffQ+uo791xFINy45z/WrMttEyRSYUMORjvXKx6/bWel21zq5WG4aNXkQcnJHNaFv4stLqItHkso3AY61MqM18KNJUpaOCOw09Ul3CYfMAOCO1VLvw/ZurDykZpOSp7+teUa18aItH1g28Vm8wQ7XB+XH+NW7X466VcXSI6Swc/eaPI/So+rV07xRySo1Yyun+J6K3hfTrWxaOGEBRyfc+tcxYaWsGoERQqDnge31qzp/jJNfizazEx5wPlxmr0d5HFdHIBbb27Gri6tO6ludFGFSEWpanSabbxrbq0igkcDNFZU2reRAqklDj09aK5VFs5Xhqk3zHF+F9ITT9MWOJQWBwpPI4PFbkKkA7/Tsa0bDTGWNV5AI61PNpJIJj6E55HeuupWTep3PEQva5iNtY4BG41n31uZ1CY4B4PvXTppAHzPk474rE1kvYo0iIT83IHpV0qibsjWlVjKVonMQaA1vqEtxuXgZVM8E1vWZdYwZlUS4+ZUbcB+NUP7ReYECPDdj0JFJFcnAkRgXIx6cV0yu9zrVKVrMddKDLLnkOMYPYVlyQswJcZPU5NbqyicAsQrgcjrVa6izKNnA7n3pxlYadtGZtjsQb13Nu+6R3/wrWRiEDFcsetVVVUcoR9TjBzjrmp+VIwzMKbd2U9SZWcMMIuzPJ3Y4+lTmQbRk9M85qKNQUye/I9qoa/PHFo9zuVWRU6MOM54/XFTy3djNomk1qyjlMUkqg5xxWN401l7S2ghtGxPdBgHTkqoxnFZkptPsVux8qSeZgC24Aqvc+59q5zxfJf6Zc29xG5aJBuKlfug9q2hSXMS3ZX2Luk6fcT3LtFeTLdICS4fnpnvVPS9RJutR0zUYF3O7Msm3OGI7+mc1c0fV11bS5Lu0t/s92jAbgfvD3pfCNu+ra1dw6pbhGaJgzgYPXitr2u2J6FXRNFkOkSm7YCSKQtGQeg9a73w7efabFRvDtH+73euB1rD1PT59OiFlZTwuGBUGUgMB6VyMt5ruh3QtrUAx53O+09T2+lRKPtVoUpKK1PXbyNpbchABLjK+xrpPAusPKstvcRlXTjkEZPt7V5npev3cD7dZttqAA+dHkgZ9a7ayuyipLCQ27kMOa4sRSbjytehhiKKrRsjvriygnl/eLudlPUZAFZN94U024TDxKMcHjrVODXp4yhZcr3Ap11r7zjagChq4I06sXoeUsLWTsWVjg0DSpvsYDGNSwA78f8A1q89X4p3k10ILCweZlb5wMkKK6HUtRe3sprhlZ9oJKrzmuC8G6pb2lrrd3NGsBRjMQgyxQ9veumjh005TV2dUMI7HYWXxKn1O4aFdKuLeEAhpZUKjivHviHoraprEl1YqEDnJz35r0rTru4vtMS5vbcxmbJSIKchexPocVWg0gXVxLKwAt1wEDcMW/iyPTpg110YQpN8qsddPDQpx0Rx3gnRX0QiSdCZGBIJHABrU1nxTbW139lYsZ2TK4HANb2p2zG3ZLdcc8cfdrlotKt572Rb2NZGf5SxGSOOtbq0tWdVuVWSNTTGtFl+0jbLOEy0jHBB9BV7VL2Sa1R7eLaijLkHJx7etYh8KahYHGlSLKjLlt3GKS1OsWB8m4i8/IyyBDgD60cqeqZKnHbqQeLb6e40eJ1EkZRgrlO61RtrZilrNaSILjO0hDziuwie31ez8kQrsb5XTHQ9OlSaH4atNInNypPmBs5PampqKsyal76HR32mvc+F5LSVNxlhKg57kV8/6P4N1S41RY0tnQo+1mJwMA9RX1Rptt59mWbIBHAPSs/+zkS4eSNAHPGa4qOKVNyTPPclKTV9iha6TDNbQRzosrxAZdhg8Vs3UMEcCLGFDqAB7VcttMMcJkdsAjgCsrVrgIrAMD/tVzObqTsmOMvaztF7FK/1Dy08oKN3THWsHUtZeyhMhcAZIH1rN1vxFFp8Ek7QtNGh+dh+uPeqlpq2jeLLPyIbk20452uAGFdkKXKr2PShThBWKY8S6nPcEK6IoOVIbrW5Yane3OWuZF9B82c1T/4Ri4tIy0TJcDsVP9KrNbXkFyAVI9eetaXi9kdipUpq8ZHa6fayY8yf51/uoeMVvRWEBjJ8vkjGVH9ao6JbyNbwq7FsjpnrXX6dZhAAw4Arz8RNqVjwsVX5HufMvxe8NyL4kKtHtjmj82OQDgeorj9N8CXdzCsqS7QzEL7+lfVnxG0G31XRDlB50R3Ie4PtXhd497ZauLeKO4W1jUbQqEktXo4at7aC7o0oTjiI87E+GugS2eoQl2LK7FJI2/wr3e3NvYxESKAQANo5IrgfBNjPA7314pW4kGIw/UD1PvXU3TyLG5twrOBks571him6kkh1I83urYL7Wba2ZVLBCDx7VgXupXF5KVgK4+8W3YrgdT1y3GuSwX9xtt423F3Pc9q9G0CfS9S0v/RWgnwmGKEHtTVKNNXOiEY0lzWOXTVLhNTgmtzHLCJNsh3ZP/665r40xzag1tMWGI85GK6TRtCuodSuNsKpavJuUn7xrZ8QeHJL+DbMI3icYJHX6YrduEZJiUlJ+8fOtlFPMQsKFio+fHcV0Hh1ZI4dRYwtLLHFvVAOTj6V3WmeCp9Jvi0MDtG55DLgYro7Tw7DpbvPbxsZMckckD0HtWsqkUrI0prVO589Kt1fazut42MgbfhQTjHPNeheDrCdvE/9pXfyyjDbR6131hp1jHdTTW2mxRTyfKzhCN2euazPEcdv4V0uXUxuaQH5UbuSePwqfaK1kQqL1cpbu5u/FSWRvh9dNExDjG8Kccd8etfNdsRBco6qSykMOMYNehaf471fXrt9Pnt4Zba4+RowDwD6GvRtA+Blle28c97eziNvnChQGwexNZw5KEb1HY4a9WnFaO5jXem3/iLw1Z6rDMI8whZIyM7wB2Pao/AunXtvJc3dzuiyNqIemBXt9h4btLDTYdOhQrbwJsX3FYt7pSxzCJVXyg3OOmPpWaxkZXiiqVfnsrnh3iPwVea3rk8+klWaVt7qeO3Y0xfhRrVuIriURiTdgxA54r3iztbS03PbogbOOO/4026vg75GM57UfWpXSginF1Hoch4M0C50WBnllKknG3PArqrUIoeaRue4JxWPrN3ci3Lx4L543VgXd1cWtsf3cly332YggiiUXV1kdKp8sbNl3XtZuNVuzZabO6BAVeQH8xRWZ4V8U6PeXv2REc3Ur4I2AID75OaKd/Z+7FC0WiPa3voLVNspAYelZk3iixW4EJlGWPQkZP0rk/HF1Ho+h3N8RJK0aBsE9T2r5mv/ABFqN3q7ai9xIJWbcuGOEx2Fc1PBxlHmbOH2FGKvLVs+5I7yCS0SRG+VgCPWue1eE3OX2YRei7etYfgLVp9S8M6ZcyhfMliVmHbJr0KyjTyFKoADgjNcbXsZHNJLCy5keV6ujRB/LTkc81QsrTzYSzBix5B7j6Gu48TWSLOzALgnOMVzFo0lrPcCXa0RO9Ao6Ljp9c5/SvRp1OaFz26NfnppoYtudqYOGHJJ7/WpY4s5IYk55HWiedf9YFOCMgVQW5k+1AKdqn8a03RsouSLThGiVgS0ZGeRg8fypglwAWJUHt0HNXxNFcQFHRs4POetZl5aIqjGeMfxGha6MiLezLslxFDA0krLHGgJLk4AHqajlRLiB1P3JE4YDPBHBFZgn2gh2kIx6g559DVqCZzIo38MCFBHTHrRaxTVjhrzR/setRm4O5IvmUjgYroFsFlt5xJcCdSQcsOCTxge2K2bqCO7UxXEab1HDAZzVSLTGBlgVwsY2itue5nyrqYujeFRazs+nziKJhgxONyc10thaRaRbXB3+bdOpYyHjOBkVatoVtotgyeOvrUV82I/XPB9wahzctwjTWxz17p9teWElyE3XDR7t5PO729q57Q9cGmanNY6/HLkr+7cr2Peq2r+Irrw1rq2cYWWBnVxnnCE/drsfEjWOu28Vw9ttdVABwM461rtpLZmcr81o69yS/vbG0t4be2YOs7ZcschBjOD61a8LNi2nSI5t43xESfrnFc9p+hWX7u4Ee5S2XR2ONvt79K6S0IRAsShY1GABWc0rWNIwb1sb9u5IKkjFNjXDnPT61QiuC5AxgLj8alV3Y43HrWPKDg0aLKDEVZsggjB714Z8QjqHh8TPERHDK23IP3upwPava41diQX7flXLeMPC1trl9aR6hLIYE+Uoh5b61dF8r1MZJpPl3PMtC+JGrzWFjYRo1xetL80sndewr1jwjqhvlng1dYorhSNmx8hvw65qY/DbQksLdtNjazmUhhIoBJ+tcto0dv4c1bUjIr3EjHcXPJxk9M9Kq9OpF8pnRnUnpJna3UKsjKm45HAxXP31hcRs0yKqHrlvmBA69Mc1Lo/jS31SUW62sqjplsf411Dwpc2rqw+Vqm7hudLk0tTh9A8ZQTavJbSK8UQHGf4j6UqeI7l7i8WKEuivtUtwSP/AK1adt4Z05LssYV3EnJAra0zTbSwJEUQOehYAkZq3KC1sTJta2MXw9pNzbhriRS8kzbtp6rmuqSxE0QWVQf7wFXrbywGIB4NNmvmt0aNAMH15rmnVlJ6IxdSUtImzp32SzhLPtWRxlsHJOPaq8k7PKZI4htPr2rJjdplMpPT17VBeajcPEUjYIgPOO9c3sG5HPHDPmdt2al5qbvHsUkAHsc1zGuTytaSmMndt4GOPrS2yXhil8uWMyMPkZ8kfiP/AK9QJcO8iJOqHLY+UV1wpKGx10oRpuyOAl/exJpckxkWeXDM/A56ge1Z154YsLLW5L4XMcVrbxgpHG3zEgdvXNeg3WhW88xG1SCxYBl6H2NW9H8F2U8khMcXyZbJGSa6fbRgrlzSWsznPB2p3F3ayEJMsY4QPy1drZ6BqV6u4x4Uc5wc1v6TotvbXEEQVAjEfdXFdnGiom2NQo9BXDWxWvuI4sRmDpJRprXucHbQTaLInnjIHPIrprXWrZ7fzGDJtHQ96satGktqQ6g54GR0rjWhMcUsakAFTzXOrVvi3MI8uMjzTWpynxE+KUVvqkFpYJvgVwJC3fnt710NmkepWy3iqRlQ43ckg815nbeFLfVfFLi6ld7eBgzRtj5mr1J9ltGBGpCIMBR0AFd06cKcVGnudkYezXJBWKiTZG1scZA5qu+6RiquFQDJxT7yJ3eIxlUQ5B9Sa8+8WfEuPQpTBaWTSsJTG5kAGdpweh5oSvojoukuY8l8fzyXHinUpAG8tZtiqe2K9O+Cmj3VusuouCIJlwVJwW9M11ejQ+H/ABvp9trb6UgdzhvMjUNnpyR1HFdQkccEcUcUaJEBkIowBWrqrl5UtTkjCU58z2LUCs/LEeuMciorzVLfT4HaU4GSOf6Vy/iLxO9kbhIIzmNSSW715fa61e6zfFrqZ2Vm2BSeFwaiGHc9XsdLp21kdt458fPbaaiaUhE05Me/P+rGOteaaR4x1vSL0kXr3MStueKRyyn15rs4vB66+s1q1wYgFDI45INZGkfC+eTXVtn1CMRxt+8IUksPauiNOEVyoiVXkS5Uddf+J31Lw+NUtkkto1xlGPXnnHrVImPxboc9o6nfPggE58s+orrPGWgxL4XWxstsSxKBkjr+Vc78KtGuoNVcTTRMI8kYyeMdDUxcXByj0B12oq50fw2+EQ0d4725nWdzhsEYAr2lFSOFUGAqgDiqVrceRYx7xu29MVzPiTxE4t2jjQqQcZB615FSdTEyPGhQnXqcsdrl3V9ZijuPLR9+GO7B9K5ufVmvL8paE8fePtXlniHxvNZXksMEJe4LHc7nj8KTwr4supjFHIi77liMjoK7qeD5Vc9uGHpUfd3Z3XiDX00wLFK8krscALyBQt1AdO+1XEywoByXOOa8Y1DWr/TdZnS/ZLpFlJ75x+NM+J2ozyalbWUcjrbiEOEBwMkZ5rodHlSRoqiitD1rTtYhkJuJLmN7Ve5PFYXjvxrpF74dvrLTr/8A0r7q7e574rgfCl9v8D69bMG3I6YOeME4rk7aBGuRFJkqzhePX1pqinK5m611zWuLE8thLFdK5WZCCCDzkUV3n/CHWsmu29nPJI0MoUNg8jPpxRWkkc8pSi7RP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Schaumann body consists of a fragmented, irregular, calcified, basophilic refractile structure in the cytoplasm of a multinucleated giant cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laga AC, Allen TC, Bedrossian C, et al. Noncellular structures. In: Color Atlas and Text of Pulmonary Pathology, 2nd Edition, Cagle PT, Allen TC, Barrios R, et al (Eds), Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41078=[""].join("\n");
var outline_f40_7_41078=null;
var title_f40_7_41079="Treatment of acute decompensated heart failure: General considerations";
var content_f40_7_41079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute decompensated heart failure: General considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41079/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/7/41079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11103510\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute decompensated heart failure (ADHF) is a common and potentially fatal cause of acute respiratory distress. The clinical syndrome is characterized by the development of dyspnea, often associated with accumulation of fluid within the lung's interstitial and alveolar spaces, which is the result of acutely elevated cardiac filling pressures (cardiogenic pulmonary edema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/1\">",
"     1",
"    </a>",
"    ]. ADHF can also present as elevated left ventricular filling pressures and dyspnea without pulmonary edema.",
"   </p>",
"   <p>",
"    ADHF is most commonly due to left ventricular (LV) systolic or diastolic dysfunction, with or without additional cardiac pathology, such as coronary artery disease or valve abnormalities. However, a variety of conditions or events can cause pulmonary edema due to an elevated pulmonary capillary wedge pressure in the absence of heart disease, including primary fluid overload (eg, due to blood transfusion), severe hypertension and severe renal disease.",
"   </p>",
"   <p>",
"    General considerations related to the management of ADHF in patients with and without acute myocardial infarction (MI) will be reviewed here. The components of therapy of ADHF and the pathophysiology and evaluation of patients with ADHF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of ADHF and cardiogenic shock in the setting of acute coronary syndrome are discussed separately. Management of right ventricular MI, which typically presents with hypotension and clear lungs, is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noncardiogenic pulmonary edema is a distinct clinical syndrome associated with diffuse filling of the alveolar spaces in the",
"    <strong>",
"     absence",
"    </strong>",
"    of elevated pulmonary capillary wedge pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/1\">",
"     1",
"    </a>",
"    ]. This disorder is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are generally in agreement with those published in the 2009 focused update of the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    heart failure guidelines and the 2010 in the Heart Failure Society of America (HFSA) guidelines for ADHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Similar recommendations were provided in the 2008 European Society of Cardiology (ESC) guidelines for acute heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/4\">",
"     4",
"    </a>",
"    ]. Additional recommendations are provided in the Society of Chest Pain Centers recommendations for the acute heart failure patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2010 HFSA guidelines, hospital admission is recommended for patients with ADHF with the following clinical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of severely decompensated HF including hypotension, worsening renal function, or altered mentation. This is also supported by the 2009",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      focused update, which recommends that patients with rapid decompensation and hypoperfusion associated with decreasing urine output or other manifestations of shock should receive rapid intervention to improve systemic perfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dyspnea at rest, which is typically reflected by resting tachypnea and less commonly reflected by oxygen saturation &lt;90 percent.",
"     </li>",
"     <li>",
"      Hemodynamically significant arrhythmia including new onset of atrial fibrillation with rapid ventricular response.",
"     </li>",
"     <li>",
"      Acute coronary syndromes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"       \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitalization should be considered for patients with ADHF with the following clinical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worsened congestion, even if without dyspnea.",
"     </li>",
"     <li>",
"      Signs and symptoms of pulmonary or systemic congestion, even in the absence of weight gain",
"     </li>",
"     <li>",
"      Major electrolyte disturbance",
"     </li>",
"     <li>",
"      Associated comorbid conditions such as pneumonia, pulmonary embolus, diabetic ketoacidosis, or symptoms suggestive of transient ischemic attack or stroke",
"     </li>",
"     <li>",
"      Repeated ICD firings",
"     </li>",
"     <li>",
"      Previously undiagnosed HF with signs and symptoms of systemic or pulmonary congestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inpatient monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are admitted to the hospital for the management of ADHF are at risk for hemodynamic instability and arrhythmias, so close monitoring is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The HFSA guidelines recommend more than daily monitoring of vital signs (including orthostatic blood pressure) and at least daily monitoring of weight, fluid intake and output, symptoms and signs of congestion, serum electrolytes, BUN, and serum creatinine, and oxygen saturation until stable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/3\">",
"     3",
"    </a>",
"    ]. Serum potassium and magnesium levels should be monitored at least daily, and more frequent monitoring may be required when diuresis is rapid. Routine tests include blood glucose, troponin, complete blood count, and the INR if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is used. Evaluation of BNP or NT-proBNP, liver function tests, and urinalysis is frequently indicated and arterial blood gas testing is occasionally indicated (eg, to detect carbon dioxide retention). Telemetry is usually continued for at least 24 to 48 hours. This may be discontinued once the patient's hemodynamics, medication regimen, and electrolytes are stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Documentation of effective diuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHF is associated with an exceptionally high rate of readmissions, which is due in part to inadequate fluid removal during the initial admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Persistent congestion may be difficult to discern and accurate intake and output assessments are often difficult to maintain.",
"   </p>",
"   <p>",
"    Daily assessment of patient weight may be the most effective method for documenting effective diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2\">",
"     2",
"    </a>",
"    ]. For accurate comparisons, daily measurements should use the same scale and should be performed at the same time each day, usually in the morning, prior to eating and after voiding. Weight comparisons may require adjustment for variations in food intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of invasive hemodynamic monitoring in patients with ADHF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of acute decompensated heart failure\", section on 'Swan-Ganz catheter'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of refractory heart failure\", section on 'Hemodynamic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with adequate acoustic windows, echocardiography may provide a noninvasive means of estimating filling pressures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7897?source=see_link&amp;anchor=H14#H14\">",
"     \"Tissue Doppler echocardiography\", section on 'Estimation of LV filling pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS FOR ACUTE VERSUS CHRONIC HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish the management of ADHF from that of chronic HF. The treatment of chronic HF, particularly when due to systolic dysfunction, is built around therapies that have been shown to reduce long-term mortality and improve symptoms (eg, ACE inhibitors and beta blockers).",
"   </p>",
"   <p>",
"    In contrast, the goals of the initial management of ADHF are hemodynamic stabilization, support of oxygenation and ventilation, and symptom relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/8\">",
"     8",
"    </a>",
"    ]. Some of the cornerstones of chronic HF therapy should not be added or should be used with caution in ADHF (eg, beta blockers), particularly during the period of initial stabilization. Such therapies may be initiated or titrated upward later in a patient's course.",
"   </p>",
"   <p>",
"    The HFSA guidelines recommend the following treatment goals for patients admitted for ADHF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improve symptoms, especially congestion and low-output symptoms",
"     </li>",
"     <li>",
"      Restore normal oxygenation",
"     </li>",
"     <li>",
"      Optimize volume status",
"     </li>",
"     <li>",
"      Identify etiology",
"     </li>",
"     <li>",
"      Identify and address precipitating factors",
"     </li>",
"     <li>",
"      Optimize chronic oral therapy",
"     </li>",
"     <li>",
"      Minimize side effects",
"     </li>",
"     <li>",
"      Identify patients who might benefit from revascularization (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"       \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Identify patients who might benefit from device therapy (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identify risk of thromboembolism and need for anticoagulant therapy",
"     </li>",
"     <li>",
"      Educate patients concerning medications and self management of HF (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link\">",
"       \"Heart failure self management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consider and, where possible, initiate a disease-management program (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=see_link\">",
"       \"Strategies to reduce hospitalizations in patients with heart failure\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with chronic HF, long-term management strategies differ according to whether or not the patient has significant systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the acute setting, however, some of the initial therapies are similar in systolic and diastolic HF, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diuresis",
"     </li>",
"     <li>",
"      Supplemental oxygen and assisted ventilation, if necessary",
"     </li>",
"     <li>",
"      Vasodilator therapy in selected patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some components of the initial treatment strategy are approached differently in patients with systolic versus diastolic HF. Among patients with systolic dysfunction, some medications should not be initiated or should be used with caution in the acute setting (eg, ACE inhibitors and beta blockers). In contrast, for patients with primarily diastolic dysfunction, treatment of hypertension and tachycardia is particularly important. Inotropic agents are not indicated in patients with diastolic dysfunction with preserved systolic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ARRHYTHMIA MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both supraventricular and ventricular arrhythmias can occur in association with pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is a common arrhythmia, particularly in patients with underlying heart disease. Among patients with both HF and AF, there are several possible relationships:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute HF can precipitate AF due to increases in left atrial pressure and wall stress.",
"     </li>",
"     <li>",
"      AF can cause acute HF, particularly if the ventricular response is rapid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=see_link\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AF may be chronic and not directly related to the acute HF decompensation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is usually difficult to determine whether AF is the cause or result of ADHF. A reliable history of palpitations that clearly precede the decompensation suggests but does not prove that AF was the cause of the pulmonary edema. The treatment of AF depends upon whether or not it is associated with significant hemodynamic instability and whether or not it is believed to be the precipitant of HF decompensation.",
"   </p>",
"   <p>",
"    In some patients with AF and ADHF, effective treatment of pulmonary edema results in slowing of the ventricular rate or spontaneous reversion of the arrhythmia. If AF persists, it is treated in the same fashion as AF in other situations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rate control is often the preferred initial strategy for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because acute HF can precipitate AF, cardioversion prior to the resolution of acute HF will often be followed by early recurrence of AF.",
"     </li>",
"     <li>",
"      AF is often a chronic condition that is not contributing to the acute decompensation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, if a rate control strategy is selected, the negative inotropic effects of beta-blockers and nondihydropyridine calcium channel blockers can be problematic in patients with systolic dysfunction. For this reason, short-acting IV formulations of such drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ) are often used. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is also potentially useful in this setting, although its use has lessened considerably due to toxicity issues and slow onset of action.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    can be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Restoration of sinus rhythm should be considered in the following settings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H952132725#H952132725\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Candidates for cardioversion'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If AF is associated with hypotension or evidence of cardiogenic shock",
"     </li>",
"     <li>",
"      If AF is clearly the cause for pulmonary edema",
"     </li>",
"     <li>",
"      If the response to effective therapy of pulmonary edema is slow or suboptimal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    should be started prior to cardioversion, if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia during pulmonary edema is usually life threatening. As a result, prompt electrical cardioversion or defibrillation is required. If the arrhythmia recurs after reversion, antiarrhythmic therapy, particularly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Monomorphic ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of ventricular fibrillation mandates prompt resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16441210\">",
"    <span class=\"h1\">",
"     RENOVASCULAR HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent unexplained heart failure decompensation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flash (sudden-onset) pulmonary edema occurs in some patients with renovascular hypertension, often with preserved (normal or near normal) left ventricular systolic function. Flash pulmonary edema appears to be more common in patients with bilateral renal artery stenosis as compared to those with unilateral disease (eg, 41 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The combination of bilateral renal artery stenosis and flash pulmonary edema has been named the Pickering syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Acute treatment of ADHF in patients with this syndrome includes blood pressure control and, in some cases, diuresis. In patients who are euvolemic or dehydrated, diuresis should be avoided as it may lead to renal insufficiency, and preload reduction with nitrates is preferable.",
"   </p>",
"   <p>",
"    Only limited observational data are available on the efficacy of revascularization for this condition. A review of revascularization (percutaneous, largely with stenting, or surgery) in 87 reported cases of bilateral renal artery stenosis and flash pulmonary edema reported that renal function improved in 81 percent and 92 percent had no further episodes of flash pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/11\">",
"     11",
"    </a>",
"    ]. However, these data must be viewed with caution given the limited controls and risk of bias in these case series.",
"   </p>",
"   <p>",
"    The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    peripheral arterial disease guidelines recommended percutaneous revascularization for patients with hemodynamically significant renal artery stenosis and recurrent, unexplained heart failure or sudden unexplained pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/13\">",
"     13",
"    </a>",
"    ]. However, an AHA writing group later noted that treatment of atherosclerotic renal artery disease is controversial since the benefits and risks are not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29369?source=see_link\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DISCHARGE FROM HOSPITAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful in-hospital management and discharge planning is indicated to reduce the risk of postdischarge mortality and readmission. Recommended discharge criteria (",
"    <a class=\"graphic graphic_table graphicRef53865 \" href=\"mobipreview.htm?43/25/44443\">",
"     table 1",
"    </a>",
"    ) include addressing exacerbating factors, achieving near optimal volume status and pharmacologic therapy, and transition to outpatient care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2\">",
"     2",
"    </a>",
"    ]. Discharge planning should address details of medication, dietary sodium restriction, and recommended activity level; early follow-up by phone or clinic visit; compliance; monitoring of body weight, electrolytes, and renal function; and consideration of referral for formal disease management.",
"   </p>",
"   <p>",
"    The importance of early outpatient follow-up after hospital discharge was illustrated by a study of 30,136 Medicare beneficiaries hospitalized for HF at 225 hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/15\">",
"     15",
"    </a>",
"    ]. The rate of 30-day hospital readmission was slightly but significantly higher (23.3 versus 20.5 percent) in the quartile of hospitals with the lowest rates of early (within seven days) follow-up than in the next quartile (early follow-up rate &lt;32.4 percent versus 32.4 to 37.9 percent). The difference in readmission rates remained significant after adjustment for baseline patient characteristics.",
"   </p>",
"   <p>",
"    Comprehensive written discharge instructions are recommended for all patients hospitalized for HF and their caregivers with special emphasis on the following issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2\">",
"     2",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link\">",
"     \"Heart failure self management\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diet (including dietary sodium restriction)",
"     </li>",
"     <li>",
"      Discharge medications (with special focus on compliance and uptitration to recommended doses of ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB,",
"      </span>",
"      and beta-blocker medication). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"       \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Activity level",
"     </li>",
"     <li>",
"      Follow-up including monitoring of electrolytes and renal function, early follow-up by phone or clinic visit, and postdischarge systems of care including consideration of referral for formal disease management",
"     </li>",
"     <li>",
"      Daily weight monitoring",
"     </li>",
"     <li>",
"      What to do if HF symptoms worsen (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=see_link&amp;anchor=H6600128#H6600128\">",
"       \"Heart failure self management\", section on 'Heart failure action plan'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence on the efficacy of discharge support is discussed separately. The available evidence suggests that discharge support must go well beyond a simple discharge instruction sheet to be effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=see_link&amp;anchor=H14824299#H14824299\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\", section on 'Inpatient and transitional care strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=see_link\">",
"       \"Patient information: When your lungs fill with fluid (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospital admission is recommended for patients with ADHF with evidence of severe decompensation (including hypotension, worsening renal function, or altered mentation), dyspnea at rest, hemodynamically significant arrhythmia including new onset atrial fibrillation, or acute coronary syndrome.",
"     </li>",
"     <li>",
"      Hospitalization should be considered for other patients with ADHF including those with signs or symptoms of pulmonary or systemic congestion (with or without weight gain), major electrolyte disturbance, or associated comorbid conditions.",
"     </li>",
"     <li>",
"      High hospital readmission rates are partly due to ineffective fluid removal. Daily assessment of patient weight may be the most effective method for documenting effective diuresis. For accurate comparisons, daily measurements should use the same scale and should be performed at the same time each day, usually in the morning, prior to eating and after voiding.",
"     </li>",
"     <li>",
"      Treatment goals for patients admitted with ADHF include improving symptoms, optimizing volume status, identifying etiology and precipitating factors (particularly ischemia), initiating and optimizing oral therapy, minimizing side effects, educating patients, and considering a disease management program.",
"     </li>",
"     <li>",
"      The following initial therapies are similar in systolic and diastolic HF: diuresis, supplemental oxygen and assisted ventilation, and vasodilator therapy in selected patients.",
"     </li>",
"     <li>",
"      Some medications should be avoided or used with caution in the acute setting (eg, ACE inhibitors and beta-blockers) in patients with systolic dysfunction. In patients on ACE inhibitors and beta blockers, the medications can be continued if the patient is relatively stable (eg, just needs diuresis). Inotropic agents are not indicated in patients with diastolic dysfunction with preserved systolic function.",
"     </li>",
"     <li>",
"      Atrial fibrillation can precipitate ADHF and ADHF can promote atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An initial strategy of rate control is reasonable if atrial fibrillation does not appear to be the precipitant of ADHF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restoration of sinus rhythm should be considered if AF is associated with hypotension or cardiogenic shock, if AF is the cause for pulmonary edema or if the response to therapy of pulmonary edema is suboptimal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H952132725#H952132725\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Candidates for cardioversion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular tachycardia during pulmonary edema generally requires prompt electrical cardioversion or defibrillation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ventricular arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful discharge planning and transition to outpatient care is indicated to reduce the risk of postdischarge mortality and readmission.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/1\">",
"      Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/2\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/3\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/4\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/5\">",
"      Heart Failure Executive Committee, Peacock WF, Fonarow GC, et al. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. Crit Pathw Cardiol 2008; 7:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/6\">",
"      Ashton CM, Kuykendall DH, Johnson ML, et al. The association between the quality of inpatient care and early readmission. Ann Intern Med 1995; 122:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/7\">",
"      Konstam MA. Relating quality of care to clinical outcomes in heart failure: in search of the missing link. J Card Fail 2001; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/8\">",
"      Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112:3958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/9\">",
"      Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 1988; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/10\">",
"      Bloch MJ, Trost DW, Pickering TG, et al. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. Am J Hypertens 1999; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/11\">",
"      Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011; 32:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/12\">",
"      Pelta A, Andersen UB, Just S, B&aelig;kgaard N. Flash pulmonary edema in patients with renal artery stenosis--the Pickering Syndrome. Blood Press 2011; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/13\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/14\">",
"      Rocha-Singh KJ, Eisenhauer AC, Textor SC, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: intervention for renal artery disease. Circulation 2008; 118:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41079/abstract/15\">",
"      Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303:1716.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3454 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41079=[""].join("\n");
var outline_f40_7_41079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11103510\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inpatient monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Documentation of effective diuresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT GOALS FOR ACUTE VERSUS CHRONIC HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SYSTOLIC VERSUS DIASTOLIC DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ARRHYTHMIA MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ventricular arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16441210\">",
"      RENOVASCULAR HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DISCHARGE FROM HOSPITAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3454\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3454|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/25/44443\" title=\"table 1\">",
"      Discharge crit HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/55/25465?source=related_link\">",
"      Heart failure self management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=related_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29369?source=related_link\">",
"      Treatment of unilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_7_41080="Cervical subluxation in rheumatoid arthritis";
var content_f40_7_41080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical subluxation in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     Bradford L Currier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41080/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/7/41080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovertebral joints in the cervical spine may be affected in patients with rheumatoid arthritis (RA) with resulting osteochondral destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A review of the clinical manifestations and treatment of atlantoaxial (C1 to C2) and subaxial subluxation in RA is presented here. The clinical features and general medical management of RA, as well as the differential diagnosis and general evaluation of the patient with neck pain and of cervical spine disorders, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=see_link\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CERVICAL INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical joint destruction in patients with RA may lead to vertebral malalignment (eg, subluxation), causing pain, neurological deficit, and deformity. Risk factors for development of cervical subluxation include older age at onset of RA, more active synovitis, higher levels of C-reactive protein, rapidly progressive erosive peripheral joint disease, and early peripheral joint subluxations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Both atlantoaxial and subaxial (below C2) joints may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Atlantoaxial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the joints of the cervical spine, the atlantoaxial joint is prone to subluxation in multiple directions, potentially leading to cervical myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/5\">",
"     5",
"    </a>",
"    ]. The atlas (C1) can move anteriorly, posteriorly, vertically, laterally, or rotationally relative to the axis (odontoid and body of C2):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal anterior movement on the axis is the most common type of subluxation. It often results from laxity of the transverse ligament induced by proliferative C1 to C2 synovial tissue but may also occur as a result of erosion or fracture of the odontoid process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posterior movement on the axis can occur only if the odontoid peg has been fractured from the axis or has been destroyed.",
"     </li>",
"     <li>",
"      Vertical movement in relation to the axis is least common; it results from destruction of the lateral atlantoaxial joints or of bone around the foramen magnum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vertical atlantoaxial subluxation may occur in those with initial anterior-posterior subluxation. Vertical subluxations are believed to have a worse prognosis than the other varieties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two possible mechanisms for involvement of the intervertebral joints in the cervical spine in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extension of the inflammatory process from adjacent neurocentral joints (the joints of Luschka, which are lined by synovium) into the discovertebral area",
"     </li>",
"     <li>",
"      Chronic cervical instability initiated by apophyseal joint destruction, subsequently leading to vertebral malalignment or subluxation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/9\">",
"       9",
"      </a>",
"      ]. This may produce microfractures of the vertebral endplates, disc herniation, and degeneration of disc cartilage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bursal spaces exist between the cervical interspinous processes. In some rheumatoid patients, bursal proliferation has led to radiographically demonstrated destruction of the spinous processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The involvement and severity of cervical spine disease in RA parallels the progression of peripheral joint erosions. As a result, cervical subluxation is more likely in those with erosions of the hands, feet, hips",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    knees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurological findings may occur when the space available for the brain stem, spinal, cord or nerve roots is compromised by vertebral subluxation.",
"   </p>",
"   <p>",
"    Asymmetric apophyseal joint erosion may cause scoliosis manifested as head tilt. Joint destruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spontaneous fusion often lead to reduced range of motion. Anterior atlantoaxial or subaxial subluxations may cause the head to protrude forward, leading to positive sagittal balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although decreases in rates of hospitalizations for certain manifestations of severe RA (eg, rheumatoid vasculitis, splenectomy for Felty&rsquo;s syndrome) were recorded in California, no significant decrease in rates of hospitalization for cervical spine surgery was noted from 1983 to 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the clinical experience of experts in spinal surgery is that the rate of occipital-cervical fusion has decreased with the advent of more effective disease-modifying antirheumatic drugs (DMARDs). The prevalence of cervical involvement among those with RA varies with the patient subset studied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 113 patients with RA referred for hip or knee arthroplasty, 61 percent had roentgenographic evidence of cervical spine instability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An inception cohort study of 103 patients with RA (of whom 69 survived at least 20 years to have lateral radiographs of the cervical spine) documented anterior atlantoaxial subluxation and vertical subluxation in 23 and 26 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/14\">",
"       14",
"      </a>",
"      ]. None of these patients required surgical procedures on the cervical spine.",
"     </li>",
"     <li>",
"      In a group of 476 hospitalized patients with RA, vertical subluxation was noted in 4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a group of 165 Greek patients in an outpatient setting, with mean age of 60 years and duration of disease of 12 years, the prevalence of atlantoaxial subluxation of &ge;2.5 mm on lateral radiograph was 21 percent, but neurologic impairment was only present in one patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/16\">",
"       16",
"      </a>",
"      ]. Subaxial subluxation &ge;1 mm at one or more levels was present in 44 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased risk of radiographic cervical spine involvement has been associated with the presence in serum of rheumatoid factor and with an elevated C-reactive protein level but has not been associated with the presence of human leukocyte antigen (HLA)-DR4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/4,17\">",
"     4,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of cervical joints may result in significant pain. However, passive range of motion may be normal in the absence of muscle spasm. The earliest and most common symptom of cervical subluxation is pain radiating superiorly towards the occiput [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/18\">",
"     18",
"    </a>",
"    ]. Additional symptoms of subluxation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spastic quadriparesis is slowly progressive.",
"     </li>",
"     <li>",
"      Sensory findings are also common, including painless sensory loss in the hands or feet.",
"     </li>",
"     <li>",
"      In patients with C1 to C2 subluxation, transient episodes of medullary dysfunction (such as respiratory irregularity) were associated with vertical penetration of the odontoid process of C2 and with probable vertebral artery compression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/19\">",
"       19",
"      </a>",
"      ]. Sudden death may occur. The rate, reported as 10 to 20 percent in the older literature, is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neurologic findings in patients with atlantoaxial subluxation may also include myelopathy; sensory loss; as well as paresthesias, in the C2 area (greater occipital neuralgia); decreased sensation in the distribution of the fifth cranial nerve; and nystagmus. Subaxial subluxations, which narrow the intervertebral foramina, may cause radiculopathy.",
"   </p>",
"   <p>",
"    Neurologic signs and symptoms often have little relationship to the size of the abnormally widened space between the arch of the atlas and the anterior aspect of the dens (anterior atlantodental interval [AADI[) or to the amount of subluxation between subaxial vertebrae. The magnitude of the space available for the cord (SAC) in the subaxial spine or at C1 to C2, where it is known as the posterior atlantodental interval (PADI), does correlate with the incidence of neurological compromise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/20\">",
"     20",
"    </a>",
"    ]. The symptoms of spinal cord compression that demand immediate attention and intervention include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A sensation of the head falling forward upon flexion of the cervical spine",
"     </li>",
"     <li>",
"      Changes in levels of consciousness",
"     </li>",
"     <li>",
"      &ldquo;Drop&rdquo; attacks",
"     </li>",
"     <li>",
"      Loss of sphincter control",
"     </li>",
"     <li>",
"      Respiratory dysfunction",
"     </li>",
"     <li>",
"      Dysphagia, vertigo, convulsions, hemiplegia, dysarthria, or nystagmus",
"     </li>",
"     <li>",
"      Peripheral paresthesias without evidence of peripheral nerve disease or compression",
"     </li>",
"     <li>",
"      Lhermitte&rsquo;s phenomenon, an electric shock-like sensation in the neck, radiating down the spine or into the arms, produced by forward flexion of the neck",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, instead of compression of the spinal cord, some of these symptoms may be due to compression of the vertebral arteries, which must wind through foramina within the lateral aspects of C1 and C2. Findings on magnetic resonance imaging may help distinguish between these two possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings relating to the spine which are suggestive of atlantoaxial subluxation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loss of cervical lordosis",
"     </li>",
"     <li>",
"      Scoliosis",
"     </li>",
"     <li>",
"      Resistance to passive spine motion",
"     </li>",
"     <li>",
"      Abnormal protrusion of the anterior arch of the atlas felt by the examining finger on the posterior pharyngeal wall",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, neurologic findings appropriate to the symptoms described above may be seen, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased deep tendon reflexes (seen in myelopathy)",
"     </li>",
"     <li>",
"      Extensor plantar responses",
"     </li>",
"     <li>",
"      Hoffman&rsquo;s sign",
"     </li>",
"     <li>",
"      Muscle weakness, spasticity, or muscle atrophy",
"     </li>",
"     <li>",
"      Gait disorders",
"     </li>",
"     <li>",
"      Decreased deep tendon reflexes (seen in radiculopathy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMAGING FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild, nonspecific neck or occipital pain can be evaluated initially by conventional radiography, but patients with evidence of subluxation or of C1 to C2 synovitis require careful observation and magnetic resonance imaging (MRI) examination if symptoms or signs progress. The use of conventional radiographs, computerized tomography, and MRI are discussed below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Symptoms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Physical findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Conventional radiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H10\">",
"     'CT scan'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Conventional radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with atlantoaxial subluxation, plain radiographic views of the cervical spine (anteroposterior, lateral, open-mouth, flexion, and extension) may reveal more than 3 mm of separation between the odontoid peg and the C1 arch [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. Separation between C1 and C2 (anterior subluxation) of 9 mm or more or a posterior atlantodental distance of less than 14 mm is associated with an increased incidence of cord compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/20,23,24\">",
"     20,23,24",
"    </a>",
"    ]. In addition, if the space available for the spinal cord is less than 13 mm anywhere in the cervical region, there is an increased risk for neurologic impairment. In symptomatic patients, the films in flexion should be taken only after radiographs (including an open-mouth view) have excluded an odontoid fracture or severe atlantoaxial subluxation.",
"   </p>",
"   <p>",
"    These structures may be difficult to visualize effectively using conventional radiographic techniques because of osteopenia, the small size of the multiple joints in the cervical spine, the large mass of soft tissue surrounding the spine, and the lower borders of the occipital bones. In addition, the usual landmarks may be obliterated in advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since neck positioning required for intubation prior to surgery may be fatal among patients with RA and unrecognized C1 to C2 disease and since subluxation is not always symptomatic, radiographic evaluation of the cervical spine is advised for all patients with RA scheduled to undergo surgery requiring manipulation of the neck for either anesthesia or surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) can demonstrate spinal cord compression by revealing the loss of subarachnoid space, attenuation of the transverse ligament, and bony and soft tissue changes in patients with C1 to C2 subluxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, not all studies have found that CT is helpful in this setting. In one study of 12 patients, for example, CT provided additional useful information in only one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/28\">",
"     28",
"    </a>",
"    ]. CT and CT angiography are useful for preoperative planning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is particularly valuable in the assessment of cervical spine disease in RA, because it permits visualization of the pannus producing cord compression, the spinal cord, and bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. The development of neurological dysfunction is strongly associated with MRI evidence of spinal canal stenosis, particularly in patients with evidence of upper cervical cord or brainstem compression or of subaxial myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/33\">",
"     33",
"    </a>",
"    ]. Bone marrow edema (BME) can be observed by MRI in patients with early cervical spine involvement; the edema may be seen in the odontoid process, in the vertebral endplates, and in the subaxial interapophyseal joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/34\">",
"     34",
"    </a>",
"    ]. Higher erythrocyte sedimentation rates were associated with more severe atlantoaxial joint synovitis.",
"   </p>",
"   <p>",
"    A dynamic (flexion-extension) MRI clearly delineates the relationship between the odontoid, foramen magnum, and cervical spinal cord, but prolonged flexion should be performed with caution because of the risk of cord compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, gradient-echo MRI pulse sequences provide reliable visualization of the transverse atlantal ligament, permitting the clinician to distinguish rupture from stretching of the ligament and to visualize pannus compressing the cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The information gained from MRI is sufficiently additive to warrant the increased cost of this procedure, particularly if surgery is contemplated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/30,36\">",
"     30,36",
"    </a>",
"    ]. However, one drawback of MR imaging is that it often underestimates the degree of atlantoaxial subluxation when compared with flexion-extension plain film radiography. This was illustrated in a series of 23 patients with RA or juvenile idiopathic arthritis (JIA) who had both radiographs and MRI with flexion and extension views performed within a one-month time frame [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/37\">",
"     37",
"    </a>",
"    ]. After accounting for magnification on the plain films, the measured atlantoaxial subluxation by MRI was less than that noted on radiographs in 19 of the 23 patients; in the worst case, the measured distance differed by 7 mm. Thus, unless flexion and extension MR images document excessive subluxation, plain film flexion-extension radiography is still needed to assess atlantoaxial stability, especially in patients with RA scheduled to undergo surgery requiring manipulation of the neck for either anesthesia or surgery. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Conventional radiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the onset of atlantoaxial subluxation alone is not inexorably associated with neurologic dysfunction or with an increased risk of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/38\">",
"     38",
"    </a>",
"    ]. Although radiographic progression is common, it does not always correlate with neurologic deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/18,39-42\">",
"     18,39-42",
"    </a>",
"    ]. Patients with plain film radiographic evidence of cervical subluxation, with or without neurologic symptoms, have a five-year mortality rate of 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some patients with severe dislocation may be at risk of death. In one series of 104 consecutive autopsies of patients with RA, 11 cases of severe dislocation were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/43\">",
"     43",
"    </a>",
"    ]. In all 11, the odontoid protruded posterosuperiorly and impinged on the medulla within the foramen magnum. In five, spinal cord compression was determined to be the only cause of death.",
"   </p>",
"   <p>",
"    Patients with subluxation and signs of spinal cord compression have a poor prognosis without surgery. In this setting, myelopathy progresses rapidly, and death may quickly ensue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. As an example, in a study of 21 patients with atlantoaxial subluxation and with signs of myelopathy who were managed medically, neurologic deterioration occurred in 16 of 21 (76 percent), and all were unable to walk within three years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/46\">",
"     46",
"    </a>",
"    ]. None survived more than eight years. A systematic review of the literature revealed neurologic deterioration was almost inevitable in Ranawat II, IIIA, and IIIB patients (ie, those with findings to indicate a neurological deficit) treated nonoperatively. The 10-year overall survival rate was 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI findings may be more helpful than plain film radiography in determining prognosis. As an example, among 82 patients with MRI evidence of cord compression at the level of C1 to C2, 60 percent deteriorated with conservative management over a median of 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/47\">",
"     47",
"    </a>",
"    ]. Those with subaxial cord compression fared better, with only 18 percent worsening with time. Among all patients, nine eventually required surgical intervention (six due to a combination of pain and progressive neurologic deficits, two due to pain only, and one due to painless neurologic deterioration).",
"   </p>",
"   <p>",
"    An inability to walk preoperatively also confers a poor prognosis. In one study, only 20 percent of such patients improved after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that the administration of combination therapy consisting of disease modifying antirheumatic drugs (DMARDs) may help prevent the development of cervical spine subluxation. As an example, 195 patients with RA of recent onset (two years or less) were randomly assigned to a regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    or to sulfasalazine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/49\">",
"     49",
"    </a>",
"    ]. Atlantoaxial impaction or anterior subluxation developed in 2 and 7 percent of the sulfasalazine alone group, respectively, but in none of those receiving combination therapy after two years of treatment. DMARD treatment was unrestricted after two years.",
"   </p>",
"   <p>",
"    At five years of follow-up, the occurrence of anterior atlantoaxial subluxations was significantly associated with initial single DMARD therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/50\">",
"     50",
"    </a>",
"    ]. Atlantoaxial impaction or anterior subluxation developed more often in the initial single therapy group compared with the initial combination therapy group (6 and 14 percent versus 1 and 3 percent, respectively).",
"   </p>",
"   <p>",
"    An overview of the management of RA is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cervical subluxation are treated medically",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgically based largely upon the presence or absence of signs of spinal cord compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe subluxation but without signs of cord compression are at risk for severe injury and perhaps death due to a variety of insults. These include minor falls, whiplash injuries, and intubation. Although the subject of some controversy, stiff cervical collars may be prescribed for stability; in one report, more than 50 percent of such patients benefited from this modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In some patients, halo traction may be of benefit, typically followed by surgery.",
"   </p>",
"   <p>",
"    Collars that are not rigid (and, therefore, that are more comfortable for the patient) give reassurance to both the clinician and the patient but provide little structural support. Spinal manipulation is contraindicated.",
"   </p>",
"   <p>",
"    The role of neck muscle strengthening exercises is uncertain. A decrease in anterior atlantoaxial subluxation was noted in a subgroup of seven patients with RA and unstable atlantoaxial joints during active isometric neck flexor muscle contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/53\">",
"     53",
"    </a>",
"    ]. While this suggests that isometric neck flexor exercise is probably safe, the efficacy of neck flexor muscle strengthening for symptoms related to subluxation, radiographic progression, and other important patient outcomes were not assessed in this study. In contrast to the neck flexors, isometric neck extensor muscle tightening worsened radiographically apparent atlantoaxial subluxation in those with unstable articulations. Thus, while further investigation of neck flexor strengthening may be warranted, isometric exercise of the neck extensors should be avoided.",
"   </p>",
"   <p>",
"    Patients who have pain due to irritation of C2 nerve root but who do not have evidence of cord compression may benefit from agents used for chronic neuropathic pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .) These patients may obtain some benefit from local nerve blocks, although the relief is generally temporary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subluxation and signs of spinal cord compression have a grave prognosis without surgical intervention to provide stability to the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/1,19,45\">",
"     1,19,45",
"    </a>",
"    ]. Although surgery for atlantoaxial subluxation has attendant risks, some data indicate that early operative treatment may delay the detrimental course of cervical myelopathy in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/45,54\">",
"     45,54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The benefits offered by surgical management of patients with atlantoaxial subluxation who have myelopathy include an improved survival rate, an improvement in myelopathy in some patients, and a decreased risk of neurologic progression. The beneficial effects of surgery were illustrated in an observational study that compared 19 patients with symptomatic atlantoaxial subluxation who underwent laminectomy and occipitocervical fusion with 21 others who were managed conservatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/46\">",
"     46",
"    </a>",
"    ]. The five-year and 10-year survival rates for those who underwent surgery were 84 and 37 percent, respectively. In contrast, none of the 21 patients managed conservatively survived more than eight years. Neurologic improvement was noted in 68 percent following surgery, while, in the nonoperative group, 76 percent had neurologic deterioration.",
"   </p>",
"   <p>",
"    Surgery is generally well-tolerated. In a prospective study of 532 patients with RA and with subluxations of the cervical spine seen between 1974 and 1999, 217 underwent surgery, of whom only 11 (5 percent) experienced residual neck pain or neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/55\">",
"     55",
"    </a>",
"    ]. Such symptoms were associated with increased risk of death during the course of the study. There were reduced survival for patients with subaxial subluxations and an association of increased vertical settling with sudden death. There were few perioperative or postoperative complications.",
"   </p>",
"   <p>",
"    Surgery should be considered carefully and on an individualized basis among patients with subluxation but without signs or symptoms of cord compression. In this setting, operative stabilization may be considered if symptoms develop, which is not uncommon. In one series of 84 patients with some form of subluxation but without cord or brainstem lesions, one-fourth worsened, and one-fourth improved without surgery over 5 to 14 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data support the hypothesis that early C1 to C2 fusion for atlantoaxial subluxation, before the development of superior migration of the odontoid, decreases the risk of further progression of cervical spine instability. A retrospective study of 110 patients with RA who underwent cervical spine fusion noted two major findings on follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifteen percent developed cervical instability; this occurred in 5.5 percent of those with atlantoaxial subluxation and in 36 percent of those with atlantoaxial subluxation and superior migration of the odontoid.",
"     </li>",
"     <li>",
"      No patient with C1 to C2 fusion for atlantoaxial subluxation subsequently developed superior migration of the odontoid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limiting factor is that the incidence of sustained neurologic deterioration related to surgery may be as high as 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/57\">",
"     57",
"    </a>",
"    ]. As a result, a skilled surgical team and a careful assessment of each patient are important elements of any therapeutic regimen.",
"   </p>",
"   <p>",
"    Fortunately, the prognosis for patients with surgery appears to be improving due, in part, to earlier referral, to enhanced technique, and to better perioperative management. The outcomes of 27 patients with RA who had cervical fusions in the period of 1991 to 1996 (late cohort) were compared with those of 32 individuals whose surgery occurred in the period of 1974 to 1982 (early cohort) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/58\">",
"     58",
"    </a>",
"    ]. Only 7 percent of patients in the more recent group had severe cervical myelopathy prior to surgery, versus 34 percent in the earlier cohort. Compared with the early group, the late cohort had fewer early postoperative deaths (0 versus 9 percent), complications (22 versus 50 percent), failed surgeries (15 versus 28 percent), and reoperations (11 versus 20 percent). Among patients in the more recent cohort in whom there was sufficient information to judge a change in neurologic status with surgery (18 patients), improvement in and maintenance of the preoperative level of function were noted three months after surgery in one-third and two-thirds, respectively.",
"   </p>",
"   <p>",
"    A systematic literature review identified 23 observational studies describing the neurologic outcome after surgery for 752 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with Ranawat I (asymptomatic patients with no neurologic deficit) and II (patients with subjective weakness with hyperreflexia and dysesthesia) neurologic status rarely deteriorated. Ranawat III patients (those with objective weakness and long tract signs) typically did not recover completely. The 10-year survival rates mirrored the Ranawat class and ranged from 77 percent to 30 percent for Ranawat I (no deficit) and IIIB (nonambulatory patients with objective weakness and long tract signs), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/45\">",
"     45",
"    </a>",
"    ]. Outcomes were better with surgery than conservative treatment in all patients with neurologic involvement but were similar for asymptomatic patients with no neurologic deficit (Ranawat I). The evidence is weak, however, and the ideal treatment for asymptomatic patients with radiographic instability awaits the results of a randomized control trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though Ranawat IIIB patients have a significantly worse outcome than all other groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/45\">",
"     45",
"    </a>",
"    ], surgery may still offer the best quality of life and survival for these severely disabled patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/60\">",
"     60",
"    </a>",
"    ]. Ideally, surgery should be offered before a significant neurologic deficit occurs.",
"   </p>",
"   <p>",
"    The decompression and stabilization may need to extend into the subaxial spine. In one series, histopathologic studies of brain stems and spinal cords of nine patients with end-stage RA revealed significant subaxial myelopathy in the cervical spine related directly to compression, stretching, and movement of the spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transpedicle screw fixation using stereotactic guidance has also been used for stabilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/62\">",
"     62",
"    </a>",
"    ]. Because the diameter of cervical pedicles is very small, this is considered a procedure with significant risk. However, use of full-scale, three-dimensional models in preoperative planning may lessen morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occipitocervical fixation has also been employed to treat patients with unstable cervical spines. When this procedure was employed in 163 RA patients, 88 percent improved, 7 percent remained unchanged, and 5 percent progressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41080/abstract/64\">",
"     64",
"    </a>",
"    ]. Complications included infection (10 percent) and progressive subluxation that required reoperation (4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95775295\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical joint destruction in patients with RA may lead to vertebral malalignment (eg, subluxation), causing pain, neurological deficit, and deformity. Risk factors for cervical subluxation include older age at onset of RA, more active synovitis, higher levels of C-reactive protein, rapidly progressive erosive peripheral joint disease, and early peripheral joint subluxations. Both atlantoaxial and subaxial (below C2) joints may be involved. Estimates of the prevalence of cervical involvement among those with RA vary widely; fewer patients appear to require surgery since the 1990s. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cervical involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The atlantoaxial joint is prone to subluxation in multiple directions, potentially leading to cervical myelopathy. The atlas (C1) can move anteriorly, posteriorly, vertically, laterally, or rotationally relative to the axis (odontoid and body of C2). Abnormal anterior movement on the axis is the most common type of subluxation; it often results from laxity of the transverse ligament induced by proliferative C1 to C2 synovial tissue but may also occur as a result of erosion or fracture of the odontoid process. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Atlantoaxial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two possible mechanisms for involvement of the intervertebral joints in the cervical spine in RA are 1) extension of the inflammatory process from adjacent neurocentral joints (the joints of Luschka, which are lined by synovium) into the discovertebral area and 2) chronic cervical instability initiated by apophyseal joint destruction, subsequently leading to vertebral malalignment or subluxation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Involvement of cervical joints may result in significant pain. However, passive range of motion may be normal in the absence of muscle spasm. The earliest and most common symptom of cervical subluxation is pain radiating superiorly toward the occiput. Additional symptoms of subluxation include slowly progressive spastic quadriparesis; sensory findings, including painless sensory loss in the hands or feet; transient episodes of medullary dysfunction (such as respiratory irregularity); and others. Sudden death may occur. Symptoms of spinal cord compression may also result from compression of the vertebral arteries. The symptoms of spinal cord compression that demand immediate attention and intervention include (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A sensation of the head falling forward upon flexion of the cervical spine",
"     </li>",
"     <li>",
"      Changes in levels of consciousness",
"     </li>",
"     <li>",
"      &ldquo;Drop&rdquo; attacks",
"     </li>",
"     <li>",
"      Loss of sphincter control",
"     </li>",
"     <li>",
"      Respiratory dysfunction",
"     </li>",
"     <li>",
"      Dysphagia, vertigo, convulsions, hemiplegia, dysarthria, or nystagmus",
"     </li>",
"     <li>",
"      Peripheral paresthesias without evidence of peripheral nerve disease or compression",
"     </li>",
"     <li>",
"      Lhermitte&rsquo;s phenomenon, an electric shock-like sensation in the neck, radiating down the spine or into the arms, produced by forward flexion of the neck",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical findings relating to the spine, which are suggestive of atlantoaxial subluxation, include loss of cervical lordosis, scoliosis, resistance to passive spine motion, and abnormal protrusion of the anterior arch of the atlas felt by the examining finger on the posterior pharyngeal wall. Neurologic findings appropriate to the symptoms described above may be seen, including increased deep tendon reflexes (seen in myelopathy); extensor plantar responses; Hoffman&rsquo;s sign; muscle weakness, spasticity, or muscle atrophy; gait disorders; and decreased deep tendon reflexes (seen in radiculopathy). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mild, nonspecific neck or occipital pain can be evaluated initially by conventional radiography, but patients with evidence of subluxation or C1 to C2 synovitis require careful observation and magnetic resonance imaging (MRI) examination if symptoms or signs progress. Radiographic evaluation of the cervical spine is advised for all patients with RA scheduled to undergo surgery requiring manipulation of the neck for either anesthesia or surgery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atlantoaxial subluxation alone is not inexorably associated with neurologic dysfunction or with an increased risk of death. Although radiographic progression is common, it does not always correlate with neurologic deterioration. However, some patients with severe dislocation may be at risk for death. Patients with plain film radiographic evidence of cervical subluxation, with or without neurologic symptoms, have a five-year mortality rate of 17 percent. Patients with subluxation and signs of spinal cord compression have a poor prognosis without surgery. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe subluxation but without signs of cord compression are at risk for severe injury and perhaps death due to a variety of insults. These include minor falls, whiplash injuries, and intubation. Such patients may benefit from rigid cervical collars. Surgery should be considered carefully and on an individualized basis among patients with subluxation but without signs or symptoms of cord compression. Patients with subluxation and signs of spinal cord compression have a grave prognosis without surgical intervention to provide stability to the spine. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Medical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/1\">",
"      Bland J. Rheumatoid arthritis of the cervical spine. J Rheumatol 1974; 1:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/2\">",
"      Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 30:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/3\">",
"      Neva MH, Isom&auml;ki P, Hannonen P, et al. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/4\">",
"      Paimela L, Laasonen L, Kankaanp&auml;&auml; E, Leirisalo-Repo M. Progression of cervical spine changes in patients with early rheumatoid arthritis. J Rheumatol 1997; 24:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/5\">",
"      Santavirta S, Kankaanp&auml;&auml; U, Sandelin J, et al. Evaluation of patients with rheumatoid cervical spine. Scand J Rheumatol 1987; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/6\">",
"      Kauppi M, Sakaguchi M, Konttinen YT, et al. Pathogenetic mechanism and prevalence of the stable atlantoaxial subluxation in rheumatoid arthritis. J Rheumatol 1996; 23:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/7\">",
"      Chang DJ, Paget SA. Neurologic complications of rheumatoid arthritis. Rheum Dis Clin North Am 1993; 19:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/8\">",
"      Davidson RC, Horn JR, Herndon JH, Grin OD. Brain-stem compression in rheumatoid arthritis. JAMA 1977; 238:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/9\">",
"      Martel W. Pathogenesis of cervical discovertebral destruction in rheumatoid arthritis. Arthritis Rheum 1977; 20:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/10\">",
"      Bywaters EG. Rheumatoid and other diseases of the cervical interspinous bursae, and changes in the spinous processes. Ann Rheum Dis 1982; 41:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/11\">",
"      Winfield J, Young A, Williams P, Corbett M. Prospective study of the radiological changes in hands, feet, and cervical spine in adult rheumatoid disease. Ann Rheum Dis 1983; 42:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/12\">",
"      Collins DN, Barnes CL, FitzRandolph RL. Cervical spine instability in rheumatoid patients having total hip or knee arthroplasty. Clin Orthop Relat Res 1991; :127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/13\">",
"      Ward MM. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis Rheum 2004; 50:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/14\">",
"      Neva MH, Kaarela K, Kauppi M. Prevalence of radiological changes in the cervical spine--a cross sectional study after 20 years from presentation of rheumatoid arthritis. J Rheumatol 2000; 27:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/15\">",
"      Henderson DR. Vertical atlanto-axial subluxation in rheumatoid arthritis. Rheumatol Rehabil 1975; 14:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/16\">",
"      Zikou AK, Alamanos Y, Argyropoulou MI, et al. Radiological cervical spine involvement in patients with rheumatoid arthritis: a cross sectional study. J Rheumatol 2005; 32:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/17\">",
"      Fujiwara K, Fujimoto M, Owaki H, et al. Cervical lesions related to the systemic progression in rheumatoid arthritis. Spine (Phila Pa 1976) 1998; 23:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/18\">",
"      Stevens JC, Cartlidge NE, Saunders M, et al. Atlanto-axial subluxation and cervical myelopathy in rheumatoid arthritis. Q J Med 1971; 40:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/19\">",
"      Nakano KK, Schoene WC, Baker RA, Dawson DM. The cervical myelopathy associated with rheumatoid arthritis: analysis of patients, with 2 postmortem cases. Ann Neurol 1978; 3:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/20\">",
"      Boden SD, Dodge LD, Bohlman HH, Rechtine GR. Rheumatoid arthritis of the cervical spine. A long-term analysis with predictors of paralysis and recovery. J Bone Joint Surg Am 1993; 75:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/21\">",
"      Mayer JW, Messner RP, Kaplan RJ. Brain stem compression in rheumatoid arthritis. JAMA 1976; 236:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/22\">",
"      MARTEL W. The occipito-atlanto-axial joints in rheumatoid arthritis and ankylosing spondylitis. Am J Roentgenol Radium Ther Nucl Med 1961; 86:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/23\">",
"      Weissman BN, Aliabadi P, Weinfeld MS, et al. Prognostic features of atlantoaxial subluxation in rheumatoid arthritis patients. Radiology 1982; 144:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/24\">",
"      Lipson SJ. Rheumatoid arthritis in the cervical spine. Clin Orthop Relat Res 1989; :121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/25\">",
"      Bell GR, Stearns KL. Flexion-extension MRI of the upper rheumatoid cervical spine. Orthopedics 1991; 14:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/26\">",
"      Neva MH, H&auml;kkinen A, M&auml;kinen H, et al. High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis 2006; 65:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/27\">",
"      Raskin RJ, Schnapf DJ, Wolf CR, et al. Computerized tomography in evaluation of atlantoaxial subluxation in rheumatoid arthritis. J Rheumatol 1983; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/28\">",
"      Braunstein EM, Weissman BN, Seltzer SE, et al. Computed tomography and conventional radiographs of the craniocervical region in rheumatoid arthritis. A comparison. Arthritis Rheum 1984; 27:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/29\">",
"      Breedveld FC, Algra PR, Vielvoye CJ, Cats A. Magnetic resonance imaging in the evaluation of patients with rheumatoid arthritis and subluxations of the cervical spine. Arthritis Rheum 1987; 30:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/30\">",
"      DAVIS FW Jr, MARKLEY HE. Rheumatoid arthritis with death from medullary compression. Ann Intern Med 1951; 35:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/31\">",
"      Stiskal MA, Neuhold A, Szolar DH, et al. Rheumatoid arthritis of the craniocervical region by MR imaging: detection and characterization. AJR Am J Roentgenol 1995; 165:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/32\">",
"      Glew D, Watt I, Dieppe PA, Goddard PR. MRI of the cervical spine: rheumatoid arthritis compared with cervical spondylosis. Clin Radiol 1991; 44:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/33\">",
"      Narv&aacute;ez JA, Narv&aacute;ez J, Serrallonga M, et al. Cervical spine involvement in rheumatoid arthritis: correlation between neurological manifestations and magnetic resonance imaging findings. Rheumatology (Oxford) 2008; 47:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/34\">",
"      Narv&aacute;ez JA, Narv&aacute;ez J, de Albert M, et al. Bone marrow edema in the cervical spine of symptomatic rheumatoid arthritis patients. Semin Arthritis Rheum 2009; 38:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/35\">",
"      Dickman CA, Mamourian A, Sonntag VK, Drayer BP. Magnetic resonance imaging of the transverse atlantal ligament for the evaluation of atlantoaxial instability. J Neurosurg 1991; 75:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/36\">",
"      Martel W. Fatal atlanto-axial luxation in rheumatoid arthritis. Arthritis Rheum 1963; 6:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/37\">",
"      Laiho K, Soini I, Kautiainen H, Kauppi M. Can we rely on magnetic resonance imaging when evaluating unstable atlantoaxial subluxation? Ann Rheum Dis 2003; 62:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/38\">",
"      Pellicci PM, Ranawat CS, Tsairis P, Bryan WJ. A prospective study of the progression of rheumatoid arthritis of the cervical spine. J Bone Joint Surg Am 1981; 63:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/39\">",
"      Smith PH, Benn RT, Sharp J. Natural history of rheumatoid cervical luxations. Ann Rheum Dis 1972; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/40\">",
"      Isdale IC, Conlon PW. Atlanto-axial subluxation. A six-year follow-up report. Ann Rheum Dis 1971; 30:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/41\">",
"      Mathews JA. Atlanto-axial subluxation in rheumatoid arthritis. A 5-year follow-up study. Ann Rheum Dis 1974; 33:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/42\">",
"      Winfield J, Cooke D, Brook AS, Corbett M. A prospective study of the radiological changes in the cervical spine in early rheumatoid disease. Ann Rheum Dis 1981; 40:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/43\">",
"      Mikulowski P, Wollheim FA, Rotmil P, Olsen I. Sudden death in rheumatoid arthritis with atlanto-axial dislocation. Acta Med Scand 1975; 198:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/44\">",
"      Meijers KA, Cats A, Kremer HP, et al. Cervical myelopathy in rheumatoid arthritis. Clin Exp Rheumatol 1984; 2:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/45\">",
"      Wolfs JF, Kloppenburg M, Fehlings MG, et al. Neurologic outcome of surgical and conservative treatment of rheumatoid cervical spine subluxation: a systematic review. Arthritis Rheum 2009; 61:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/46\">",
"      Matsunaga S, Sakou T, Onishi T, et al. Prognosis of patients with upper cervical lesions caused by rheumatoid arthritis: comparison of occipitocervical fusion between c1 laminectomy and nonsurgical management. Spine (Phila Pa 1976) 2003; 28:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/47\">",
"      Hamilton JD, Johnston RA, Madhok R, Capell HA. Factors predictive of subsequent deterioration in rheumatoid cervical myelopathy. Rheumatology (Oxford) 2001; 40:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/48\">",
"      Casey AT, Crockard HA, Bland JM, et al. Surgery on the rheumatoid cervical spine for the non-ambulant myelopathic patient-too much, too late? Lancet 1996; 347:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/49\">",
"      Neva MH, Kauppi MJ, Kautiainen H, et al. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis Rheum 2000; 43:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/50\">",
"      Kauppi MJ, Neva MH, Laiho K, et al. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs. J Rheumatol 2009; 36:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/51\">",
"      Kauppi M, Anttila P. A stiff collar for the treatment of rheumatoid atlantoaxial subluxation. Br J Rheumatol 1996; 35:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/52\">",
"      Althoff B, Goldie IF. Cervical collars in rheumatoid atlanto-axial subluxation: a radiographic comparison. Ann Rheum Dis 1980; 39:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/53\">",
"      Hakkinen A, Makinen H, Ylinen J, et al. Stability of the upper neck during isometric neck exercises in rheumatoid arthritis patients with atlantoaxial disorders. Scand J Rheumatol 2008; 37:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/54\">",
"      Schmitt-Sody M, Kirchhoff C, Buhmann S, et al. Timing of cervical spine stabilisation and outcome in patients with rheumatoid arthritis. Int Orthop 2008; 32:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/55\">",
"      Paus AC, Steen H, R&oslash;islien J, et al. High mortality rate in rheumatoid arthritis with subluxation of the cervical spine: a cohort study of operated and nonoperated patients. Spine (Phila Pa 1976) 2008; 33:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/56\">",
"      Agarwal AK, Peppelman WC, Kraus DR, et al. Recurrence of cervical spine instability in rheumatoid arthritis following previous fusion: can disease progression be prevented by early surgery? J Rheumatol 1992; 19:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/57\">",
"      Yonenobu K, Hosono N, Iwasaki M, et al. Neurologic complications of surgery for cervical compression myelopathy. Spine (Phila Pa 1976) 1991; 16:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/58\">",
"      Hamilton JD, Gordon MM, McInnes IB, et al. Improved medical and surgical management of cervical spine disease in patients with rheumatoid arthritis over 10 years. Ann Rheum Dis 2000; 59:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/59\">",
"      Wolfs JF, Peul WC, Boers M, et al. Rationale and design of The Delphi Trial--I(RCT)2: international randomized clinical trial of rheumatoid craniocervical treatment, an intervention-prognostic trial comparing 'early' surgery with conservative treatment [ISRCTN65076841]. BMC Musculoskelet Disord 2006; 7:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/60\">",
"      Nannapaneni R, Behari S, Todd NV. Surgical outcome in rheumatoid Ranawat Class IIIb myelopathy. Neurosurgery 2005; 56:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/61\">",
"      Henderson FC, Geddes JF, Crockard HA. Neuropathology of the brainstem and spinal cord in end stage rheumatoid arthritis: implications for treatment. Ann Rheum Dis 1993; 52:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/62\">",
"      Rath SA, Moszko S, Sch&auml;ffner PM, et al. Accuracy of pedicle screw insertion in the cervical spine for internal fixation using frameless stereotactic guidance. J Neurosurg Spine 2008; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/63\">",
"      Mizutani J, Matsubara T, Fukuoka M, et al. Application of full-scale three-dimensional models in patients with rheumatoid cervical spine. Eur Spine J 2008; 17:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41080/abstract/64\">",
"      Zygmunt SC, Christensson D, S&auml;veland H, et al. Occipito-cervical fixation in rheumatoid arthritis--an analysis of surgical risk factors in 163 patients. Acta Neurochir (Wien) 1995; 135:25.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7518 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41080=[""].join("\n");
var outline_f40_7_41080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95775295\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CERVICAL INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Atlantoaxial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMAGING FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Conventional radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95775295\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_7_41081="Macular erythema in toxic shock syndrome";
var content_f40_7_41081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82561%7EDERM%2F61786%7EID%2F77600%7EDERM%2F54896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82561%7EDERM%2F61786%7EID%2F77600%7EDERM%2F54896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular erythema in toxic shock syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular erythema is present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rash in Staphylococcal toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous maculopapular eruption on the abdomen in a patient with staphylococcal toxic shock syndrome (TSS). The erythroderm of TSS can be subtle and resemble a sunburn.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic shock syndrome: desquamation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The epidermis is desquamating on the wrist and volar hand in a female with menstrual TSS; 7 days previously, the skin was diffusely erythematous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Toxic Shock Syndrome. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41081=[""].join("\n");
var outline_f40_7_41081=null;
var title_f40_7_41082="Treatment of relapsing-remitting multiple sclerosis in adults";
var content_f40_7_41082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsing-remitting multiple sclerosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41082/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41082/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/7/41082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/7/41082/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/7/41082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults. The annual mean cost, including patient care, alterations to home and vehicle, medications, purchase of special equipment, and loss of earnings, is $47,000 per patient in 2004 dollars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/1\">",
"     1",
"    </a>",
"    ]. This translates into a national annual cost of $13 billion in the United States and a mean lifetime cost per case of $3.4 million.",
"   </p>",
"   <p>",
"    The treatment of MS varies depending upon individual disease characteristics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapsing-remitting MS (RRMS) is characterized by clearly defined relapses with full recovery or with sequelae and residual deficit upon recovery. There is no disease progression during the periods between disease relapses.",
"     </li>",
"     <li>",
"      Primary-progressive MS (PPMS) is characterized by disease progression from onset with occasional plateaus and temporary minor improvements allowed.",
"     </li>",
"     <li>",
"      Secondary-progressive MS (SPMS) is characterized by an initial RR disease course followed by progression with or without occasional relapses, minor remissions, and plateaus.",
"     </li>",
"     <li>",
"      Progressive-relapsing MS (PRMS) is characterized by progressive disease from onset, with clear acute relapses, with or without full recovery. Progression continues during the periods between disease relapses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relapsing form of MS is generally associated with a better prognosis than progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/2\">",
"     2",
"    </a>",
"    ]. Measures of disease progression and prognosis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of relapsing forms of MS is reviewed here. The treatment of progressive forms of MS is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical aspects of MS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute attacks (relapses) of MS are typically treated with glucocorticoids. Indications for treatment of a relapse include functionally disabling symptoms with objective evidence of neurologic impairment. This is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3061?source=see_link\">",
"     \"Treatment of acute exacerbations of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF DISEASE MODIFYING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain immunomodulatory agents, including interferon beta preparations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    , have shown several important beneficial effects for patients with relapsing-remitting multiple sclerosis (RRMS):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A decreased relapse rate",
"     </li>",
"     <li>",
"      A slower accumulation of brain lesions on MRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, everyone with a diagnosis of definite RRMS should begin disease modifying therapy. However, the impact of these disease modifying therapies on the progression of brain atrophy in MS is still unclear, as some studies have reported decreased atrophy with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We now know that most of the immune response in MS occurs early in the disease course. This is demonstrated by the findings that most of the gadolinium-enhanced lesions occur early in MS and that the relapse rate slows over the natural history of the disease. The later stages of MS are typically less inflammatory and more degenerative.",
"   </p>",
"   <p>",
"    Therefore, treatment of MS should be early and aggressive. Evidence supporting this strategy can be found in clinical trials showing that early treatment with interferons reduces the attack rate, whether measured clinically or by MRI, in patients with clinically isolated syndromes suggestive of multiple sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinically isolated syndromes suggestive of multiple sclerosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The variety of patient disabilities and variation in the course of MS make the choice of treatment for the individual patient difficult. While the choice of disease modifying therapy typically relies upon the results of controlled trials, patients may differ markedly from those that have been treated in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTERFERONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different interferon beta preparations have been investigated for treatment of relapsing-remitting multiple sclerosis (RRMS). A discussion of the different types of interferon and evidence of their effectiveness is presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interferon beta-1b (Betaseron)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first disease modifying medication approved for use in MS was recombinant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    (Betaseron). The drug is a cytokine that modulates immune responsiveness, although its precise mechanism of action in MS is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    was demonstrated in a double-blind, placebo-controlled trial of 372 patients with RRMS who were randomly assigned to treatment with either interferon beta-1b 50 mcg every other day, interferon beta-1b 250 mcg every other day, or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After two years, the annual exacerbation rate was significantly lower for both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      treatment groups and appeared to be dose related; the frequency of relapses was",
"      <span class=\"nowrap\">",
"       1.27/year",
"      </span>",
"      in the placebo group, compared with",
"      <span class=\"nowrap\">",
"       1.17/year",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       0.84/year",
"      </span>",
"      in the low and high-dose interferon beta-1b groups, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At five-year follow-up, the incidence of disease progression was lower in the high-dose (250 mcg)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      group compared with the placebo group (35 versus 46 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/10\">",
"       10",
"      </a>",
"      ]. There was also a 30 percent decrease in the annual exacerbation rate in the high-dose interferon beta-1b group over five years. Although this was not statistically significant, the treatment benefit trend was maintained. There was no significant increase in the median brain MRI lesion burden (3.6 percent) in the interferon beta-1b group, while the placebo group had a 30 percent increase in median MRI lesion burden over five years.",
"     </li>",
"     <li>",
"      At a median of 21 year follow-up with nearly complete ascertainment (98 percent) of patients, the rate of all-cause mortality was significantly lower for those originally assigned to low and high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      treatment (17.9 and 18 percent, versus 30.6 percent for those originally assigned to placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients in this trial received the assigned treatment for up to five years, and subsequent use of disease modifying therapy was optional and unmasked. Therefore, these data suggest that earlier",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      longer exposure to interferon beta-1b treatment improves survival for patients with MS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     Interferon beta-1b",
"    </a>",
"    also appears to be effective for RRMS in Japanese populations, where the frequency of the optic-spinal variant of MS is much higher than in Western populations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized clinical trial of 205 Japanese patients with RRMS that was not placebo controlled, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    250 mcg every other day was associated with a significant reduction in the annual relapse rate compared with the \"control\" group that received interferon beta-1b 50 mcg every other day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/12\">",
"     12",
"    </a>",
"    ]. A subgroup analysis suggested that interferon beta-1b efficacy was similar for patients with optic-spinal variant (about 21 percent of the study population) and classic MS. However, the study was not powered to confirm treatment efficacy in subgroups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     Interferon beta-1b",
"    </a>",
"    is administered every other day subcutaneously by self injection. The side effect profile was similar to the other interferons (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Side effects of interferons'",
"    </a>",
"    below). Not all patients respond to the drug, and with time all patients have had additional attacks. In addition, 34 percent of patients developed neutralizing antibodies that could reduce the drug's clinical efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Neutralizing antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The INCOMIN study compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    with intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    in 188 patients with RRMS and found the former to be more effective on both clinical and MRI outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/14\">",
"     14",
"    </a>",
"    ]. The trial design did not include blinding, but careful randomization was performed and clinical results were consistent with MRI results, the latter of which were obtained from a blinded analysis. Over two years, significantly more patients receiving interferon beta-1b remained relapse-free than those assigned to interferon beta-1a (51 versus 36 percent, relative risk of relapse 0.76, 95% CI 0.59-0.9); similarly, more patients receiving interferon beta-1b remained free from new T2 lesions on MRI (55 versus 26 percent, relative risk of new T2 lesion 0.6, CI 0.45-0.8).",
"   </p>",
"   <p>",
"    In contrast to the INCOMIN results, a multicenter open-label randomized Danish trial involving 310 patients with RRMS compared subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Rebif) 22 mcg once weekly with subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    (Betaseron) 250 mcg every other day and found that the annual relapse rates were nearly equal in the two treatment groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Interferon beta-1a (Avonex)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of intramuscular (IM)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Avonex) in patients with RRMS was demonstrated in a randomized, double-blind study of 301 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/16\">",
"     16",
"    </a>",
"    ]. Weekly intramuscular injections of 6 million units (30 mcg) of Avonex or placebo were administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/16\">",
"     16",
"    </a>",
"    ]. Over two years, treatment with Avonex resulted in a reduction in the annual exacerbation rate compared with placebo (0.61 and 0.9, respectively), a decrease in MRI lesion volume (mean 74 versus 122), and fewer patients progressing by one point on the Expanded Disability Status Scale (EDSS) (22 versus 35 percent). In a subsequent randomized, double-blind study, a higher dose of Avonex (60 mcg per week) was not superior to 30 mcg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/17\">",
"     17",
"    </a>",
"    ]. As mentioned above, Avonex may also have beneficial effects on cognitive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects with Avonex are similar to those with other interferons (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Side effects of interferons'",
"    </a>",
"    below). Approximately 2 to 5 percent of patients develop neutralizing antibodies that may limit efficacy over time (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Neutralizing antibodies'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interferon beta-1a (Rebif)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Rebif) was established by the double-blind PRISMS trial that randomly assigned 560 patients with RR disease to placebo, 22 mcg, or 44 mcg of Rebif three times per week for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment with 22 or 44 mcg was associated with a significant reduction in relapse rate (27 and 33 percent, respectively) compared with placebo. Treatment also reduced the MRI lesion burden in the low and high-dose treatment groups (1.2 and 3.8 percent) versus an increase in the placebo group (10.9 percent).",
"   </p>",
"   <p>",
"    The side effect profile was similar to the other interferons (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Side effects of interferons'",
"    </a>",
"    below). Approximately 24 percent of the 22 mcg group and 13 percent of the 44 mcg group were positive for neutralizing antibodies, but this did not affect the mean relapse count (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Neutralizing antibodies'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In an extension of the PRISMS study, patients originally randomized to placebo began treatment with one of two doses of Rebif, while those originally randomized to Rebif continued the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who received Rebif therapy for the entire four years had significantly less change in impairment, disability, and MRI measures of pathology than patients who initially received placebo; the latter group never regained the losses associated with delaying interferon therapy.",
"   </p>",
"   <p>",
"    In a later PRISMS extension study that followed 68 percent of the original trial cohort for either seven or eight years, patients who received Rebif therapy three times a week at either dose (44 mcg or 22 mcg) for the entire study period had a significantly lower relapse rate than patients who initially received placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients originally assigned to the Rebif 44 mcg group, but not those originally assigned to the 22 mcg group, had a significantly lower MRI burden of disease than patients who initially received placebo.",
"   </p>",
"   <p>",
"    These findings from the PRISMS extension studies suggest, but do not establish, that earlier subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    therapy in patients with RRMS results in sustained long-term benefits compared with later therapy. Definitive conclusions are precluded by limitations of these studies, including lack of a control group, open label treatment with unblinded and retrospective assessment of clinical events, and large numbers of patients lost to follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A head to head comparison study (the EVIDENCE trial) enrolled 677 patients who were randomly assigned to receive Rebif (44 mcg three times weekly injection) or Avonex (30 mcg once weekly injection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/22\">",
"     22",
"    </a>",
"    ]. Relapse was less frequent with Rebif (25 versus 37 percent), and the mean number of active unique MRI lesions per patient per scan was fewer (0.17 versus 0.33). However, treatment with Rebif was associated with a substantially higher rate of developing neutralizing antibodies (25 versus 2 percent). The percentage of relapse-free patients, the primary outcome measure, was significantly decreased in the Rebif patients with neutralizing antibodies.",
"   </p>",
"   <p>",
"    In addition to concerns regarding neutralizing antibody formation, there were several criticisms of the EVIDENCE trial: the subjects were not blind to treatment assignment, the duration was relatively short (six months), disability was not used as an outcome measure, and different doses, frequencies, and routes of administration were compared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an extension of the EVIDENCE trial, patients who changed from low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (30 mcg once weekly injection) to high-dose interferon beta-1a (44 mcg three times weekly injection) experienced a statistically significant (50 percent) decrease in the annualized relapse rate, while patients continuing on high-dose interferon beta-1a experienced a nonsignificant (26 percent) decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/25\">",
"     25",
"    </a>",
"    ]. The higher dose of interferon beta-1a was associated with an increased rate of adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Long term benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of long-term treatment with interferon beta (IFNB) preparations for RRMS remains unproven. As reviewed above, randomized controlled trials of these agents provide evidence of benefit only for the relatively short duration (generally two years) of the trials. Results from a number of clinical trial extension studies suggest that there is continued benefit of IFNB treatment beyond two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/11,19,20\">",
"     11,19,20",
"    </a>",
"    ]. However, definitive conclusions are precluded by limitations of these studies, which involve uncontrolled open-label treatment with unblinded and retrospective assessment of clinical events, and often large numbers of patients lost to follow-up. Long-term blinded randomized controlled trials of IFNB therapy for RRMS are ideally suited to settling this issue, but are considered impractical and possibly unethical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term observational studies are more practical but are similarly limited by nonrandomized retrospective methodology. These studies too have provided no convincing evidence that IFNB treatment for MS prevents long-term disability.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Propensity score weighting, a statistical method proposed to reduce the effects of bias in observational studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/27-29\">",
"       27-29",
"      </a>",
"      ], was employed in an uncontrolled prospective observational study of 1504 patients with RRMS, in which 1103 patients were treated with various IFNBs (Betaferon, Avonex, and two different dose regimens of Rebif) and 401 were untreated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/30\">",
"       30",
"      </a>",
"      ]. At a median follow-up of 5.7 years, IFNB treatment compared with no IFNB treatment was associated with a significant reduction in the probability of worsening to secondary progressive MS (hazard ratio [HR] 0.38, 95% CI 0.24-0.58), and significant reductions in the probability of progressing to an Expanded Disability Status Scale (EDSS) score of &ge;4 (HR 0.7, 95% CI 0.53-0.94) or EDSS &ge;6 (HR 0.6, 95% CI 0.38-0.95). However, this study was criticized for being subject to &ldquo;immortal time bias&rdquo; related to different definitions of cohort entry for treated and untreated groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients not treated with IFNB were entered at the time of their first admission to the MS center, whereas treated patients were entered at the time of first administration of IFNB after admission; the time between admission and first administration of IFNB constitutes &ldquo;immortal time&rdquo;, during which no outcome event could occur without excluding the patient from analysis. In contrast, the IFNB-untreated patients could experience outcome events immediately after admission, thereby artificially inflating the outcome rate for untreated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A subsequent uncontrolled observational study analyzed patients with RRMS registered in a database, including 868 treated with IFNBs, 829 contemporary controls eligible for but not treated with IFNBs, and 959 historical controls eligible for IFNBs prior to approval (April 1985 &ndash; June 1995) and therefore not treated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/32\">",
"       32",
"      </a>",
"      ]. The median follow-up times for the treated, contemporary and historical control groups were 5.1, 4.0, and 10.8 years, respectively. In adjusted regression analysis, with IFNB exposure as a time-dependent variable, there was no statistically significant relationship between IFNB-exposed time and the risk of reaching an EDSS score of 6 (ie, loss of ability to walk 100 m unaided) when the IFNB-treated patients were compared with contemporary controls (HR 1.30, 95% CI 0.92-1.83) or historical controls (HR 0.77, 95% CI 0.58-1.02). The findings were similar when the analysis included propensity score adjustment. The trend towards a more favorable outcome for the contemporary control group may be attributable to &ldquo;indication bias&rdquo;, whereby patients with mild disease were not treated with IFNBs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/32\">",
"       32",
"      </a>",
"      ]. Additional limitations of this study include the inability to account for the impact of IFNB neutralizing antibodies, to compare outcomes associated with different IFNBs, or to consider the effect of switching among IFNBs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Side effects of interferons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferons have significant side effects. Reactions at the injection site are common and can include injection site necrosis. Flu-like symptoms are also common and may be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , and glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/33\">",
"     33",
"    </a>",
"    ]. Acetaminophen may also be used to treat these symptoms, but its routine use should probably be avoided as it may increase the risk of liver dysfunction associated with interferon beta (IFNB) use. Flu-like symptoms and depression tend to diminish with time.",
"   </p>",
"   <p>",
"    There is a high prevalence of mainly asymptomatic liver dysfunction associated with IFNB therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A postmarketing retrospective review of patients with MS prescribed a beta-interferon found new elevations of alanine aminotransferase (ALT) in 243 (37 percent) of 659 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/34\">",
"       34",
"      </a>",
"      ]. All of the IFNB drugs caused elevated ALT levels. Their relative effect on ALT was approximated as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      SC (Betaseron) =",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      SC (Rebif) &gt; interferon beta-1a IM (Avonex). Liver function test abnormalities were typically minimal, but they were mild to moderate in 4 to 7 percent and severe in 1 to 2 percent. The risk was increased with male sex, obesity, alcohol use, and simultaneous use of other medications (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An analysis of pooled data from six clinical trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      in patients with MS, as well as postmarketing surveillance data, found asymptomatic and dose-related elevations of ALT at 24 months in up to 67 percent of patients taking interferon beta-1a [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/35\">",
"       35",
"      </a>",
"      ]. More than 50 percent of elevations in liver enzymes occurred during the first three months of treatment, and more than 75 percent occurred during the first six months. Most of the elevated liver enzyme levels resolved spontaneously or with dosage adjustment. By two years, abnormal liver enzyme levels in those receiving interferon beta-1a (Rebif) 44 mcg three times weekly declined to 11 percent, compared with 6 percent of placebo-treated patients. Hepatic adverse effects led to discontinuation of interferon beta-1a treatment in only 0.4 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serious hepatotoxicity associated with IFNB is rare. Nevertheless, the potential risk of using Avonex in combination with known hepatotoxic drugs or other products (eg, alcohol) should be considered prior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    administration, or when adding new agents to the regimen of patients already on interferon beta-1a.",
"   </p>",
"   <p>",
"    Other reactions possibly related to IFNB therapy have been reported, including leukopenia, anemia, and suicide. A partially reversible polyneuropathy was described in a small series of patients with MS who were treated with IFNB therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periodic monitoring of complete blood count, liver function and thyroid function is suggested for patients on IFNB therapy, but the optimal frequency of monitoring has not been established. It is unclear whether monitoring these laboratory studies is helpful for detecting and avoiding the rare cases of serious IFNB-related toxicity. We suggest checking liver function tests monthly for six months after initiating therapy. We also suggest decreasing the IFNB dose by 50 percent if leukopenia develops or if transaminases are persistently elevated (three to five times normal) in the absence of another identifiable cause (eg, illness, a new medication, or alcohol intake). Monitoring should then be continued for another six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13708205\">",
"    <span class=\"h2\">",
"     Interferon response status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responsiveness to interferon beta (IFNB) treatment may vary among treated individuals. Patients with MS who have ongoing disease activity despite IFNB treatment have been termed nonresponders, but this classification is not clearly defined given the highly variable course of MS disease activity and the modest effectiveness of IFNB treatment.",
"   </p>",
"   <p>",
"    No validated measures exist to classify IFNB responsiveness. A study of 200 patients with RRMS and 62 patients with relapsing secondary progressive MS (SPMS) found that older age and longer disease duration were associated with responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/37\">",
"     37",
"    </a>",
"    ]. Responders with RRMS had a higher relapse rate during the year prior to IFNB therapy, and responders with SPMS had a higher EDSS score at initiation of IFNB treatment. The authors concluded that patients with relapsing MS who respond to IFNB have more inflammatory and less neurodegenerative disease at the time IFNB is initiated than do nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential biologic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/38-43\">",
"     38-43",
"    </a>",
"    ] and radiologic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/42,44\">",
"     42,44",
"    </a>",
"    ] markers of IFNB responsiveness have also been examined, such as myxovirus resistance protein A (MxA). The clinical utility of these markers remains to be proven.",
"   </p>",
"   <p>",
"    Results from a small randomized trial suggest that the addition of statin therapy leads to increased disease activity in patients with RRMS who are on IFNB treatment, but more data are needed clarify the effect of statins in patients with MS. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Statins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neutralizing antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests that the development of neutralizing antibodies (NAbs) can limit the effectiveness of interferon beta (IFNB) as measured by MRI activity, relapses, and disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. All of the interferons are capable of stimulating the production of NAbs, which reduce the bioavailability of interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of NAb formation varies with the type of interferon, the dosing regimen, and duration of IFNB therapy, as supported by the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a comparative study that tested sera from 125 patients, the risk of antibody formation over 18 months of treatment was highest with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron), intermediate with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Rebif), and lowest with interferon beta-1a (Avonex) (31, 15, and 2 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 455 patients with MS treated with different IFNB preparations and followed from six up to 78 months, the probability of remaining free of a positive NAb test decreased over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/52\">",
"       52",
"      </a>",
"      ]. Overall, NAb status was definitely positive (at least two consecutive positive samples) in 41 percent, fluctuating in 7 percent, and persistently negative in 52 percent. The cumulative probability of becoming definitely Nab positive was about 60 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Rebif) treatment, while the probability was significantly lower for interferon beta-1a (Avonex) at about 20 percent.",
"     </li>",
"     <li>",
"      Of those who were definitely NAb positive, spontaneous reversion to NAb negative status over several years occurred in 34 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/7\">",
"       7",
"      </a>",
"      ]. Reversion to NAb negative status was significantly more likely to occur with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron) than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Rebif) (52 versus 19 percent, respectively). Only seven patients treated with interferon beta-1a (Avonex) were definitely NAb positive, precluding their inclusion in this analysis.",
"     </li>",
"     <li>",
"      Patients who remained NAb negative for at least 24 months of IFNB therapy were unlikely to develop NAb positivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of larger protein loads associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    (Betaseron) treatment may be more likely to lead to the reestablishment of immune tolerance and reversion to negative NAb status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings may have implications for the choice of therapy. While using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Avonex) administered once weekly to avoid the NAb problem is a viable strategy, interferon beta-1a (Avonex) has a lower cumulative biologic activity than both interferon beta-1a (Rebif) administered three times a week or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    (Betaseron) administered every other day, suggesting that there is no single drug that has optimal effectiveness with minimal NAb formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neutralizing antibody and MxA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative impact of NAbs on relapses and disease progression has led some experts to call for NAb testing in clinical practice at 12 and 24 months of interferon beta (IFNB) therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The proposed role of testing would be mainly predictive, with positive NAb status identifying patients who are more likely to fail IFNB therapy than those who are NAb negative. However, national guidelines and expert opinion are conflicting regarding the utility of NAb testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An evidence-based review of NAbs published in 2007 by the American Academy of Neurology (AAN) concluded that there is insufficient information on the utilization of NAb testing to provide recommendations regarding which test to use, when to test, how many tests are needed, and what cutoff titer to apply [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence-based guidelines from the European Federation of Neurological Societies (EFNS) published in 2005 recommend that all patients undergo NAb testing at 12 and 24 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/57\">",
"       57",
"      </a>",
"      ]. The EFNS further recommends discontinuing IFNB therapy in patients with sustained high NAb titers at repeated measurements with three to six month intervals.",
"     </li>",
"     <li>",
"      A European expert panel report published in 2010 concluded that information about NAbs and markers of IFNB biologic activity such as myxovirus resistance protein A (MxA) can be used to guide individual treatment decisions as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/58\">",
"       58",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      NAb and MxA measurements should have &ldquo;therapeutic consequences&rdquo;, even for stable patients with low MS disease activity. For those with sustained high NAb titers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a lack of MxA bioactivity, a switch to non-IFNB therapy should be considered.",
"     </li>",
"     <li>",
"      In the setting of intermediate MS disease activity, continuation of IFNB therapy could be considered for patients who are NAb-negative, whereas a switch to non-IFNB therapy should be suggested for those with high NAb titers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of MxA bioactivity.",
"     </li>",
"     <li>",
"      In the setting of high disease activity, therapy should be changed independent of Nab or MxA results. For patients who have NAb titers, a switch to a non-IFNB therapy would be indicated. For those with absent Nab titers, some panel members felt that a switch to another IFNB product (ie, from a low",
"      <span class=\"nowrap\">",
"       dose/frequency",
"      </span>",
"      IFNB to a higher",
"      <span class=\"nowrap\">",
"       dose/frequency",
"      </span>",
"      IFNB) could still be an option.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our view, further trials incorporating therapeutic interventions based on NAb status seem warranted before Nab or MxA testing can be widely recommended for patients with MS receiving IFNB therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinically isolated syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     Interferon beta-1a",
"    </a>",
"    (Avonex and Rebif) and interferon beta 1b",
"    <span class=\"nowrap\">",
"     (Betaseron/Betaferon)",
"    </span>",
"    treatment has shown benefit in randomized controlled trials for patients experiencing a first clinical demyelinating event suggestive of MS. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinically isolated syndromes suggestive of multiple sclerosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GLATIRAMER",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     Glatiramer acetate",
"    </a>",
"    (copolymer 1) is a mixture of random polymers of four amino acids. The mixture is antigenically similar to myelin basic protein, a component of the myelin sheath of nerves. In experimental models, the immunomodulatory mechanism of action for glatiramer involves binding to major histocompatibility complex molecules and consequent competition with various myelin antigens for their presentation to T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, glatiramer is a potent inducer of specific T helper 2 type suppressor cells that migrate to the brain and lead to bystander suppression; these cells also express antiinflammatory cytokines.",
"   </p>",
"   <p>",
"    The following trials demonstrate the effectiveness of glatiramer in RRMS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      was first established in a double-blind trial of 251 patients with RRMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/60\">",
"       60",
"      </a>",
"      ]. At two years, patients treated with glatiramer acetate (20 mg subcutaneously daily) had a significantly lower relapse rate than those receiving placebo (1.19 versus 1.68) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/60\">",
"       60",
"      </a>",
"      ]. Furthermore, over 140 weeks, a significantly larger proportion of patients in the placebo group experienced increased disability by &ge;1.5 EDSS steps compared with the treatment group (41 versus 22 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another trial with 239 patients found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      treatment led to a significant reduction in the number of new T2 lesions on brain MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Side effects of glatiramer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    include local injection site reactions and transient systemic postinjection reactions such as chest pain, flushing, dyspnea, palpitations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety. No laboratory monitoring is necessary. Neutralizing antibodies to glatiramer acetate were not detected in the trial cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/60\">",
"     60",
"    </a>",
"    ], but have been detected in other studies; their clinical significance is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/63\">",
"     63",
"    </a>",
"    ]. Desensitization to glatiramer acetate has been successfully performed in patients with either systemic allergic reactions or recurrent local reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     Glatiramer acetate",
"    </a>",
"    is categorized as pregnancy category B, while both Avonex and Betaseron are category C (",
"    <a class=\"graphic graphic_table graphicRef73903 \" href=\"mobipreview.htm?1/12/1228\">",
"     table 1",
"    </a>",
"    ). However, the clinical importance of this difference may be small, since treatment with all three drugs is discontinued when pregnancy occurs, and relapses during pregnancy are treated with intravenous glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Trials comparing interferons with glatiramer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence from controlled trials suggests that interferons and glatiramer have similar clinical utility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The blinded BEYOND trial randomly assigned patients with early RRMS in a 2:2:1 ratio to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (n = 1796) at 250 mcg or 500 mcg or to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      (n = 448) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/66\">",
"       66",
"      </a>",
"      ]. Patients were followed for at least two years. There were no differences among treatment groups for relapse risk, disease progression, or MRI measures of lesion burden. Flu-like symptoms were more common with interferon beta-1b, while injection site reactions were more frequent with glatiramer acetate.",
"     </li>",
"     <li>",
"      An open-label randomized trial (the REGARD study) of 764 patients with RRMS compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Rebif) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/67\">",
"       67",
"      </a>",
"      ]. There was no significant difference between treatment groups in the primary outcome of time to first relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/67\">",
"       67",
"      </a>",
"      ]. Relapse rates were low in both groups.",
"     </li>",
"     <li>",
"      Another open-label trial (the BECOME study) of 75 patients with RRMS or clinically isolated syndromes compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/68\">",
"       68",
"      </a>",
"      ]. Over two years, there were no differences between treatment groups in new lesions or clinical relapses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26726955\">",
"    <span class=\"h1\">",
"     FINGOLIMOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     Fingolimod",
"    </a>",
"    is sphingosine analogue that modulates the sphingosine-1-phosphate receptor and thereby alters lymphocyte migration, resulting in sequestration of lymphocytes in lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/69\">",
"     69",
"    </a>",
"    ]. There is evidence from two large controlled trials that fingolimod is effective for reducing the relapse rate in patients with RRMS. However, this benefit is associated with an increased risk of life-threatening infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FREEDOMS trial randomly assigned 1272 adults with RRMS to treatment in a 1:1:1 ratio with either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      (0.5 mg daily or 1.25 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/70\">",
"       70",
"      </a>",
"      ]. At 24 months, the following observations were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The annualized relapse rate, the primary outcome measure, was significantly reduced on intention-to-treat analysis for both the high and low",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      groups compared with placebo (0.18, 0.16, and 0.40 respectively). In addition, fingolimod treatment resulted in statistically significant reductions in both the risk of sustained disability progression and new lesions on brain MRI.",
"     </li>",
"     <li>",
"      The incidence of serious infections and herpes virus infections were similar in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      and placebo groups.",
"     </li>",
"     <li>",
"      Macular edema developed in seven patients in the high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TRANSFORMS trial randomly assigned over 1200 adults with RRMS to treatment with either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      (0.5 mg daily or 1.25 mg daily) or intramuscular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (30 mcg weekly) in a 1:1:1 ratio [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/71\">",
"       71",
"      </a>",
"      ]. At 12 months, the following outcomes were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the cohort of subjects who received at least one dose of a study drug, the annualized relapse rate, the primary end point, was significantly lower in both the high and low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      groups than in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      group (0.20, 0.16, and 0.33, respectively). MRI measures also favored fingolimod. Progression of disability was infrequent in all three groups.",
"     </li>",
"     <li>",
"      There were more serious adverse events in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      groups. These included two deaths in the high-dose fingolimod group (one from disseminated varicella-zoster infection and the other from herpes simplex encephalitis) versus none for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      group. In addition, 12 patients on fingolimod developed skin or breast cancer (versus one in interferon beta-1a group), and 19 developed dose-related bradycardia or atrioventricular block (versus none assigned to interferon beta-1a).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a preliminary randomized trial that evaluated 255 patients with relapsing MS, treatment with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      (1.25 mg daily or 5.0 mg daily) resulted in a significant reduction in the total number of gadolinium-enhancing lesions on brain MRI at six months (the primary endpoint) compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/72\">",
"       72",
"      </a>",
"      ]. One patient in the fingolimod treatment group developed a reversible posterior leukoencephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    is an effective disease-modifying agent for RRMS, but its use is associated with a risk of varicella-zoster virus infections, potentially fatal, and tumor development. In case reports, fingolimod treatment has been linked to additional varicella-zoster infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/73,74\">",
"     73,74",
"    </a>",
"    ] and to the paradoxical worsening of MS disease activity with severe MS relapses (some following cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    ) or the development of tumefactive MS lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In one case, marked exacerbation of MS activity was observed after fingolimod was withdrawn due to the development of severe herpes zoster infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/73\">",
"     73",
"    </a>",
"    ]. These case reports suggest but do not establish that fingolimod can cause or contribute to paradoxical worsening of MS disease activity, and further support the likelihood that the immunomodulating and lymphocytopenic effects of fingolimod increase the risk of viral infection. Additional data are needed to determine both the risk profile and the optimal dose of oral fingolimod for RRMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24015215\">",
"    <span class=\"h2\">",
"     Clinical use of fingolimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eleven deaths have been linked to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    internationally as of late February 2012, including four patients who had cardiac events and seven with unexplained death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Although these deaths may be coincidental and unrelated to fingolimod, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    starting fingolimod for patients with MS until the cause of death in these cases has been clarified. A preliminary review by the FDA concluded that the contribution of fingolimod to these deaths is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even before the concerns about",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    -linked deaths arose, some experts believed that fingolimod should be reserved for patients who have an inadequate response to treatment with beta interferons or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    , at least until long-term safety data are available for fingolimod [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    include patients with recent (within six months) myocardial infarction, unstable angina, stroke, TIA, or heart failure, a history of second or third degree atrioventricular block or sick sinus syndrome (unless treated with a pacemaker), a prolonged QT interval at baseline, or treatment with anti-arrhythmic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. Since the trials of fingolimod excluded patients with diabetes, we further suggest",
"    <strong>",
"     not",
"    </strong>",
"    using fingolimod to treat patients who have diabetes.",
"   </p>",
"   <p>",
"    The most common side effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    include headache, influenza, diarrhea, back pain, elevated liver enzymes, and cough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/81\">",
"     81",
"    </a>",
"    ]. Less common but potentially serious adverse events associated with fingolimod include bradyarrhythmia and atrioventricular block (potentially fatal), macular edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/82\">",
"     82",
"    </a>",
"    ], diminished respiratory function, and tumor development.",
"   </p>",
"   <p>",
"    Before starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    , patients should have the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count and liver function test (LFT) results within six months",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG)",
"     </li>",
"     <li>",
"      Ophthalmologic examination",
"     </li>",
"     <li>",
"      Varicella serology and varicella zoster virus vaccination if antibody negative for those without a history of chicken pox or prior vaccination;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"       fingolimod",
"      </a>",
"      should not be started until one month after vaccination",
"     </li>",
"     <li>",
"      Women of childbearing potential should be informed of risk for adverse fetal outcomes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, we suggest a skin examination at baseline to screen for evidence of precancerous skin lesions.",
"   </p>",
"   <p>",
"    The first dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    should be given in a setting where symptomatic bradycardia can be managed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/79,81\">",
"     79,81",
"    </a>",
"    ]. At treatment initiation, baseline pulse and blood pressure should be measured. These measurements should be repeated hourly for six hours after the first dose while the patient is observed for signs of bradycardia or atrioventricular block, and an ECG should be obtained at the end of the six hour observation period. For patients who are at higher risk for bradycardia or who may not tolerate it, cardiovascular monitoring should be extended overnight using continuous ECG monitoring. Patients who develop symptomatic bradycardia or atrioventricular block (second degree or higher) should be managed appropriately and monitored with continuous ECG until the symptoms resolve.",
"   </p>",
"   <p>",
"    During",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    treatment (and for two months after stopping), patients should be monitored for symptoms and signs of infection, and live attenuated vaccines should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/81\">",
"     81",
"    </a>",
"    ]. Ophthalmologic examination should be repeated three to four months after starting fingolimod, and routinely in patients with diabetes mellitus or a history of uveitis. Pulmonary function testing with spirometry and diffusion lung capacity for carbon monoxide (DLCO) should be obtained if indicated clinically, and LFTs should be monitored for patients with symptoms suggestive of hepatic dysfunction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     Fingolimod",
"    </a>",
"    is pregnancy class C and should be stopped two months prior to conception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NATALIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is an effective drug for the treatment of RRMS. However, it not a first-line agent because its use is rarely associated with the development of progressive multifocal leukoencephalopathy, a potentially fatal complication. Natalizumab should be reserved for patients with active RRMS that is refractory or resistant to beta interferons and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    , and for patients who are intolerant of these medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23032?source=see_link\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H34\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104685535\">",
"    <span class=\"h1\">",
"     TERIFLUNOMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunomodulator",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    is the active metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    that inhibits pyrimidine biosynthesis and disrupts the interaction of T cells with antigen presenting cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a preliminary randomized controlled trial involving 179 patients with RRMS or SPMS, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"       teriflunomide",
"      </a>",
"      was effective in reducing MRI lesions compared with placebo and was well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A larger trial of 1088 adults (ages 18 to 55) with relapsing MS found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"       teriflunomide",
"      </a>",
"      (either 7 mg or 14 mg once daily for just over two years) significantly reduced the annualized relapse rate by approximately 31 percent compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/86\">",
"       86",
"      </a>",
"      ]. In addition, teriflunomide at the higher dose (14 mg daily) significantly reduced disability progression compared with placebo (27 versus 20 percent) and improved MRI measures of MS disease activity. This trial has been criticized due to a relatively high drop-out rate (approximately 27 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    were diarrhea, nausea, hair thinning, and elevated alanine aminotransferase levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the risk of hepatotoxicity, patients with known liver disease should not be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    . The manufacturer recommends obtaining baseline transaminase and bilirubin levels before starting treatment with teriflunomide, and to monitor alanine aminotransferase levels monthly for at least six months once treatment is started. The drug should be discontinued if drug-induced liver injury is suspected.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     Teriflunomide",
"    </a>",
"    is pregnancy category X [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/88\">",
"     88",
"    </a>",
"    ]. Due to the risk of teratogenicity, teriflunomide is contraindicated for women who are pregnant or trying to conceive, and women of childbearing age must have a negative pregnancy test before starting the drug. Teriflunomide is also found in semen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/89\">",
"     89",
"    </a>",
"    ]. Thus, men and women who wish to conceive a child should discontinue teriflunomide and undergo an accelerated drug elimination procedure using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    powder for 11 days. Otherwise, teriflunomide may remain in the serum for up to 2 years. Pregnancy should be avoided until the serum concentration of teriflunomide is &lt;0.02",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"   </p>",
"   <p>",
"    We suggest oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    7 mg daily for men or post-menopausal women with relapsing remitting MS who don&rsquo;t want treatment with the better established MS therapies (eg, interferons and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    ) that require injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MITOXANTRONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     Mitoxantrone",
"    </a>",
"    is approved for use in both relapsing-remitting and progressive forms of MS. However, guidelines published in 2003 by the American Academy of Neurology recommended that, because of cardiac toxicity and the limited evidence of benefit, mitoxantrone should be reserved for patients with rapidly advancing disease who have failed other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/90\">",
"     90",
"    </a>",
"    ]. In addition, mitoxantrone treatment is associated with a low risk of developing therapy-related acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of progressive multiple sclerosis in adults\", section on 'Mitoxantrone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients older than age 50, those with long-standing disability, and those with substantial spinal cord atrophy may be less likely to respond to intense immunosuppression with agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    than patients without these characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    is a humanized monoclonal antibody that causes depletion of CD52-expressing T cells, natural killer cells, and monocytes. Data from randomized controlled trials show that alemtuzumab is more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    for reducing the relapse rate in RRMS. This benefit is associated with a small increased risk of potentially serious infections and autoimmune disorders, including immune thrombocytopenic purpura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CARE-MS I was a rater-blind trial that evaluated over 550 adults with RRMS, low disability levels, and no prior disease modifying therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/95\">",
"       95",
"      </a>",
"      ]. Subjects were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (44 mcg three times per week) in a 2:1 ratio. Alemtuzumab was infused intravenously at 12 mg daily for five days at the start of treatment and for three days at 12 months. At two years, alemtuzumab significantly reduced the proportion of patients with any relapse (22 percent, versus 40 percent for interferon beta-1a, rate ratio 0.45, 95% CI 0.23-0.63) and the annualized relapse rate (0.18 versus 0.39). However, there was no significant difference between groups for sustained accumulation of disability (8 versus 11 percent). Imaging outcomes were mixed; there was no significant difference between groups for median change in volume of T2-hyperintense brain lesions, but the alemtuzumab group had significantly fewer new or enlarging T2-hyperintense lesions, and fewer gadolinium-enhancing lesions.",
"     </li>",
"     <li>",
"      The similar CARE-MS II trial evaluated nearly 800 adults with RRMS and at least one relapse while on treatment with interferon beta or glatiramer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/96\">",
"       96",
"      </a>",
"      ]. At two years,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      significantly reduced the proportion of patients with any relapse (35 percent, versus 53 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      , rate ratio 0.52 (95% CI 0.39-0.65) and the annualized relapse rate (0.26 versus 0.52). Unlike CARE-MS I, the alemtuzumab group in CARE-MS II had a significantly lower rate of sustained accumulation of disability (13 versus 20 percent, hazard ratio 0.58, 95% CI 0.38-0.87). Similar to CARE-MS I, the imaging outcomes in CARE-MS II showed no significant difference between groups for median change in volume of T2-hyperintense brain lesions, but the alemtuzumab group had significantly fewer new or enlarging T2-hyperintense lesions, and fewer gadolinium-enhancing lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in these and earlier trials were infusion reactions, infections, and autoimmune disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. Infusion reactions occurred in approximately 90 percent of patients and were characterized by headache, rash, nausea, and fever. Infections, though generally not severe, were observed in two-thirds or more of the patients treated with alemtuzumab. Herpes viral infections occurred in 16 to 18 percent, leading to a change in the protocol of the in-progress CARE MS trials with the addition of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    treatment during alemtuzumab infusion and for 28 days after infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Thyroid autoimmunity was seen in 16 to 18 percent of patients at two years after alemtuzumab treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/95,96\">",
"     95,96",
"    </a>",
"    ], and in 30 percent with longer follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/97\">",
"     97",
"    </a>",
"    ]. Immune thrombocytopenia developed in 1 percent of patients at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/95,96\">",
"     95,96",
"    </a>",
"    ], and in 3 percent at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/94,97\">",
"     94,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although its precise role in the management of RRMS is not yet settled,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    will probably be used as a second-line agent for patients with RRMS who have an inadequate response to treatment with interferons and glatiramer. The role that alemtuzumab will play in the context of other newer MS disease-modifying agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    , and BG-12) is still undefined. Alemtuzumab therapy requires monitoring for infusion reactions and prophylaxis for herpes virus infections and Pneumocystis jirovecii (PCP) pneumonia during treatment and for several weeks after treatment. Prolonged surveillance for bone marrow suppression, infections, and autoimmune disorders such as immune thrombocytopenia is also necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for MS were small and conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. Nevertheless, in a meta-analysis that identified five randomized controlled trials involving 698 patients with MS, azathioprine compared with placebo was associated with a statistically significant reduction in the number of patients who had MS relapses during the first, second, and third years of treatment; relative risk reductions for these periods were 20, 23, and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/101\">",
"     101",
"    </a>",
"    ]. Approximately 55 percent of the pooled patients included in the meta-analysis had RRMS, while the remainder had progressive forms of MS; all of the trials were published prior to 1994.",
"   </p>",
"   <p>",
"    Few studies have evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for MS in the modern MRI era. One small, open-label study found that azathioprine up to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day was well tolerated and reduced the rate of new gadolinium-enhancing brain lesions in patients with RRMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/102\">",
"     102",
"    </a>",
"    ]. The benefit and tolerability of azathioprine for patients with RRMS requires confirmation in larger blinded, randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H219002360\">",
"    <span class=\"h2\">",
"     CCSVI treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous angioplasty and venous stent placement have been proposed as a treatment for chronic cerebrospinal venous insufficiency (CCSVI), a controversial condition characterized by putative anomalies of cerebrospinal veins that interfere with venous drainage from the brain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link&amp;anchor=H176638034#H176638034\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Chronic cerebrospinal venous insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data supporting these endovascular interventions for CCSVI, sometimes referred to as &ldquo;liberation procedures&rdquo;, are limited. The first report, from the investigators who first defined CCSVI, was an open-label study of 65 patients with MS who met criteria for CCSVI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/103\">",
"     103",
"    </a>",
"    ]. Percutaneous transluminal venoplasty was associated with significant improvement in some MS outcome measures, particularly for 35 patients with relapsing-remitting MS. A subsequent study of 31 patients with MS and CCSVI reported that treatment with balloon dilatation of extracranial veins was associated with improvement in fatigue scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/104\">",
"     104",
"    </a>",
"    ]. The methodologic limitations of these studies include small patient numbers, lack of control groups, and open-label designs. Thus, these findings require confirmation in more rigorous trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/105\">",
"     105",
"    </a>",
"    ]. In addition, such endovascular interventions are not benign, and there are now several reports of death following stent placement for the treatment of CCSVI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/106-108\">",
"     106-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the lack of compelling evidence that CCSVI causes MS or that invasive treatments for CCSVI are beneficial, and reports of harm with such treatments, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    treating patients with MS using interventional endovascular or stenting procedures for CCSVI unless performed in the context of a randomized controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cladribine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     Cladribine",
"    </a>",
"    , an immunosuppressive agent that targets lymphocyte subtypes, appears to reduce the relapse rate in patients with RRMS. However, this benefit may be associated with an increased risk of life-threatening infection. Supporting evidence comes from the CLARITY trial of 1326 adults with RRMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/110\">",
"     110",
"    </a>",
"    ]. Subjects were randomly assigned in a 1:1:1 ratio to treatment with either oral cladribine (3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 5.25",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo. At 96 weeks, the following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annualized relapse rate, the primary outcome measure, was significantly reduced on intention-to-treat analysis for both the high and low",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      groups (0.14 and 0.15 versus 0.33 with placebo). In addition, cladribine resulted in statistically significant reductions in both the risk of sustained disability progression and brain lesion count on MRI.",
"     </li>",
"     <li>",
"      Lymphocytopenia, generally mild to moderate, was more frequent among those assigned to the high and low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      groups (32 and 22 versus 2 percent with placebo).",
"     </li>",
"     <li>",
"      One patient treated in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      group developed a fatal reactivation of latent tuberculosis, while 20 developed nonfatal reactivation of latent herpes zoster infection. In addition, benign or malignant neoplasms developed in 10 patients assigned to cladribine and none assigned to placebo. One patient in the cladribine group died of pancreatic cancer. Overall, the incidence of serious adverse events was higher in the cladribine than placebo groups (9 versus 6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    is a promising disease-modifying agent for RRMS, but further research is needed to better define the risk of infection and tumor development associated with its use.",
"   </p>",
"   <p>",
"    The evidence regarding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    for progressive forms of MS is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of progressive multiple sclerosis in adults\", section on 'Cladribine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited observational evidence supports the use of pulse (eg, monthly) intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for RRMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/111\">",
"     111",
"    </a>",
"    ]. There is a greater experience with pulse cyclophosphamide for progressive forms of MS, but data are conflicting regarding benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of progressive multiple sclerosis in adults\", section on 'Cyclophosphamide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another option under investigation employs high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as immunoablative treatment without bone marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In an open-label study, nine patients with active inflammatory RRMS were treated with IV cyclophosphamide (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) for four days, followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/113\">",
"     113",
"    </a>",
"    ]. At a mean follow-up of 23 months, there was a statistically significant improvement in disability and a reduction in the mean number of gadolinium enhancing lesions compared with pretreatment, and there were no serious adverse events. However, two patients developed MS exacerbations and required rescue treatment with other immunomodulatory drugs. Larger studies are needed to determine the effectiveness and safety of this approach, and it is not recommended for use outside of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Daclizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daclizumab is a humanized monoclonal antibody that has specific binding activity for the alpha chain component of the high-affinity interleukin 2 receptor. Preliminary clinical data from a phase 2 randomized controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/114\">",
"     114",
"    </a>",
"    ] and small open label studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/115-118\">",
"     115-118",
"    </a>",
"    ] in patients with RRMS and secondary progressive MS suggest that daclizumab treatment is well tolerated and is associated with reductions in MRI evidence of disease activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175133010\">",
"    <span class=\"h2\">",
"     Dalfampridine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6725?source=see_link\">",
"     Dalfampridine",
"    </a>",
"    (4-aminopyridine; fampridine), a potassium channel blocker, may improve walking speed in some patients with MS. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link&amp;anchor=H12#H12\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\", section on 'Dalfampridine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fumarate (BG-12)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fumarates may have neuroprotective and immunomodulatory properties. In two large trials, an oral formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/16/9476?source=see_link\">",
"     dimethyl fumarate",
"    </a>",
"    (BG-12) significantly reduced relapse rates and the development of new brain lesions on MRI in patients with active MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/119,120\">",
"     119,120",
"    </a>",
"    ], and results from one of these trials suggest that BG-12 reduces the rate of disability progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CONFIRM trial randomly assigned over 1400 adults with RRMS to treatment with oral BG-12 at 480 mg daily in two divided doses, oral BG-12 at 720 mg daily in three divided doses, subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      20 mg daily, or placebo in a 1:1:1:1 ratio [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/119\">",
"       119",
"      </a>",
"      ]. At two years compared with placebo, the annualized relapse rate was significantly lower in groups assigned to BG-12 480 mg daily, BG-12 720 mg daily, and glatiramer (0.22, 0.20, and 0.29, versus 0.40 for placebo). In addition, the number of new or enlarging brain lesions by MRI was significantly reduced for groups assigned to both doses of BG-12 and to glatiramer compared with placebo. There was a trend towards lower rates of disability progression with BG-12 and glatiramer treatment, but the differences compared with placebo were not statistically significant. In post hoc analyses comparing BG-12 with glatiramer, there were no significant differences in relapse rates or MRI outcomes.",
"     </li>",
"     <li>",
"      The DEFINE trial randomly assigned over 1200 adults with RRMS to oral BG-12 at 480 mg daily in two divided doses, oral BG-12 at 720 mg daily in three divided doses, or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/120\">",
"       120",
"      </a>",
"      ]. At two years, treatment with BG-12 480 mg daily and 720 mg daily resulted in significant reductions in the proportion of patients who had a relapse (27 and 26 percent, versus 46 percent for placebo), the annualized relapse rate (0.17 and 0.19, versus 0.36 for placebo), and the proportion of patients with progression of disability (16 and 18 percent, versus 27 percent for placebo). BG-12 treatment also significantly reduced the number of new brain lesions on MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common side effects of BG-12 in these trials were flushing and gastrointestinal symptoms, including diarrhea, nausea, and abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Glucocorticoids in combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monthly intravenous glucocorticoid bolus, typically 1000 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , is used at many institutions for the treatment of primary or secondary progressive MS alone or in combination with other immunomodulatory or immunosuppressive medications. However, randomized trial data are limited and conflicting with respect to the use of oral or parenteral glucocorticoids in combination with interferon beta preparations for RRMS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MECOMBIN trial enrolled 341 treatment-na&iuml;ve adults with RRMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/121\">",
"       121",
"      </a>",
"      ]. All patients were started on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      treatment and after three months were randomly assigned to adjunct treatment with monthly pulses (three consecutive days per month) of oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo. Treatment continued for three to four years. At follow-up, the proportion of patients with sustained disability progression, the primary outcome, was no different for the methylprednisolone and placebo groups (26 versus 27 percent). The methylprednisolone group did have significant benefit on some of the secondary outcomes, including a reduction in the annualized documented relapse rate (0.21 versus 0.33, hazard ratio [HR] 0.63, 95% CI 0.47-0.84). More patients from the methylprednisolone group discontinued therapy or were lost to follow-up compared with the placebo group (51 versus 39 percent), particularly in the first year of the study, suggesting that combination therapy was not as well-tolerated.",
"     </li>",
"     <li>",
"      In the ACT trial, 313 patients with RRMS and continued disease activity on intramuscular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      were randomly assigned to adjunctive treatment with either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (20 mg once a week), intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000 mg daily for three days every other month), or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/122\">",
"       122",
"      </a>",
"      ]. At one year, there was no statistically significant benefit for either adjunctive therapy, although there were trends suggesting modest benefit for intravenous methylprednisolone on some outcomes.",
"     </li>",
"     <li>",
"      In the NORMIMS trial, discontinued prematurely due to slow recruitment, 130 adults with RRMS and recent relapse on subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      were randomly assigned to 96 weeks of adjunctive treatment with either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (200 mg for five consecutive days every four weeks) or matching placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/123\">",
"       123",
"      </a>",
"      ]. On intention-to-treat analysis, oral methylprednisolone led to a significant reduction in mean yearly relapse rate (0.22 versus 0.59 with placebo, relative risk reduction 62 percent, 95% CI 39-77 percent). However, small patient numbers and a high dropout rate preclude definitive conclusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the role of glucocorticoids combined with beta interferons for the treatment of RRMS remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are equivocal, there is no compelling evidence that intravenous immune globulin (IVIG) is effective for patients with RRMS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/124-127\">",
"       124-127",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/128\">",
"       128",
"      </a>",
"      ] early clinical trials reported beneficial effects for IVIG in RRMS. A systematic review that analyzed these trials concluded that IVIG is effective for reducing the proportion of patients with relapses, for reducing the mean number of annual exacerbations, and for improving disability in RRMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2002 AAN guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/130\">",
"       130",
"      </a>",
"      ], looking at essentially the same data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/124-126\">",
"       124-126",
"      </a>",
"      ], noted that trials of IVIG generally involved small numbers of patients, lacked complete data on clinical and MRI outcomes, or used questionable methodology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/130\">",
"       130",
"      </a>",
"      ]. The AAN concluded that IVIG is of little benefit for slowing disease progression.",
"     </li>",
"     <li>",
"      A later multicenter placebo-controlled trial of 127 patients with RRMS found that IVIG treatment conferred no benefit for reducing relapses or new lesions on MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Laquinimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laquinimod is a synthetic immunomodulatory compound with high oral bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. The effectiveness of oral laquinimod was evaluated in two large randomized controlled trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the multicenter ALLEGRO trial, 1106 patients with RRMS were randomly assigned to oral laquinimod (0.6 mg daily) or to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/134\">",
"       134",
"      </a>",
"      ]. At 24 months, oral laquinimod treatment led to a statistically significant though modest reductions in the annual relapse rate (0.30, versus 0.39 for placebo; risk ratio 0.77, 95% CI 0.65-0.91) and the risk of confirmed disability progression (11.1 versus 15.7 percent, hazard ratio 0.64, 95% CI 0.45-0.91). Laquinimod was generally well-tolerated, but transient reversible liver enzyme elevations were two-fold more frequent in the laquinimod group.",
"     </li>",
"     <li>",
"      The multicenter BRAVO trial enrolled 1331 patients with RRMS and randomly assigned them to either laquinimod (0.6 mg daily),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (30 mcg weekly), or placebo in a 1:1:1 ratio [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/135\">",
"       135",
"      </a>",
"      ]. Preliminary findings show that laquinimod treatment at 24 months resulted in a trend towards a reduction in the annualized relapse rate that missed statistical significance in the unadjusted analysis (0.28, versus 0.34 with placebo, risk ratio [RR] 0.82, 95% CI 0.66-1.02) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/136\">",
"       136",
"      </a>",
"      ]. In contrast, the reduction in annualized relapse rate with interferon beta 1-a treatment compared with placebo was significant. However, in a prespecified analysis that adjusted for baseline imbalances on brain MRI T2 lesion volume and the number of gadolinium-enhancing lesions, laquinimod treatment led to a statistically significant reduction in annualized relapse rate (0.29 versus 0.37 for placebo, RR 0.78, 95% CI 0.64-0.97) and disability progression (hazard ratio 0.67, 95% CI 0.45-0.99). The trial was not designed to compare laquinimod with beta interferon 1-a.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials suggest that laquinimod is modestly effective for reducing the relapse rate and disability progression for patients with RRMS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112882592\">",
"    <span class=\"h2\">",
"     Ocrelizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocrelizumab is a recombinant human anti-CD20 monoclonal antibody that binds to a different, but overlapping, CD20 epitope than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . It was designed to optimize B cell depletion by modification of the Fc region, which enhances antibody-dependent cell-mediated cytotoxicity and reduces complement-dependent cytotoxicity compared with rituximab.",
"   </p>",
"   <p>",
"    A phase 2 randomized trial of over 200 patients with RRMS demonstrated that ocrelizumab, compared with placebo, reduced the appearance of gadolinium-enhancing brain lesions on MRI by approximately 90 percent and reduced the annualized relapse rate by 70 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/137\">",
"     137",
"    </a>",
"    ]. In addition, ocrelizumab was better than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    for reducing the appearance of new gadolinium-enhancing lesions on brain MRI and the annualized relapse rate. No opportunistic infections were observed. However, the development of ocrelizumab for use in rheumatoid arthritis was halted because of safety concerns raised in clinical trials by the occurrence of opportunistic infections, including fatal infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H23#H23\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Ocrelizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a monoclonal antibody directed against the CD20 antigen on B lymphocytes that causes B cell depletion. In a preliminary randomized trial of 104 adult patients with RRMS, treatment with intravenous rituximab (1000 mg) given on days 1 and 15 was associated with a significant reduction in both total and new gadolinium-enhancing lesions on brain MRI at 24 weeks when compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/138\">",
"     138",
"    </a>",
"    ]. In addition, rituximab treatment was associated with a significant reduction in the proportion of patients who had a clinical relapse by week 24.",
"   </p>",
"   <p>",
"    While these results are promising, further clinical trials are needed to establish the long-term effectiveness and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for RRMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/139\">",
"     139",
"    </a>",
"    ]. Rare cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with rituximab. However, it is unknown if rituximab increases the risk of PML, since rituximab is often used to treat patients who have an underlying risk factor for PML. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins have immunomodulatory effects that may be beneficial in MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/140-142\">",
"     140-142",
"    </a>",
"    ], but are also known to have proinflammatory effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/143\">",
"     143",
"    </a>",
"    ]. Available clinical data regarding statins in the treatment of MS are not entirely consistent, but most of the studies showed no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial of 307 patients with RRMS found no benefit at 12 months for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      as add-on therapy to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/145\">",
"       145",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A post hoc analysis of data from the SENTINEL trial found no effect of statins in patients with RRMS assigned to intramuscular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/146\">",
"       146",
"      </a>",
"      ]. The study compared subgroups of patients taking statins (n = 40) and those not taking statins (n = 542) and found no significant differences in annualized relapse rates, disability progression, or MRI lesion burden.",
"     </li>",
"     <li>",
"      A preliminary study enrolled 30 patients with active RRMS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/147\">",
"       147",
"      </a>",
"      ]. Patients were treated with open-label",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      80 mg daily. Brain MRI scans obtained after four, five, and six months of treatment showed a significant decrease in the number of gadolinium-enhancing lesions compared with pretreatment brain MRI scans. These results must be interpreted cautiously because the study had no placebo group.",
"     </li>",
"     <li>",
"      A small double-blind trial of patients with clinically stable RRMS receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      therapy found that the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      resulted in increased clinical and MRI disease activity compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these findings, off-label use of statins for MS treatment is",
"    <strong>",
"     not",
"    </strong>",
"    recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266784142\">",
"    <span class=\"h2\">",
"     Stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cell transplantation is under investigation as a treatment for patients with progressive forms of MS and refractory relapsing-remitting MS. This approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of progressive multiple sclerosis in adults\", section on 'Stem cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus about how often a patient with MS should undergo a brain MRI while stable on treatment.",
"   </p>",
"   <p>",
"    Since disease-modifying treatments are only partially effective, many MS experts recommend more aggressive treatment when acute or progressive disease activity is seen on MRI, even when the patient is on a specific treatment and appears to be doing well clinically. From this perspective, a conservative approach is to repeat the brain MRI once a year. More frequent neuroimaging may be desirable, but is impractical due to financial constraints.",
"   </p>",
"   <p>",
"    However, this view is not universally shared, and other experts do not recommend repeat or serial brain MRIs for patients with MS who are clinically stable on treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with RRMS have disease activity that is refractory to initial disease-modifying therapy with interferon beta (IFNB) drugs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    . In this situation, we suggest the following options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adding intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      1000 mg monthly bolus.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      300 mg by intravenous infusion every four weeks as monotherapy only. Natalizumab should be reserved for patients with highly active RRMS who are either poor responders to both beta interferons and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      or are intolerant of these immunomodulators. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23032?source=see_link\">",
"       \"Natalizumab for relapsing-remitting multiple sclerosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with RRMS who are poor responders to IFNB agents, glatiramer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and who develop accumulating disability despite therapy, we suggest the following options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      combined with pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . The dose regimen for this treatment is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of progressive multiple sclerosis in adults\", section on 'Cyclophosphamide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      4 to 12",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      every three months up to a maximum lifetime cumulative dose of 140",
"      <span class=\"nowrap\">",
"       mg/m2.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mitoxantrone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications are available as disease modifying therapy of relapsing-remitting multiple sclerosis (RRMS). These include three interferon beta drugs (Avonex, Rebif, and Betaseron),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     fingolimod",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is approved as monotherapy only. There are no consensus guidelines, with the exception that mitoxantrone should be reserved for patients with rapidly advancing disease who have failed other therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/7/41082/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After making a diagnosis of definite MS, it is important to present the data in summary form to the patient and to discuss the risks and benefits of each treatment. One of the most important points is to remind the patient that these therapies slow the disease, but they do not stop it or make the patient feel better.",
"   </p>",
"   <p>",
"    It is reasonable to start newly diagnosed patients with RRMS on one of the following disease modifying agents:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       Interferon beta-1a",
"      </a>",
"      (Avonex) 30 mcg intramuscular injection weekly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"       Glatiramer acetate",
"      </a>",
"      20 mg subcutaneous injection daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/13/16597?source=see_link\">",
"       Interferon beta-1b",
"      </a>",
"      (Betaseron) 0.25 mg (1 mL) subcutaneously every other day",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/10/8358?source=see_link\">",
"       Interferon beta-1a",
"      </a>",
"      (Rebif) 22 or 44 mcg subcutaneously three times a week",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      (7 or 14 mg tablet) once daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon clinical experience, the available clinical data, neutralizing antibody formation, side effect profile, route of administration, and MRI data, we suggest Avonex or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    as agents of first choice for patients with RRMS, depending upon the patient's lifestyle and laboratory data. These drugs are typically continued indefinitely unless side effects are intolerable or the patient begins to fail in terms of response, after which use of another agent can be considered. For patients with highly active RRMS who have a poor response to both beta interferons and glatiramer acetate, or intolerance of these immunomodulators, we suggest adding intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    monthly bolus or treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Refractory disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    therapy is associated with a risk of progressive multifocal leukoencephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23032?source=see_link\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/11/26806?source=see_link\">",
"     Fingolimod",
"    </a>",
"    use has been linked with a number of deaths, and although these may be coincidental and unrelated to fingolimod, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    starting fingolimod for patients with MS until the cause of death in these cases has been clarified. (See",
"    <a class=\"local\" href=\"#H24015215\">",
"     'Clinical use of fingolimod'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/1\">",
"      Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/2\">",
"      Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994; 36 Suppl:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/3\">",
"      Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/4\">",
"      Sormani MP, Rovaris M, Valsasina P, et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004; 62:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/5\">",
"      Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/6\">",
"      Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123 ( Pt 11):2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/7\">",
"      Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/8\">",
"      Arnason BG. Interferon beta in multiple sclerosis. Neurology 1993; 43:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/9\">",
"      Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/10\">",
"      Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/11\">",
"      Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN&beta;-1b trial. Neurology 2012; 78:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/12\">",
"      Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005; 64:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/13\">",
"      Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/14\">",
"      Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/15\">",
"      Koch-Henriksen N, S&oslash;rensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006; 66:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/16\">",
"      Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/17\">",
"      Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/18\">",
"      Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/19\">",
"      PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/20\">",
"      Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/21\">",
"      Noseworthy JH. How much can we learn from long-term extension trials in multiple sclerosis? Neurology 2006; 67:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/22\">",
"      Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/23\">",
"      Lublin FD. When marketing and science intersect: do patients with MS benefit? Neurology 2002; 59:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/24\">",
"      Kieburtz K, McDermott M. Needed in MS: evidence, not EVIDENCE. Neurology 2002; 59:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/25\">",
"      Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol 2005; 62:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/26\">",
"      Rudick RA, Cutter G. Interferon-beta for multiple sclerosis: Long-term benefits? Ann Neurol 2007; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/27\">",
"      D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/28\">",
"      Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med 2004; 11:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/29\">",
"      St&uuml;rmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/30\">",
"      Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/31\">",
"      Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol 2008; 64:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/32\">",
"      Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/33\">",
"      R&iacute;o J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004; 63:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/34\">",
"      Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology 2004; 62:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/35\">",
"      Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003; 26:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/36\">",
"      Ekstein D, Linetsky E, Abramsky O, Karussis D. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis. Neurology 2005; 65:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/37\">",
"      Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/38\">",
"      Petereit HF, Nolden S, Schoppe S, et al. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002; 8:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/39\">",
"      Killestein J, Hintzen RQ, Uitdehaag BM, et al. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J Neuroimmunol 2002; 133:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/40\">",
"      Wandinger KP, L&uuml;nemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/41\">",
"      Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008; 70:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/42\">",
"      Durelli L, Barbero P, Bergui M, et al. MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/43\">",
"      Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009; 73:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/44\">",
"      Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/45\">",
"      Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/46\">",
"      Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/47\">",
"      Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/48\">",
"      Francis GS, Rice GP, Alsop JC, PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/49\">",
"      Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/50\">",
"      Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003; 60:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/51\">",
"      Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002; 73:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/52\">",
"      Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/53\">",
"      Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/54\">",
"      Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004; 75:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/55\">",
"      Giovannoni G, Goodman A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005; 65:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/56\">",
"      Rudick RA, Ransohoff RM. Biomarkers for interferon response in MS: are we there yet? Neurology 2008; 70:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/57\">",
"      S&oslash;rensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/58\">",
"      Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/59\">",
"      Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/60\">",
"      Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/61\">",
"      Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/62\">",
"      Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/63\">",
"      Salama HH, Hong J, Zang YC, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003; 126:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/64\">",
"      Bains SN, Hsieh FH, Rensel MR, et al. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. Ann Allergy Asthma Immunol 2010; 104:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/65\">",
"      Fox RJ, Arnold DL. Seeing injectable MS therapies differently: they are more similar than different. Neurology 2009; 72:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/66\">",
"      O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/67\">",
"      Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/68\">",
"      Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009; 72:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/69\">",
"      Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/70\">",
"      Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/71\">",
"      Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/72\">",
"      Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/73\">",
"      Gross CM, Baumgartner A, Rauer S, Stich O. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 2012; 79:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/74\">",
"      Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 2012; 79:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/75\">",
"      Visser F, Wattjes MP, Pouwels PJ, et al. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 2012; 79:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/76\">",
"      Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012; 79:2004.",
"     </a>",
"    </li>",
"    <li>",
"     The Globe and Mail. Health Canada launches investigation of oral MS drug. www.theglobeandmail.com/life/health/new-health/health-news/health-canada-launches-investigation-of-oral-ms-drug/article2351665/ (Accessed on February 28, 2012).",
"    </li>",
"    <li>",
"     Health officials launch investigation in deaths of patients taking fingolimod. Neurology Today 2012; 12(4):1. file://journals.lww.com/neurotodayonline/Fulltext/2012/02160/Health_Officials_Launch_Investigation_in_Deaths_of.1.aspx (Accessed on April 03, 2012).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). www.fda.gov/Drugs/DrugSafety/ucm303192.htm (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/80\">",
"      Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366:339.",
"     </a>",
"    </li>",
"    <li>",
"     Gilenya medication guide. Novartis Pharmaceuticals Corporation. www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/82\">",
"      Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012; 78:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/83\">",
"      Goodin DS, Cohen BA, O'Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/84\">",
"      Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005; 52:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/85\">",
"      O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/86\">",
"      O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/87\">",
"      He D, Xu Z, Dong S, et al. Teriflunomide for multiple sclerosis. Cochrane Database Syst Rev 2012; 12:CD009882.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves new multiple sclerosis treatment Aubagio. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319277.htm (Accessed on September 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/89\">",
"      New drugs for relapsing multiple sclerosis. Med Lett Drugs Ther 2012; 54:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/90\">",
"      Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003; 61:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/91\">",
"      Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/92\">",
"      Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011; 77:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/93\">",
"      Boster A, Edan G, Frohman E, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008; 7:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/94\">",
"      CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/95\">",
"      Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/96\">",
"      Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/97\">",
"      Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon &beta;-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012; 78:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/98\">",
"      Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/99\">",
"      Goodkin DE, Bailly RC, Teetzen ML, et al. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991; 41:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/100\">",
"      Milanese C, La Mantia L, Salmaggi A, Eoli M. A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol 1993; 240:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/101\">",
"      Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007; :CD003982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/102\">",
"      Massacesi L, Parigi A, Barilaro A, et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005; 62:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/103\">",
"      Zamboni P, Galeotti R, Menegatti E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009; 50:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/104\">",
"      Malagoni AM, Galeotti R, Menegatti E, et al. Is chronic fatigue the symptom of venous insufficiency associated with multiple sclerosis? A longitudinal pilot study. Int Angiol 2010; 29:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/105\">",
"      van Zuuren EJ, Fedorowicz Z, Pucci E, et al. Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. Cochrane Database Syst Rev 2012; 12:CD009903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/106\">",
"      Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann Neurol 2010; 67:A13.",
"     </a>",
"    </li>",
"    <li>",
"     FDA safety communication: Chronic cerebrospinal venous insufficiency treatment in multiple sclerosis patients. www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm303318.htm (Accessed on June 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/108\">",
"      Kuehn BM. FDA warns about the risks of unproven surgical therapy for multiple sclerosis. JAMA 2012; 307:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/109\">",
"      Reekers JA, Lee MJ, Belli AM, Barkhof F. Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol 2011; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/110\">",
"      Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/111\">",
"      Killian JM, Bressler RB, Armstrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 1988; 45:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/112\">",
"      Gladstone DE, Zamkoff KW, Krupp L, et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006; 63:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/113\">",
"      Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/114\">",
"      Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/115\">",
"      Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/116\">",
"      Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/117\">",
"      Bielekova B, Richert N, Herman ML, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011; 77:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/118\">",
"      Gorman MP, Tillema JM, Ciliax AM, et al. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol 2012; 69:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/119\">",
"      Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/120\">",
"      Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/121\">",
"      Ravnborg M, S&oslash;rensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/122\">",
"      Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009; 72:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/123\">",
"      Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/124\">",
"      Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/125\">",
"      Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/126\">",
"      Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/127\">",
"      Lewaska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/128\">",
"      Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000; 55:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/129\">",
"      Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005; 45:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/130\">",
"      Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/131\">",
"      Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/132\">",
"      Brunmark C, Runstr&ouml;m A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/133\">",
"      J&ouml;nsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004; 47:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/134\">",
"      Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366:1000.",
"     </a>",
"    </li>",
"    <li>",
"     BRAVO study: Laquinimod double blind placebo controlled study in RRMS patients with a rater blinded reference arm of interferon &beta;-1a (Avonex&reg;). file://clinicaltrials.gov/ct2/show/study/NCT00605215 (Accessed on March 31, 2012).",
"    </li>",
"    <li>",
"     Vollmer TL, Sorensen PS, Arnold DL. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. file://registration.akm.ch/einsicht.php?XNABSTRACT_ID=139560&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=150&amp;XNMASKEN_ID=900 (Accessed on March 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/137\">",
"      Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/138\">",
"      Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/139\">",
"      He D, Zhou H, Han W, Zhang S. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2011; :CD009130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/140\">",
"      Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002; 59:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/141\">",
"      Sena A, Pedrosa R, Gra&ccedil;a Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 2003; 250:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/142\">",
"      St&uuml;ve O, Prod'homme T, Youssef S, et al. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/143\">",
"      Polman CH, Killestein J. Statins for the treatment of multiple sclerosis: cautious hope. Lancet 2004; 363:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/144\">",
"      Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis. Cochrane Database Syst Rev 2011; :CD008386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/145\">",
"      Sorensen PS, Lycke J, Er&auml;linna JP, et al. Simvastatin as add-on therapy to interferon &beta;-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011; 10:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/146\">",
"      Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009; 72:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/147\">",
"      Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/7/41082/abstract/148\">",
"      Birnbaum G, Cree B, Altafullah I, et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008; 71:1390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1687 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-07C1274D5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41082=[""].join("\n");
var outline_f40_7_41082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES OF DISEASE MODIFYING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTERFERONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interferon beta-1b (Betaseron)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Interferon beta-1a (Avonex)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interferon beta-1a (Rebif)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Long term benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Side effects of interferons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13708205\">",
"      Interferon response status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neutralizing antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neutralizing antibody and MxA testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinically isolated syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GLATIRAMER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Side effects of glatiramer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Trials comparing interferons with glatiramer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26726955\">",
"      FINGOLIMOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24015215\">",
"      Clinical use of fingolimod",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NATALIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104685535\">",
"      TERIFLUNOMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MITOXANTRONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H219002360\">",
"      CCSVI treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cladribine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Daclizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175133010\">",
"      Dalfampridine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fumarate (BG-12)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Glucocorticoids in combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Laquinimod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112882592\">",
"      Ocrelizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266784142\">",
"      Stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MONITORING RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1687|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/12/1228\" title=\"table 1\">",
"      Safety of MS drugs in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=related_link\">",
"      Clinically isolated syndromes suggestive of multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=related_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3061?source=related_link\">",
"      Treatment of acute exacerbations of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_7_41083="Clinical manifestations of zinc deficiency";
var content_f40_7_41083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of zinc deficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alopecia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blepharitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corneal opacities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed wound healing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis (especially around mouth and anus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysarthria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysgeusia (impaired taste)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glossitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypogonadism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intention tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nervousness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Night blindness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paronychia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomatitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldschmid S, Graham M. Trace element deficiencies in inflammatory bowel disease.&nbsp;Gastroenterol Clin N Am 1989; 18:579.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41083=[""].join("\n");
var outline_f40_7_41083=null;
var title_f40_7_41084="TNM staging adrenal CA";
var content_f40_7_41084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for adrenal gland cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor 5 cm or less in greatest dimension, no extra-adrenal invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor greater than 5 cm, no extra-adrenal invasion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor of any size with local invasion, but not invading adjacent organs*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor of any size with invasion of adjacent organs*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in regional lymph node(s)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage III",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage IV",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Adjacent organs include kidney, diaphragm, great vessels, pancreas, spleen, and liver.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41084=[""].join("\n");
var outline_f40_7_41084=null;
var title_f40_7_41085="Treatment of DR";
var content_f40_7_41085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management strategies for diabetic retinopathy*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Level of DR",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Evaluation",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Follow-up interval",
"        <br/>",
"        (months; approx)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Fundus photo",
"       </td>",
"       <td class=\"subtitle2\">",
"        OCT exam",
"       </td>",
"       <td class=\"subtitle2\">",
"        Fluorescein angiography",
"       </td>",
"       <td class=\"subtitle2\">",
"        Intravitreal anti-VEGF",
"       </td>",
"       <td class=\"subtitle2\">",
"        Focal photocoagulation",
"       </td>",
"       <td class=\"subtitle2\">",
"        Scatter photocoagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Mild NPDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ndash;ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Occasional",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Occasional",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes or no along with anti-VEGF",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Moderate NPDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ndash;ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Occasional",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        6 to 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Occasional",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes or no along with anti-VEGF",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Severe NPDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ndash;ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Occasional",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Consider",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes or no along with anti-VEGF",
"       </td>",
"       <td>",
"        Consider",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Very severe NPDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ndash;ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Consider",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes or no along with anti-VEGF",
"       </td>",
"       <td>",
"        Consider",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Early PDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ndash;ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Likely",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes or no along with anti-VEGF",
"       </td>",
"       <td>",
"        Likely",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        High risk PDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ndash;ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        +ME",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes or no along with anti-VEGF",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Severe PDR",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        Photos/OCT/fluorescein angiogram/ultrasound as indicated",
"       </td>",
"       <td colspan=\"3\">",
"        Panretinal photocoagulation, focal laser, vitrectomy with endolaser, and anti-VEGF as indicated",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     DR: diabetic retinopathy; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; &ndash;ME: macular edema absent; +ME: macular edema present.",
"     <br/>",
"     * Precise management guidelines have not yet been established at the time of this writing. This table summarizes current recommendations of Donald J. D'Amico, MD and Szilard Kiss, MD and includes modifications from earlier recommendations from: Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41085=[""].join("\n");
var outline_f40_7_41085=null;
var title_f40_7_41086="Cook Gianturco Z stent";
var content_f40_7_41086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single Cook-Gianturco Z-stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown fully expanded, it can be compressed into a narrow cylinder prior to bronchoscopic deployment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41086=[""].join("\n");
var outline_f40_7_41086=null;
var title_f40_7_41087="Pilonidal cyst PI";
var content_f40_7_41087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Pilonidal cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_7_41087=[""].join("\n");
var outline_f40_7_41087=null;
